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ABSTRACT
Chemical fluorophores have superior photophysical properties to fluorescent
proteins and are much smaller. However, in order to use these probes for live-cell protein
imaging, highly specific labeling methods are required. Here, we will describe three
efforts to re-engineer the E. coli enzyme, lipoic acid ligase (LplA), to catalyze the
ligation of small-molecule probes onto recombinant proteins. We call this collection of
methods the PRIME (PRobe Incorporation Mediated by Enzymes) methodologies. First,
we describe the structure-guided mutagenesis of LplA and the identification of an LplA
variant that can ligate a blue coumarin fluorophore onto a 13-amino acid LplA acceptor
peptide (LAP2). This "coumarin ligase" can be used to image cellular proteins with high
specificity, sensitivity, and minimal perturbation of the biology of the protein of interest.
We also demonstrate how subpopulations of a protein of interest can be labeled using
genetically targeted coumarin ligase. Second, we describe our attempts to use yeast
display evolution and fluorescence activated cell sorting (FACS) to evolve a truncated
LplA enzyme. The original truncated enzyme had severely decreased activity for LplA's
natural substrate, lipoic acid. We created a 107 library of LplA mutants and, after four
rounds of selection, produced a truncated LplA mutant with lipoylation activity
equivalent to full-length LplA. We next sought to evolve activity for an unnatural small
molecule probe, but found that this strategy was limited by both increased hydrophobic
probe sticking when using the truncated enzyme and some enzyme-dependent non-
specificity. Finally, from a library of 107 LplA mutants, we evolved a full-length LplA
capable of ligating an unnatural picolyl azide (pAz) substrate. We demonstrated
improved activity of the "pAz ligase" in the secretory pathway and cell surface, two
regions where coumarin ligase is inactive. This enzyme can also be used to image cell
surface protein-protein interactions as well as label proteins as they are trafficked through
the endoplasmic reticulum. These probe ligases will be useful tools for cell biologists
interested in studying protein function or protein-protein interactions in the context of
living cells.
Thesis Supervisor: Alice Y. Ting
Title: Associate Professor of Chemistry
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Introduction
Over the past decade, fluorescence microscopy has become a leading tool for
probing the function, localization, and interactions of cellular proteins. Although
fluorescence microscopy allows for precise visualization of proteins with high temporal
and spatial resolution, highly specific and minimally perturbative labeling methods are
required in order to study biological function. The most common method for the
fluorescent imaging of proteins utilizes recombinant fusions to fluorescent proteins (FPs).
Fluorescent proteins are genetically encodable, and thus easy to target and perfectly
specific. FPs are available in a wide range of colors and new developments in
photoswitchable FPs and split-FPs allow for superresolution imaging and more
sophisticated experiments investigating protein-protein interactions -3 . However, there are
several limitations when using FPs to probe biological function. The most obvious
limitation is that FPs are large tags, which can interfere with target protein localization,
trafficking, and function4-6. FP fusions have been reported to increase receptor
aggregation7'8 , alter target protein localization 4''' 9 as well as interfere with protein
function 0 . In addition, the FP chromophores are not as bright as smaller organic dyes,
have a lag time in maturation, and are more susceptible to photobleaching. Small
molecule probes, on the other hand, are desirable for their brightness, small size, and the
variety of reporting functions they can perform. Unfortunately, since these probes must
be incorporated into the target protein post-translationally, there is a challenge of
achieving specific targeting. This challenge is particularly daunting when working in the
complex and heterogeneous environment of the living cell.
Many labs have been working to develop new protein labeling methods with the
goal of capitalizing on the superior photophysical properties of small, organic
fluorophores and probes while relying on genetically encoded sequences for probe
targeting. While there are a few tagless protein labeling methods such as unnatural amino
acid mutagenesis and ligand-directed tosyl chemistry4 (Figure 1-lA), most protein
labeling methods use a genetically encoded protein or peptide fusion to the protein of
interest. Several labeling methods use a protein or peptide recognition sequence to
directly recruit the small chemical probe. The final recruitment can result in a tight non-
19
covalent interaction (Figure 1-1B e.g. FKBP', DHFR ,", FlAsH" 9, polyhistidine 20,2 1
TexasRed binding peptide2 2 ) or a covalent conjugation of the probe to the recognition
sequence (Figure 1-iC, e.g. cutinase 23, SNAP/CLIP 24-26 , and HaloTag27 ). Recently,
several labs have used proximity-induced reactivity to successfully transform existing
non-covalent tags to covalent tags (e.g. DHFR(L28C) 28 and covalent polyhistidine 29).
These methods use a ligand-directed reactive group and a nucleophilic residue on either
the tag or the protein of interest to achieve covalent attachment of the entire ligand-probe
conjugate (Figure 1-1D). In the previously outlined labeling schemes, labeling specificity
is largely dependent on the bimolecular interaction between probe and the protein or
peptide recognition sequence. With the idea of achieving exquisite labeling specificity
while using a small tag, our lab and others have developed enzyme-mediated labeling
techniques30-34 (Figure 1-1E). The enzyme-mediated labeling methods rely on the
intrinsic specificity enzymes have for their peptide substrates to achieve specific labeling
of a very small tag. In this chapter, we will briefly describe the various protein labeling
strategies that have been demonstrated on cell-surface and intracellular proteins. The
information presented herein is summarized in Table 1-I at the end of the chapter.
20
A Tagless labeling
B Non-covalent protein- or peptide-directed labeling
C Covalent protein-directed labeling
D Proximity-induced covalent protein- or peptide-directed labeling
is4 
=
E Enzyme-mediated labelingA + c
Figure 1-1: Strategies for labeling proteins with small molecule probes. (A) Tagless labeling. Ligand-
directed tosyl chemistry uses a high-affinity ligand modified with an introduced reactive group. After
ligand binding, the tosyl group reacts with a nucleophillic residue on the protein of interest (POI),
producing covalent conjugation of the probe. (B) Non-covalent protein- or peptide-directed labeling. The
protein or peptide tag directly binds probe or probe-ligand conjugate. (C) Covalent protein-directed
labeling. A probe-conjugated suicide substrate is used for covalent probe attachment to the protein tag. (D)
Proximity-induced covalent protein- or peptide-directed labeling. A probe or ligand is modified with a
reactive group. After binding of probe or ligand, the reactive group covalently attaches the probe or probe-
ligand to an introduced cysteine residue on either the protein tag or protein of interest. (E) Enzyme-
mediated labeling. An enzyme catalyzes the covalent ligation of the probe to a peptide tag fused to the
protein of interest.
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Protein-based labeling methods
It is important to note that when using probe-recruiting tags there are significant
trade-offs between labeling specificity and tag size. In general, protein-based recognition
sequences give better labeling specificity than peptide-based recognition sequences. For
non-covalent interactions, the increased specificity with protein recognition sequences is
primarily the result of increased interaction surface area for ligand or probe binding.
However, some protein-based labeling methods produce covalent modifications, which
are by nature stronger than binding interactions.
Cell-surface protein labeling
Cutinase is a covalent protein-based labeling method that has been applied to the
labeling of cell-surface proteins. Cutinase is a fungal serine esterase that reacts
irreversibly with para-nitrophenyl phosphonate (p-NPP). For labeling, cutinase is
genetically fused to the protein of interest and then can react with fluorophore p-NPP
conjugates, producing covalently labeled recombinant protein fusions . Cutinase is a
large tag (22 kDa), comparable in size to many FPs, so it may disrupt the biology of the
target protein. This labeling method is limited to the cell surface because p-NPP
derivatives are highly charged and membrane-impermeant. Moreover, cutinase itself is a
secreted enzyme that contains two disulfide bridges which are required for activity3;
even if a membrane-permeable substrate were created, it is likely that recovering cutinase
activity in the reducing environment of the cytosol would be a challenge.
Intracellular protein labeling
Several protein-based labeling methods use genetic fusions to proteins that are
capable of binding small molecules with high affinities. One example of this type of
labeling strategy developed by the Cornish lab uses E coli dihydrofolatereductase
(DHFR)17 . The DHFR method relies on the ability of two DHFR inhibitors: methotrexate
and trimethoprim to bind the enzyme with picomolar affinities16 '1 7' 36. By making
fluorophore conjugates to either methotrexate or trimethoprim, specific fluorescent
labeling can be achieved. Since methotrexate and trimethoprim are themselves cell-
permeant, this method can be extended to intracellular labeling simply by utilizing cell-
permeant fluorophores. Unfortunately, because methotrexate is also an inhibitor of
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mammalian DHFR, labeling with methotrexate-based fluorophores requires using DHFR-
deficient cell lines to eliminate background labeling of endogenous DHFR 7 . In order to
eliminate the need for DHFR null cell lines, the Cornish lab developed the trimethoprim-
based probes. Since trimethoprim has a higher affinity for E coli DHFR over the
mammalian DHFR, DHFR-deficient cell-lines are no longer required16 ,37 . However,
trimethoprim conjugates must be tested to ensure minimal background labeling of
endogenous DHFR in each new cell line used37.
In a conceptually similar approach, the Nolan lab developed a labeling method
15that uses a mutated protein and synthetic ligand pair to achieve specific probe targeting".
The technique uses an F36V point mutant of the FK506 binding protein (FKBP) which
has picomolar affinity for a "bumped" synthetic ligand for FKBP (SLF') (Kd 0.094
nM)". Since SLF' is a designed ligand, it has high affinity for the modified F36V FKBP,
but very low affinity for endogenous mammalian FKBP. This technique of using a
protein mutant and specifically designed synthetic ligand reduces the background from
endogenous protein labeling that initially plagued the DHFR technique. However, both
the FKBP and DHFR methods have a few drawbacks that are inherent to the techniques.
First, both methods use large tags that can interfere with protein function, trafficking and
interactions. Second, since both methods are non-covalent, labeling signal can deteriorate
over time as the ligand or inhibitor dissociates from the protein, which prevents long-term
imaging. This problem is particularly obvious for DHFR where methotrexate conjugates
have been reported to dissociate from the protein in just 1 hour17. To address this issue of
quick probe-dissociation, a covalent form of DHFR labeling was recently developed28.
By using the high affinity trimethoprim binding to bring a reactive acrylimide
electrophile in close proximity to an introduced cysteine residue (L28C), Gallagher and
colleagues were able to achieve covalent labeling with DHFR-tagged proteins.
The problem of probe-dissociation from a protein tag can alternatively be
addressed by using suicide substrates that can covalently modify enzyme active sites.
This technique is used in two recently developed covalent protein-based labeling
methods. Both the HaloTag2 7 and the SNAP/CLIP 24-26 methods rely on modified enzymes
that are capable of self-labeling with fluorophore conjugated suicide-substrates. SNAP-
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tag was the first such method introduced by Johnsson and colleagues. This method uses
the human DNA repair enzyme 06 -alkylguanine-DNA alkyltransferase (hAGT). In the
natural reaction, hAGT repairs 0 6-alkylated guanine residues by covalent transfer of the
alkyl group to an active site cysteine residue2 5 . However, by using fluorophore-
conjugated derivatives of 0 6-benzylguanine, labeling of recombinant proteins fused to
hAGT can be achieved. While SNAP tag was originally limited to AGT-deficient cell
lines, the evolution of an orthogonal mutant eliminated this restriction and opened the
method to labeling in any human cell line26 . CLIP is an orthogonal labeling method that
uses a mutant of hAGT that can only recognize 0 6-benzylcytosine derivatives24 . Using
SNAP/CLIP in tandem allows for orthogonal two-color labeling of intracellular protein
pairs . In a similar approach, the HaloTag method uses a modified bacterial haloalkane
dehalogenase to achieve covalent labeling using fluorophore-haloalkane conjugates. In
the natural reaction, the dehalogenase removes halides from aliphatic substrates by
nucleophilic displacement of the halide. In the wild-type enzyme, an active-site aspartate
forms an ester bond with the alkane substrate. Subsequent hydrolysis of the bond is
catalyzed by a proximal histidine residue functioning as a general base, allowing release
of the dehalogenated product and regenerates the aspartate residue. In the modified
dehalogenase, that histidine residue has been mutated allowing covalent trapping of the
enzyme-substrate complex27 . Developed by Promega, this method has been used to attach
not only organic fluorophores to cell surface and intracellular proteins, but also has been
used to target halo-alkane coated quantum dots to cell-surface proteins38 . These three
covalent protein-based labeling methods have very high intracellular specificity and fast
labeling reactions (under 30 minutes). However, all of these methods require large tag
fusions (182-213 amino acids), which can interfere with target protein function,
localization, and trafficking.
Peptide-based labeling methods
Peptide-based labeling methods modify the protein of interest via a genetically
encoded peptide tag that is capable of binding small molecule probes with high affinity.
While peptides are less perturbative than large protein tags, it is more difficult to achieve
high binding affinity with peptides because of the reduced number of binding interactions
between the peptide tag and the probe. In all of the methods introduced in this section,
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specific peptide-probe interactions must be weighed against the potential for low binding
affinities, fast probe off-rates, and non-specific background interactions between the
probe and endogenous cellular components.
Cell-surface protein labeling
Ion-binding peptides have been used to site-specifically label proteins on the cell
surface. Polyhistidine peptides have been used to specifically target nickel(II)
20,21nitrilotriacetic acid (Ni-NTA) complexes to proteins on the cell surface2 . However, the
binding affinity of this interaction is low compared to similar peptide-based targeting
methods described below. With a Kd in the low micromolar range, the signal deterioration
is very rapid and target protein expression must be very high in order to see strong
labeling. Ni2 + toxicity is also an issue with this labeling method. The development of a
dizinc probe with improved binding affinity and lower toxicity corrected some of these
issues, but the method is still non-covalent and limited to cell-surface proteins39 . A
similar approach utilizes a polyaspartate peptide to recruit and bind a dinuclear Zn(II)
complex 0 . As with the polyhistidine peptide, the polyaspartate peptide has low affinity
and exhibits rapid dissociation of zinc-based probes. To correct the issue of rapid probe
dissociation, Nonaka and colleagues developed a probe that included a chloroacetamide
moiety which allows for covalent conjugation of the probe to the protein of interest;
covalent labeling requires an accessible cysteine residue near the site of labeling which
generally must be engineered into the protein of interest4 . While the covalent
modification prevents probe dissociation, this method is still limited to the cell surface
due to the properties of the dinuclear zinc probes.
Peptides that bind the proteins streptavidin or bungarotoxin have also been used
for cell surface protein labeling42. However, the large size of streptavidin and
bungarotoxin makes the overall label large and partially defeats the purpose of using a
small peptide tag. While the fusion protein will likely traffic properly and function
properly prior to labeling, any analysis of labeled protein is complicated by a large
overall tag size. Moreover, since the large size of streptavidin and bungarotoxin prevents
intracellular delivery, this method is limited to the cell surface.
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Intracellular protein labeling
Arguably the most successful peptide-based labeling method is the FlAsH method
developed by the Tsien laboratory 19,43 . This method uses a 6-12 amino acid peptide that
contains a tetracysteine motif (CCPGCC) that is capable of binding a biarsenical dye with
picomolar affinity (Kd= 4-10 pM). The high affinity of this interaction means that the
labeling signal does not deteriorate over time. Another feature of this method is that the
biarsenical dyes become fluorescent upon binding to the peptide, which helps to reduce
background fluorescence from unbound probe inside living cells. The small biarsenical
dyes have been made in multiple colors along with singlet oxygen generators that are
applicable to electron microscopy 44. The combination of small tag size and cell
permeable dyes with tight binding affinity has led to quick commercialization of this
technology and repeated use in multiple cell biology studies*- . However, even with all
of these advantages, the FlAsH technology does have significant drawbacks that limit its
utility. First, the biarsenical probes have weak affinity for mono- and di-cysteines which
results in high background5 3. To address this issue, competing chelating agents such as 1,
2-ethanedithiol can be used to reduce background. However, this extends the labeling
time significantly5 3. A higher affinity peptide (FLNCCPGCCMEP) was engineered that
increases labeling signal and thus improves signal-to-noise ratios when performing
labeling, but background is still a significant issue when labeling lower-expressing
targets. Unwanted palmitoylation and oxidation of the tetracysteine motif can also
decrease specific labeling signal43. Finally, the requirement for reduced cysteines
prevents labeling in the secretory pathway or cell surface.
Peptides that bind small organic molecules have also been developed. The only
one that has been demonstrated inside living cells is a peptide that specifically binds the
fluorophore Texas Red, developed by Nolan and colleagues15 . The peptide binds with
picomolar affinity (Kd ~25pM) and has been used on the cell surface and inside living
cells. However, accumulation of the TexasRed fluorophore in mitochondria gives high
15intracellular background and restricts labeling to only the most highly expressed targets".
Moreover, since the peptide is specific for the Texas Red fluorophore, labeling with other
dyes is not possible using this method.
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Tagless labeling methods
Intracellular protein labeling
Unnatural amino acid mutagenesis is one of the most versatile methods for
labeling intracellular proteins"'"4-". This method labels proteins by using engineered
tRNA synthetases to charge tRNAs with unnatural amino acids. The engineered tRNAs
can recognize the amber stop codon (UAG) and incorporate the unnatural amino acid co-
translationally and site-specifically into the protein of interest. Unnatural amino acid
mutagenesis has been used to directly incorporate probes such as benzophenone 58 and
fluorescent coumarin 59 derivatives as well as functional groups like ketones 57, azides5 s6 ,
and hydrazines". While this method is minimally perturbative to the target protein,
allows incorporation of a variety of reporters, and is, in theory, perfectly specific, there
are significant drawbacks. The first issue is the requirement to evolve new aminoacyl-
tRNA synthetases for each new unnatural amino acid target. This can be time-consuming
and technologically challenging for labs that don't already have the required bacterial
strains or experience with the selection protocol. Other significant problems include
competing termination at amber stop codons with accumulation of truncated target
protein and concomitant read-through of endogenous amber stop codons". The latter
becomes particularly problematic when using this method in mammalian cells, as amber
stop codons are more frequent in the mammalian genome than in the E. coli genome.
Another recent tagless protein labeling method was developed by Tsukiji and
colleagues 14 . The strategy behind this method is to use a high affinity ligand to target a
reactive probe specifically to a native protein. The first example of this method used a
ligand-directed tosyl group to label carboxyanhydrase. Similar to the covalent Asp tag
and covalent DHFR modifications, this method requires tight binding of a ligand-
fluorophore conjugate with an introduced reactive group for proximity-dependent
labeling of the target protein. Unlike the previously described methods, however, this
chemistry is an SN2-type reaction wherein the tosyl moiety forms a covalent bond to the
14
nucleophilic protein residue with the original inhibitor structure as the leaving group4.
This means that the inhibitor itself is not covalently attached to the protein, so function is
not inherently disrupted. Examples of this method have been demonstrated in living cells,
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in tissue, and in mice' 4 . Unfortunately, one drawback to this method is that it is only
applicable to proteins that have known high affinity ligands or inhibitors61 . Even if such
ligands exist, the chemistry to produce the reactive probe-tosyl-ligand compounds can be
quite challenging. Finally, the nature of the chemistry requires that the probe be
conjugated to a residue proximal to the native ligand binding site; it is possible that the
added bulk of the probe in a biologically critical portion of the protein of interest may
interfere with subsequent ligand binding events and the biological activity of the protein
of interest.
While tagless methods are minimally perturbative, there are drawbacks that limit
the utility of these methods for intracellular protein labeling. There is significant demand
for less technologically challenging methods that allow for specific incorporation of a
wider range of probes. The methods discussed in the final section attempt to address this
unmet need.
Enzyme-mediated labeling methods
As mentioned previously, vast improvements have been made to peptide-based
labeling methods by utilizing enzymes to improve labeling specificity. These methods
hijack endogenous post-translational modification enzymes and engineer them to perform
site-specific ligation of small molecule probes onto an introduced peptide tag. These
methods combine the high specificity of enzyme-substrate interactions with the benefits
small peptide tags. The crux of these labeling schemes is that the enzyme must be highly
sequence specific but flexible in terms of small molecule substrate.
Cell-surface protein labeling
The first reported example of an enzyme-mediated labeling method exploits
phosphopantetheine transferases (PPTases, AcpS and Sfp) to perform site-specific protein
labeling62 -6 4 . PPTases in their natural reaction catalyze the transfer of 4'-
phosphopantetheine from coenzyme A (CoA) to a serine residue of an acyl or peptidyl
carrier protein (ACP and PCP, respectively), which are involved in the biosynthesis of
polyketides and nonribosomal polypeptides. PPTases are quite permissive in the CoA
derivatives that they are able to use as substrates, making this method quite versatile.
While the original method was demonstrated on ACP and PCP proteins, evolved 12-mer
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peptides (Al and S6 for AcpS and Sfp, respectively) are now frequently used for this
labeling method6 5 . The ligation is fast, specific, covalent, and the method has been used
successfully to probe biological function 34,66; however, since the CoA derivatives are
highly charged, this technique is limited to the cell surface.
A recently developed method, SorTag, utilizes a bacterial transpeptidase to
covalently label cell-surface proteins 67. The method relies on Sortase A from
Staphylococcus aureus, which in its natural reaction functions as both a protease and
transpeptidase to attach pilli and perform additional decoration of proteins anchored in
the cell wall. Sortase A specifically recognizes LPXTG peptide sequences and cleaves
between the T and G residues while forming a new peptide bond with a polyglycine-
protein. Specific protein labeling can be achieved by using a LPXTG tag to the protein of
interest and supplying polyglycine-probe conjugates. This method uses a very small tag
(5aa) and is fast and specific. Recently, Chen and colleagues have used yeast-display
evolution to develop a Sortase A mutant with improved coupling activity over the wild-
type ligase6 8. This advance gives better labeling of low-expressing target proteins.
However, this method is still limited to the cell surface as polyglycine-probe conjugates
are not cell permeable.
Another enzyme-mediated cell-surface labeling method is based on guinea pig
transglutamninase (gpTGase)30. The natural reaction of transglutaminases is to catalyze
amide bond formation between glutamine and lysine side-chains in a calcium-dependent
reaction. The guinea pig transglutaminase was selected because it is sequence specific for
the glutamine-containing peptide (Q-tag) but is permissive of a range of amine
substrates 69. This is a key feature that is a goal of all enzyme-mediated labeling methods.
Q-tags have been used to label recombinant proteins in vitro and were extended by our
lab for fast labeling of cell surface proteins ' - . Unfortunately, the method is hindered
by nonspecificity on the cell surface. Specific labeling of the glutamine residue in the Q-
tag competes against non-specific labeling of endogenous glutamine residues found in
cell surface proteins. While intracellular labeling would not be advisable due to
nonspecific labeling, it is likely impossible because basal intracellular calcium
concentrations are too low for gpTGase activity.
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Our lab has developed a method that utilizes E. coli biotin ligase (BirA) for site-
specific protein labeling31 . The natural reaction of BirA is to catalyze the ATP-dependent
ligation of biotin to a specific lysine residue of biotin carboxyl carrier protein (BCCP).
Previous engineering developed a 15-amino acid acceptor peptide (AP) that BirA can
biotinylate with identical ligation kinetics to the protein substrate. Biotinylation of the AP
tag can be detected using streptavidin-fluorophore or streptavidin-coated quantum dots73.
Using these strategies, our lab has demonstrated ensemble and single-molecule imaging
of AP-tagged surface proteins73 74. We also developed an orthogonal yeast biotin ligase
and yeast acceptor peptide pair that allows us to perform multi-color imaging. This
labeling method is highly specific and fast, but using large streptavidin conjugates for
labeling, as previously mentioned, restricts labeling to cell-surface proteins and defeats
the purpose of a small tag. To reduce the overall size of the label, we developed a ketone
isostere of biotin that can be efficiently ligated by the wild-type BirA enzyme31. Ketones
can be chemoselectively derivatized with hydrazines or hydroxylamines, thus eliminating
the need for streptavidin-based detection of the site-specific labeling. However, reaction
kinetics of ketones with hydrazines or hydroxylamines is very slow which limits the
temporal resolution of this method. Moreover, this method is still restricted to the cell
surface because, while absent from the cell surface, ketones are present in the cytosol.
Intracellular protein labeling
The enzyme-mediated labeling methods described so far are limited to the cell
surface and crippled by either slow labeling kinetics or poor specificity. After finding E
coli BirA to be difficult to engineer and failing to find biotin ligases from other species
with increased small molecule promiscuity7 5 , our lab sought out a new ligase that
performed similar chemistry. We settled on E coli lipoic acid ligase (LplA), which, in its
natural reaction, catalyzes the ligation of lipoic acid to proteins involved in oxidative
metabolism. Like BirA, it is highly specific for the protein substrates, but LplA is more
malleable in terms of small molecule substrates, ligating both lipoic acid and octanoic
acid. Our lab quickly determined that LplA can accept alkyl-azide substrates which can
then be chemoselectively derivatized, allowing site-specific cell surface labeling33 . The
challenge was to adapt this to an intracellular labeling method. This motivated the work
described in Chapters 2 and 3 of this thesis and led to the development of the intracellular
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labeling method we call PRobe Incorporation Mediated by Enzymes, or PRIME. Using
LplA as a platform for a protein labeling method proved very lucrative; our lab produced
ligases for intracellular labeling with coumarin 76-78, resorufin, azides 79, alkynes33 , and
tetrazines o. More recently we were able to develop an interaction-dependent form of the
coumarin ligase labeling technology8 1 . However, there were several limitations to this
intracellular labeling method (summarized in Chapter 2) including a lack of enzyme
activity in the secretory pathway. After attempts to solve this problem through rational
design of the ligase failed, we resorted to in vitro evolution techniques, the results of
which are summarized in Chapters 5-7.
We believe that the LplA labeling technology holds a wealth of potential for site-
specific protein labeling. The varieties of probes that can be incorporated using this
technology make it one of the most versatile discussed herein. Moreover, the fast ligation
kinetics and small tag size make it applicable for minimally perturbative labeling of
biologically relevant proteins with good temporal control. The progress described in this
thesis of adapting the method to intracellular protein labeling and evolving a ligase with
activity on the cell surface and endoplasmic reticulum makes this method one of the most
generalizable protein labeling methods to-date. However, there is a significant hurdle for
labs that want to adapt the method for use in their own systems; individual labs must
synthesize the PRIME labeling substrates if they wish to use the method. The importance
of probe availability on method adoption is exemplified by the drastic increase in
experiments utilizing HaloTag and SNAP/CLIP after the commercial availability of
various alkylhalide-, benzylguanine- and benzylcytosine-probe conjugates82 -9 0
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Table 1-1: Summary of methods for cell-surface and intracellular protein labeling.
Method Genetic Tag Tag size Enzyme Covalent Other comments Refs
Protein Tags
Cutinase Cutinase 213 aa - Yes Large tag 23
Peptide Tags
PolyHis PolyHis 6-12 aa - No/Yes Low probe affinity for non-covalent 20, 21, 29, 39
version
PolyAsp PolyAsp 8-22 aa - No/Yes Low probe affinity for non-covalent 40, 41
version
Streptavidin and bungarotoxin SA or BT binding peptide 13 aa No Detection method produces large tag 42binding peptides 
________________
AP AP 17 aa Biotin ligase Yes Slow kinetics for ketone-biotin 31, 32, 73-75
PPTase A1/S6 11 aa AcpS/Sfp Yes Fast and specific labeling with small 65
tag
Transglutaminase labeling Q-tag 7 aa Transglutaminase Yes High background from endogenous 30
glutanine residues
Sortase labeling SorTag 5 aa Sortase A Yes Fast and specific labeling with small 67, 68
1__ _tag I
W
- - _=_ - .. ... . - - - _.. , .. I I ,- - - _ _ _ . . .. ........................... .  .   ....... ...........
Table 1-1(cont): Summary of methods for cell-surface and intracellular protein labeling.
Method Genetic Tag Tag size Enzyme Covalent Other comments Refs
Protein Tags
FKBP FKBP12 98 aa - No Non-covalent labeling, eventual loss 15
of labeling signal
DHFR DHFR/DHFR(L28C) 157 aa - No/Yes Fast off-rates for non-covalent 16, 17, 28, 37
version
HaloTag Dehalogenase 296 aa - Yes Fast and specific labeling with large 27, 38, 84-88
tag
SNAP/CLIP 0 6-alkylguanine-DNA-alkyltransferase 182 aa - Yes Fast and specific labeling with large 25,26,34,80-
____________________I I_________________ I_____ _______ _  tag 83
Peptide Tags
TexasRed Binding Peptide TexasRed Binding Peptide 23-38 aa No High mitochondrial background 22
Tetracysteine CCPGCC or FLNCCPGCCMEP 6-12 aa No Low specificity 18, 19, 43-52
PRIME/ID-PRIME LAP2/LAPI 13/17 aa LplA Yes Fast and specific labeling with small 32, 76-79
I_ I tag
Tagless
UAA mutagenesis UAG codon 0 aa - Yes Truncated protein products, native 11-13, 56-60
stop-codon read-through
Ligand-directed tosyl chemistry - 0 aa Yes Covalent modification near native 14,61
ligand binding site
.. .... .. .......
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Chapter 2. Engineering E. coli lipoic acid ligase for site-specific labeling
of intracellular proteins
The work presented in this chapter has been published in part in C. Uttamapinant, K.A.
White, H. Baruah, S. Thompson, M. Femndez-Suirez, S. Puthenveetil, A.Y. Ting A
fluorophore ligase for site-specific protein labeling inside living cells. Proc Natl Acad Sci
U S A, 2005 107, 10914-9. The experimental section of that publication is reproduced
here in part and with permission. Hemanta Baruah performed the initial alanine mutant
screening and Samuel Thompson performed much of the W37 mutant screening on E2p.
Chayasith Uttamapinant performed synthesis of the protected coumarin probes and
determined kinetics for coumarin ligation using w37vLplA and W371LplA.
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Introduction
As outlined in Chapter 1, the Ting lab has developed several different enzyme-
mediated methods for site-specific labeling of cell surface proteins. The most promising
method utilizes E coli lipoic acid ligase (LplA) to ligate an azidoalkanoic acid, which
can then be chemoselectively derivatized using cyclooctyne-fluorophore conjugates'.
This method is fast, specific, and can be used to incorporate many different fluorophores
and probes. While the other enzyme-mediated labeling methods developed by our lab are
limited to the cell surface by either incompatible chemistry2 (in the case of BirA) or poor
specificity 3 (in the case of transglutaminase), the LplA labeling technology has no
intrinsic feature that would prohibit its use for intracellular protein labeling. In this
chapter we will introduce the biochemical properties of E coli LplA, discuss the
considerations that must be made for intracellular protein labeling, and then describe how
we have extended this robust cell-surface labeling method to intracellular protein
labeling.
Properties of E. coli lipoic acid ligase
Lipoic acid is an essential cofactor found in multi-enzyme complexes involved in
oxidative metabolism. Through the activity of lipoate protein ligases (Lpls), free lipoic
acid is covalently attached to a specific lysine residue of lipoyl domains in these
complexes4 . LplA is the lipoate protein ligase found in E coli and it catalyzes the ATP-
dependent ligation of lipoic acid in a two-step reaction. In the first step, LplA uses ATP
to activate lipoic acid, forming the lipoyl-AMP ester and releasing pyrophosphate. In the
second step of the reaction, the enzyme binds the protein substrate and the target lysine
residue attacks the adenylate ester, resulting in amide bond formation and covalent
attachment of lipoic acid to the lysine (Figure 2-1). The function of the resulting lipoyl-
lysine modification is to serve as a "swinging arm" that shuttles reaction intermediates
and reducing equivalents between the active sites of the enzyme subunits. While E coli
LplA can catalyze both the adenylation and the transfer of lipoic acid, most mammalian
Lpls6 -9 (and some non-mammalian Lpls)10-16 can catalyze only the transfer step. In these
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systems, a separate enzyme, lipoate activating enzyme (LAE), is required to produce the
adenylate ester prior to the action of the Lpl enzyme7.
In E coli there are three protein substrates that must be lipoylated for function:
the E2 dihydrolipoamide acetyltransferase subunit (E2p) of pyruvate dehydrogenase
(PDH), the E2 dihydrolipoamide succinyltransferase subunit (E2o) of 2-oxogluterate
dehydrogenase, and the H-protein of the glycine cleavage system. Mammals have an
additional lipoylated protein: the E2 acyltransferase subunit of the branched chain a-
ketoacid dehydrogenase. These protein substrates and analysis of Lpl sequence and
structure conservation between species will be discussed in depth in Chapter 4 of this
thesis.
E. coli
lipoic acid ligase (LpIA)
'NH3  HO 4H
+ ATP
LpIA-ipoyl-AMP
E2p lipoyl-E2p
Figure 2-1. The site-specific ligation of lipoic acid catalyzed by E. coli lipoic acid ligase. The
lipoylation of endogenous E. coli proteins is catalyzed by lipoic acid ligase (LpIA) in two distinct steps.
First, the enzyme uses ATP to activate the carboxylic acid of lipoic acid, producing the adenylate ester
(lipoyl-AMP). The enzyme then binds the protein substrate (here E2p, indicated in grey ribbon) and the
reactive lysine residue attacks the lipoyl-AMP resulting in amide bond formation and release of AMP.
Even though the endogenous abundance of LplA is extremely low (reported to be
as few as 10 copies per cell4 ), endogenous lipoyl domains in E. coli are nearly 100%
lipoylated4 , which could be explained by the fast kinetics of the lipoic acid ligation (kcat is
0.25 sec-')'. Since LplA plays a key role in the production of active enzyme complexes
involved in oxidative metabolism, it first appeared that LplA might be an essential
enzyme; however, LplA null strains are growth-competent and have the full complement
of lipoylated substrates4 . While LpIA uses exogenously supplied or scavenged lipoic acid
to lipoylate protein substrates, there is a complementary pathway in E coli that produces
lipoylated substrates using endogenously synthesized lipoic acid. In this pathway,
endogenously synthesized octanoic acid is first transferred from octanoyl-acyl carrier
protein onto the lipoyl acceptor protein by the enzyme LipB. Then LipA, an S-adenosyl
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methionine-dependent enzyme, acts on the octanoyl-protein substrate and inserts sulfur
atoms at the C6 and C8 positions of the octanoyl-lysine modification, producing the
lipoyllysine modification.
Considerations for intracellular labeling
As we have already mentioned, one feature that makes LplA such an attractive
candidate for an intracellular labeling method is its exquisite sequence specificity.
Another intriguing feature is the ability of WTLplA to catalyze the ligation of other
substrates such as selenolipoic acid, octanoic acid, and the unnatural azidoalkanoic acid
substrates that we use for cell surface protein labeling"4 "7 (Figure 2-2). While BirA is also
highly sequence specific, it is not permissive in terms of small-molecule substrates, only
ligating biotin or a ketone isostere of biotin, neither of which is applicable to live-cell
intracellular labeling.
A
q 0
HO HOHO
S HOS
lipoic acid octanoic acid 8-methyl lipoic acid
HO HOHON
SH SHO
6-thiooctanoic acid selenolipoic acid w-azido carboxylic acid (Azide 7)
B
F
N F N HO HOOHHO' HI HO"' I HOaF N3  H
6,8-fluorine-7-hydroxycoumarin derivative benzophenone carboxylic acid 7-hydroxycoumarin (coumarin 4)
C
H HO 2 HO
FHF 00H NH2  0 0 OH
6,8-fluorine-7-hydroxycoumarin derivative 7-aminocoumarin resorufin derivative
HN
HON HO NH
_O N _N3
transcyclooctene carboxylic acid picolyl azide derivative (pAz 4)
Figure 2-2. Range of substrates incorporated by WTLpIA or a mutant. (A) Structures of lipoic acid
analogues and probes ligated by WTLpIA in vitro or on the cell surface. (B) Structures of useful probes that
had been ligated by LpIA mutants in vitro or on the cell surface before starting the intracellular labeling
project. (C) Structures of probes incorporated by LplA mutants since the publication of the intracellular
labeling paper.
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The versatile two-step cell-surface protein labeling method previously developed
by our lab allows for the incorporation of virtually any fluorophore or reporter (Figure 2-
3, middle). However, we recognized that extending this two-step labeling scheme to
intracellular protein labeling presented several challenges. First, the sensitivity of the
labeling would be limited by the kinetics of the [3 + 2] strain-promoted cycloaddition,
which has a rate constant of 4.3 x 10-3 M-1sec-' 18. Second, performing a two-step labeling
protocol inside cells would require two washout steps, first to remove any unligated azide
and then to wash out excess cyclooctyne-fluorophore conjugate. Third, and perhaps most
importantly, preliminary attempts at intracellular azide labeling indicated that azide 7
labeling with wild-type LplA was nonspecific inside living cells (data not shown). While
the two-step labeling protocol was eventually extended to site-specific intracellular live-
cell labeling in beautiful work done by Jen Yao 1, we decided to explore a simpler one-
step fluorophore ligation scheme for the first inroads into intracellular protein labeling.
The first concern with this plan was that fluorophores applicable to live-cell
imaging20 are much larger than any substrate WTLplA had previously been shown to ligate
(Figure 2-2A). Fortunately, as we began the work described in this chapter, Dr. Hemanta
Baruah demonstrated that a mutant of LplA could accept and ligate a larger arylazide
photocrosslinker with no change in sequence specificity2 1 . This was an encouraging result
because it indicated that larger small molecule substrates might be incorporated with
some engineering of the enzyme's substrate binding pocket. With this information, we
settled on a 7-hydroxycoumarin as our target fluorophore for this project. This blue
fluorophore was selected because it is one of the smallest fluorophores suitable for live-
cell imaging. We also hypothesized that its small size and hydrophobicity would make it
a good substrate for LplA. While the photophysical properties of 7-hydroxycoumarin are
not ideal (c = 36,700 M- cm- and QY 0.7)22 it is brighter than EBFP (c = 31,500 M-1 cm-
I and QY 0.2)23 and hundreds of times smaller. The goal is to engineer LplA to ligate the
fluorophore directly (Figure 2-3, bottom).
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Lipoic acid ligase
9H, (LpIA) HN 4
Lipoic acid, ATP
LpIA HN 0N
-0.^A # 7  H__ Y
Azide 7, ATP Cyclooctyne
H Mutant HN OH
Coumarin 4, ATP /.i 0
13-amino acid
LAP
Figure 2-3. Natural and engineered ligation reactions catalyzed by LpIA. Top row shows the natural
reaction catalyzed by LpIA. Middle row shows the cell-surface two-step probe targeting via alkyl azide 7
ligation followed by [3 + 2] cycloaddition. Bottom row shows proposed intracellular one-step 7-hydroxy
coumarin fluorophore ligation by a mutant LpIA. LAP = LpIA Acceptor Peptide.
We were also concerned that the kinetics of ligation onto the rationally designed
LplA Acceptor Peptide (LAP) would need to be improved in order to achieve fast and
specific intracellular labeling. While LAP (DEVLVEIETDKAVLEVP)' is labeled by
WTLplA with similar in vitro ligation kinetics to E2p (Az 7 kca, = 0.05 sec' for LAP1 vs.
0.11 sec- for E2p), the enzyme affinity for LAPI is very low (Km > 300 pM).
Unfortunately, with an affinity that low, it is likely that labeling of LAP1-tagged
intracellular proteins will not be highly sensitive. To address this, a higher affinity LAP
peptide (LAP2 = GFEIDKVWYDLDA) was evolved using yeast-display24 . This peptide
has similar lipoylation kinetics to the protein substrate (lipoic acid kca, = 0.2 sec' for
LAP2 vs. 0.25 sec-1 for E2p) but a much higher affinity (Km = 13 pM) compared to
LAP1.
In the results section of this chapter we describe the engineering of a blue
fluorophore ligase and its application to intracellular protein labeling of peptide-tagged
recombinant proteins. First, we present the structure-guided rational mutagenesis of LplA
to produce an enzyme that is capable of ligating a 7-hydroxycoumarin probe. Second, we
describe the in vitro characterization of this enzyme and confirmation of specificity on
mammalian cell lysate. Third, we describe the application of this enzyme to intracellular
protein labeling. Finally, we describe several shortcomings of this labeling method that
motivated the enzyme engineering work that is subsequently described in Chapters 5-7 of
this thesis.
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Results
Structure-guided mutagenesis and screening for a coumarinfluorophore ligase
Identification of Trp3 7 as a 'gatekeeper' residue
For the first stage of LplA engineering, we synthesized four 7-hydroxycoumarin
substrates with varying linker lengths (Figure 2-4). These probes were synthesized by
reacting succinimidyl 7-hydroxycoumarin-3-carboxylate with one of four amino alkanoic
acids (n =3, 4, 5, or 6). We performed an in vitro activity assay to determine if wild-type
LplA could accommodate any of these coumarin substrates. High performance liquid
chromatography (HPLC) was used to monitor the extent of ligation onto a 9kD hybrid
lipoyl domain from pyruvate dehydrogenase (E2p) 4. Using this assay, we determined that
the wild-type enzyme was unable to ligate any of the coumarin substrates.
HO 0 H 0 n=3-6
0 H2N KoH HO, N 0  0
TEA, 30 OC I -& H
0 O0 0
Figure 2-4. Synthesis of 7-hydroxycoumarin substrates with varying linker lengths.
This result is not surprising when we consider the crystal structure of E. coli LplA
bound to the lipoyl-AMP intermediate (PDB: 3A7R)25 (Figure 2-5). Note that the
dithiolane ring of the bound lipoyl-AMP is located at the very end of the hydrophobic
binding tunnel and there is not much room deeper into the existing binding pocket. We
proposed mutating LplA residues that were in close proximity to the dithiolane ring of
lipoyl-AMP in order to expand the binding pocket and better accommodate the larger,
two-ring coumarin structure (Figure 2-5, left). To that end, we selected thirteen residues
within 7.5A of the dithiolane moiety of lipoic acid: N16, L17, V19, E20, F35, W37, S71,
S72, H79, T87, R140, H149 (shown in green stick in Figure 2-5). We made LplA point
mutants wherein each of these residues was mutated to alanine and then screened these
alanine point mutants for ligation activity using the two smaller 7-hydroxycoumarin
substrates (n = 3, 4). Of the thirteen alanine point mutants tested, only W37A produced
detectable coumarin-E2p ligation product. This result makes sense given the orientation
of W37 (shown in red stick in Figure 2-5) at the end of the lipoate binding pocket and
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given its close proximity to the dithiolane ring (3.6A). Interestingly, the W37 residue of
LplA was also identified in the engineering of the aryl azide ligase as the position most
important in expanding substrate specificity of LplA . Since mutations at W37 seem to
open the door to new and useful probe ligation using LplA, we call W37 the "gatekeeper"
residue.
HO lipoic acid
f7-hydroxy
HO'?N _ __ coumarin /
ipoyl-AMP
E. col lipoic acid ligase with bound lipoyl-AMP
Figure 2-5. LpIA active site residues selected for mutagenesis. Residues within 7.5A of the dithiolane
ring of lipoyl-AMP are rendered in green or red stick. These residues were mutated to alanine in the initial
screen in order to expand the binding pocket to accommodate the larger coumarin structure (left). Trp37,
indicated in red, was identified as the gatekeeper residue. This image was generated from the original PDB
file (3A7R)25 using PyMol software.
Secondary screen of Trp37 mutants identifies two coumarin ligases
While coumarin ligation with W37ALplA was detectable in short in vitro reactions,
we wondered whether different mutations at the gatekeeper residue might further
improve coumarin ligation activity. To that end, we prepared a panel of LplA mutants
wherein W37 was mutated to all possible amino acids. We screened this panel of W37
point mutants against the four 7-hydroxycoumarin probes (Figure 2-6A). When we had
completed analysis of the enzyme/probe matrix, we noticed some clear trends in the
coumarin ligation activities of these mutants. There were 11 inactive mutants that
exhibited no labeling of E2p in the in vitro screen. These inactive enzymes were ones
where W37 had been mutated to charged residues (K, R, D, E), bulky residues (F, Y, N,
Q, M, H), or proline (P). It is likely that large groups at the W37 position are not able to
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accommodate even the shortest coumarin probes, while charged residues may interfere
with binding of the hydrophobic coumarin probe.
W37 mutant
GASCTLIVPNDQKEMHFRY
It
Activity
H nOH
0
LpIA mutant % Conversion
with Coumarin 4
W37V 100± 8.3
W371 27.9 ± 5.6
W37A 15.5 ± 2.8
W37L 5.9 ± 1.1
W37G < 2
W37S < 2
W37C < 2
W37T < 2
Figure 2-6. wmLpIA and wr7LpIA are identified as the best coumarin ligases. Assays were performed
for 12 hours using the indicated probes and mutants. Production of the coumarin-E2p conjugate was
monitored by HPLC. Array shows relative activities of W37 Lp1A mutants with 7-hydroxycoumarin
substrates, black quadrants indicate that no product was detected. Active ligases were subsequently
screened for coumarin 4 LAP4.3D peptide in a 40-minute labeling protocol. Table shows quantification of
coumarin 4 ligation onto LAP4.3D. Assay performed in triplicate, errors ± 1 s.d.
Eight mutants demonstrated activity for coumarin ligation onto E2p in this screen.
Without exception, these mutants preferred the smaller coumarin substrates (n = 3, 4) and
very little product was seen with the longer substrates. This indicates that there is a limit
to how much we can enlarge the binding pocket using gatekeeper mutations and also
suggests that engineering LplA to incorporate fluorophores larger than coumarin will
require additional mutations to carve out even more space in the enzyme. Interestingly,
simply enlarging the binding pocket of LplA by mutating the gatekeeper residue to the
smallest residues (alanine and glycine) did not actually produce the highest coumarin
ligation activity; we found that mutations with intermediate-sized hydrophobic side
chains such as isoleucine and valine gave the biggest activity increase. We hypothesize
that these side chains are best able to complement the size and hydrophobicity of the
coumarin probe. This trend of increased ligation activity with hydrophobic residues
suggests that the ligase actually binds the neutral form of 7-hydroxycoumarin, rather than
the deprotonated form (pKa =7.5)22.
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To better distinguish between the activities of the eight active mutants, we
performed a secondary screen for coumarin 4 (n=4) ligation activity where we replaced
the E2p protein substrate with one of the evolved LAPs fused to the carrier protein HP 1
(LAP4.3D = GFEHEKVWYDLDA) . Note that we chose LAP4.3D as opposed to the
best yeast-evolved peptide (LAP2 = GFEIDKVWYDLDA) simply because it gives
superior chromatographic traces on HPLC when fused to the carrier protein HP 1, making
product conversion easier to quantify. The results of this more stringent labeling protocol
can be found in the table in Figure 2-6. Although W37vLplA is by far the best ligase in
vitro, we had some evidence that intracellular expression of W37vLplA might be
problematic; Marta Fernandez-Suarez had demonstrated that W37vLplA, when expressed
as a fusion to the fluorescent protein mCherry, was prone to aggregation inside
mammalian cells (data not shown). Primarily because of this issue, we decided to carry
both W37vLplA and W371LplA through for further in vitro characterization and downstream
testing in mammalian cells.
In vitro characterization of coumarin ligases
WLp1A and WmLplA catalyze fast and specific covalent ligation of coumarin onto LAP2
We first characterized the coumarin ligation in vitro. Using our most kinetically
efficient LAP2 peptide, we performed in vitro coumarin 4 ligation reactions with
W37vLplA and W371LplA. Figure 2-7A shows that both W37vLplA and W371Lp1A covert
LAP2 to LAP2-coumarin in a 20-minute labeling protocol. The LAP2-coumarin 4
covalent conjugate was verified via mass spec (Figure 2-7B). Controls where ATP is
omitted or wild-type LplA is used demonstrate that the coumarin ligation is ATP-
dependent and requires the specific mutation we have introduced into the enzyme.
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Figure 2-7. In vitro characterization of coumarin ligases. (A) HPLC traces showing conversion of LAP2
peptide to the LAP2-coumarin conjugate with w37vLpIA and W37 LplA. Negative controls are shown whereWTLplA is used or ATP is omitted. (B) Starred peaks in (B) were collected and analyzed via mass
spectrometry, confirming the identity of the LAP2-coumarin conjugates.
We next characterized the kinetics of coumarin ligation (Figure 2-8). For
W37vLp1A we obtained a kcat of 0.019 * 0.004 sec' and a K, of 56 ± 20 gM. While
W37 ILplA has a similar kcat (0.016 ± 0.002 sec'), we found it has a much higher Km of
261 ± 69 gM. While the calculated coumarin kca, values are poor compared to the wild-
type lipoylation reaction1,4,24,26 and even some of the unnatural substrates'' 2 1 , the
coumarin Km for w37vLplA compares favorably to previous K values for unnatural
probes '2 1(Table 2-1). For comparison, wild-type LplA has a catalytic efficiency (kcaI/Km)
of 1.2 x 105 while Wn7vLplA has a catalytic efficiency of 3 x 102.
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Figure 2-8. Kinetics of coumarin ligation with W3 7VLplA and Wa7 LplA. Michaelis-Menten curves give
kca, and Km, values for coumarin 4 ligation with W37vLplA (left) and W37 LpIA (right). Curves were generated
from HPLC measurements of initial rates (Vo) using 2 IM enzyme, 150 pM LAP2 and coumarin 4
concentrations ranging from 12.5 and 1,600 pM. Plots were made using Origin 6.1 software. Error bars ± I
s.d.
Probe kcat(seC- 1) Km (pM) LpIA mutant Acceptor Reference
sequence
lipoic acid 4.5 wild-type H-protein [11]
lipoic acid 1.7 wild-type PDH* [4]
lipoic acid 0.25 wild-type E2p [1]
lipoic acid 0.22 wild-type LAP2 [24]
alkyl azide 7 0.111 127 ±11 wild-type E2p [1]
alkyl azide 7 0.048 wild-type LAPI [1]
aryl azide 0.31 <80 W37V LAP1 [21]
coumarin 4 0.019 56 ± 20 W37V LAP2 (this work)
cou vharin 4 0.016 261 ± 69 W37i LAP2 mains
*Pyruvate dehydrogenase: protein substrate for LpIA with 3 E2p domains
O S-
HO
Lipoic acid
0
HO eN37
Aikyl azide 7
0 0 F
HO N O F FH I
F N3
F
Aryl azide
0 H OH
HORN -
C 0Coumnarn 4
Table 2-1. Comparison of kinetic constants for ligation of lipoic acid and unnatural probes using
LpIA and mutants
Coumarin ligases are site-specific and do not recognize endogenous mammalian proteins
It was unclear whether or not remodeling the binding pocket of LplA would affect
its protein and peptide substrate specificity. To probe this issue, we tested the specificity
of both W37vLplA and W37 LplA on mammalian cell lysates. First we created a LAP2
fusion to yellow fluorescent protein (YFP) and expressed it in human embryonic kidney
(HEK) cells. HEK lysates were prepared and then labeled with coumarin 4, ATP, and
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either W37VLplA or w37 LplA. We then analyzed these samples by in-gel coumarin
fluorescence. Figure 2-9 shows that even in the presence of thousands of other
mammalian proteins in the cell lysate, only LAP2-YFP is labeled by coumarin (Lane 1
and 4). To confirm site-specificity we performed labeling on HEK lysate from cells
expressing LAP2(ala)-YFP wherein the lysine modification site of LAP2 is mutated to an
alanine and this abolishes labeling (Lane 2 and 5). This demonstrated that coumarin
labeling is site-specific and no endogenous mammalian proteins are labeled with
coumarin. We were somewhat surprised at the lack of background, given that there are
four endogenous substrates for mammalian Lpl and LplA has been demonstrated to cross-
react with substrates from other species4 ,2 7 ,2 8 . Based on our data, we hypothesized that
mammalian Lpl substrates present in the lysate are not labeled with coumarin because
labeling sites are already saturated with lipoic acid. To test this hypothesis, we performed
anti-lipoic acid western blotting of the samples (Figure 2-9, bottom). We found that while
the endogenous lipoylated protein substrates of mammalian Lpl are present, in vitro
lipoylation of the lysate does not increase lipoylation level of these proteins.
vv37vLplA WILplA wild-type LpIA
LAP2-YFP + - - + - + +
LAP2(K--A)-YFP . + + - -
Coumarin 4 + + + + + + + -
Lipoic acid - - - - - - - +
Lane 1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 882 gmuumDuu
37 kD -
26 kD - IOP
19 kD - 'as
15 kD - Coomassie - Coumarin fluorescence -
1 2 3 4 5 6 7 8
82 kD - Endogenous
4kD. J lipoylated proteins
37 kD - LAP2-YFP
Figure 2-9. Coumarin labeling is site-specific on Anti-lipoic acid blot mammalian
cell lysate. Lanes 1 and 4 show specific labeling of LAP2-YFP in HEK cell lysate monitored by in-gel
coumarin fluorescence. Negative controls are shown for coumarin labeling on cells expressing LAP2(ala)-
YFP (lanes 2 and 5), untransfected lysate (lanes 3 and 6) and using TLp1A, The samples were also
analyzed by western blot using anti-lipoic acid antibody (bottom). Coomassie staining of the gel shows all
proteins present in the lysate.
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Optimizing conditions for intracellular protein labeling
In order to extend this robust in vitro coumarin labeling method to intracellular
labeling, several considerations must be made (Figure 2-10). First we must co-express the
enzyme and LAP2-fused substrate inside mammalian cells. Second, we must deliver the
coumarin probe across the cell membrane and then washout excess unligated probe. Note
that we can rely on endogenous ATP for the ligation, since ATP is present in millimolar
concentrations inside the cell. Third, we needed to test the evolved LAP peptides in an
intracellular context and select the best sequence for coumarin labeling. While LAP2 is
the most kinetically efficient peptide in vitro, it was not inevitable that it would be best
for intracellular applications; for example, we have determined that LAP4.2 gives the
best surface expression and that LAP4.3D is the best-behaved for in vitro analysis as a
fusion.
coumnarin coumnarin
ligase 1. 20 pM coumarin-AM 2, ligase
10 min
0
cellN3 aAP2. Wash out excess,
cell 030 min - 1 hour
interior LAP LAP
Figure 2-10. Scheme for intracellular coumarin labeling. First, the coumarin ligase and LAP-tagged
protein of interest must be co-expressed inside living cells. Then we must deliver the coumarin probe
across the cell membrane. After labeling, we must be able to remove excess unligated coumarin in order to
observe specific labeling.
Coumarin-AM2 is cell permeable and has clean washout from cells
We first tackled the issue of probe delivery. Since the coumarin 4 probe has 1-2
charges at physiological pH, it cannot cross the cell membrane. To achieve intracellular
delivery we protected the carboxylate and 7-hydroxy group with acetoxymethyl groups,
which have been shown to be cleaved by endogenous esterases in mammalian cells2 . Tao
Uttamapinant synthesized the protected coumarin 4 probe (coumarin-AM 2; structure
shown in Figure 2-11) by reacting the 7-hydroxycoumarin probe with
bromomethylacetate to get nucleophilic substitution at both the carboxylate (coumarin-
AM) and, after an overnight reaction, substitution at the hydroxyl, giving the doubly-
protected coumarin-AM 2. We discovered that, while coumarin-AM was not membrane
permeable, coumarin-AM 2 entered cells readily (data not shown). We determined that
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after incubating HEK cells with 20 pM coumarin-AM 2 for just 10 minutes, intracellular
probe concentrations were >400 gM. This was reassuring because this concentration is
well above the calculated Km for either w37vLplA or W71LplA. We were also able to
achieve complete washout of the probe by replacing the media several times over 30
minutes.
HO, O0 0 O
0 + _ k-o -,-Ok
HO 0 0 AO Br 0
Coumarn-AM
4 OH DIEA, RT 0
0 0 0
0
Coumarin-AM2
Figure 2-11. Synthesis of coumarin-AM and cell-permeable coumarin-AM 2 probes.
WLP1A expression level must be controlledfor specific intracellular lipoylation
The next challenge was to achieve good expression of LplA inside mammalian cells.
As we mentioned above, we found that E. coli LplA did not express well, aggregating
inside cells when expressed as a fusion to mCherry and giving very low expression
otherwise (data not shown). However, we found that by using human-preferred codons
for LplA expression, we were able to see good intracellular expression of mCherry-LplA.
Encouraged by this, we decided to first test whether WTLplA could catalyze intracellular
lipoylation of E2p and LAP peptide substrates. We added lipoic acid to cells expressing
WTLp1A and either nuclear E2p (E2p-BFP-NLS) or nuclear LAPI (LAP1-BFP-NLS) and
incubated for several hours; we then fixed the cells and detected substrate lipoylation
using immunofluorescence staining (Figure 2-12A). We routinely use nuclear-targeted
substrates to have an internal control for specificity; if the enzyme is specific, we should
see only nuclear labeling. Unfortunately, we found that while lipoylation of E2p was
specific, there was non-specific labeling when using nuclear-targeted LAP1 and almost as
much signal when using LAP1(ala) where the target lysine has been mutated to alanine.
Through various optimizations we discovered that the nonspecificity towards the LAP1
peptide correlated with wTLplA expression level (data not shown). In order to achieve
specific lipoylation inside mammalian cells, we needed to control the expression level of
mCherry-WTLplA. For intracellular lipoylation, the non-specific labeling is such a
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problem that we needed to use tetracycline-controlled expression system to consistently
achieve the low expression required for specific labeling of LAP peptides (Figure 2-12B).
A B
Tetracycline
controlled
mCherry-LpA BFP + DIC mCherry-LpLA BFP
E2p-BFP-NLS
LAP1-BFP-NLS
LAP1(ala)-BFP
treated with 30pg/mL of tetracycline for 12 hours
Figure 2-12. Intracellular expression of wTLpIA must be controlled in order to achieve specific
lipoylation. (A) Intracellular non-specific lipoylation of E2p-BFP-NLS, LAP1-BFP-NLS and LAP1(ala)
when WTLplA is overexpressed. Lipoylation was performed in live cells and detected using
immunofluorescence staining post-fixation. (B) Specific lipoylation of E2p-BPF-NLS and LAP] -BFP-NLS
is achieved when using tetracycline-inducible expression plasmid (tet-controlled-WTLptA); under these
conditions, LAPI(ala) is not lipoylated.
WLPlA gives higher labeling and sensitivity but WLplA is the more specific ligase
The previous result was disheartening because we realize that when a labeling
method is restricted a particular cell line (in this case a stable cell line expressing the
tetracycline repressor) there is a huge barrier to adoption by outside labs; an example of
this is the limited use of DHFR labeling until the requirement for DHFR- cell lines was
relieved by trimethoprim derivatives' 3 '. Fortunately, when we tested the intracellular
expression of W37vLplA and W37LplA we found that these enzymes have lower intrinsic
intracellular expression than the wild-type ligase. More importantly, we were able to
control expression level of these enzymes by simply titrating the amount of plasmid we
transfected into the cells (Figure 2-13A). We therefore decided to test coumarin labeling
using both W37vLplA and W37LplA under high expression conditions (200 ng transfected
DNA) and low expression conditions (20 ng transfected DNA). For each of the four
experimental conditions we used LAP2-YFP substrate as a readout of specific labeling
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(Figure 2-13B, upper panels). We additionally tested each condition using LAP2(ala)-
YFP (Figure 2-13B, lower panels), which allowed us to compare specific vs. non-specific
labeling. With both ligases, we observed specific coumarin labeling of intracellular
LAP2-YFP at low expression levels. However, when overexpressed, we observed some
nonspecific labeling with W37vLp1A (Figure 2-13). We quantified the imaging data from
Figure 2-13B and plotted the ratio of coumarin labeling to LAP2-YFP or LAP2(ala)-YFP
expression in Figure 2-13C. From these plots, we concluded that w37vLplA gives the best
coumarin signal to background when its expression level could be controlled, but
W37 ILplA would be the preferred ligase when ligase overexpression cannot be avoided.
Our original hypothesis for the nonspecific coumarin signal observed with
W37 vLplA was that the enzyme might be retaining the coumarin-AMP ester in the active
site, as biotin ligase is known to do with biotin-AMP , which would result in increasing
background signal when the enzyme is over-expressed. This theory also explains why we
do not see this behavior with W371LplA, which has a much higher Km for coumarin. To
support this claim of non-covalent probe-AMP retention, we demonstrated that
nonspecific labeling follows the localization of over-expressed W37vLplA (Figure 12-14).
However, these results do not reveal whether the coumarin signal is due to
covalent enzyme self-modification or non-covalent probe retention. When we performed
in-gel fluorescence analysis on in vitro reactions with highly concentrated enzyme, we
found that there appeared to be covalent modification of the enzyme that was present
even after boiling the samples (Figure 12-15). We performed in-gel trypsin digest of the
samples and submitted the sample to mass spectrometry, hoping to determine whether the
enzyme was being self labeled at a specific residue or non-discriminately. However, the
data obtained from this experiment was inconclusive (data not shown). This curiosity was
not investigated further, since specific labeling was achieved with optimization of ligase
expression conditions.
60
Amount of transfected monLpA plasmid
0
U-
0O
0
E
E
B High W7LplA expression
(200 ng transfected DNA)
Counarin LAP2-YFP
LAP2
LAP2(K-+A)
C
Low vvLpA expression
(20 ng transfected DNA)
Coumarin LAP2-YFP
200 ng w7LplA
High W37'LpIA expression
(200 ng transfected DNA)
Coumarin LAP2-YFP
200 ng M7'LpIA
Low 37'LplA expression
(20 ng transfected DNA)
Couniarin LAP2-YFP
0 20000 40000 60000
YFP fluorescence (a.u.)
8
4 LAP2
I LAP2(K-+A) 120
E
00
20 ng wNLplA
20000 40000
YFP fluorescence (a.u.)
* LAP2(K-A)
- M LAP2(K-+A) 0
- E
0
-- -0
60000
20000
18000
16000
14000
12000
10000
8000
6000
4000
2000
0
20000 40000 60000
YFP fluorescence (a.u.)
20 ng M7'LplA
20000
18000
16000
14000
12000
10000
8000
6000
4000
2000
0
+ LAP2(K-A)
M LAP2(K-A)
0 20000 40000
YFP fluorescence (a.u.)
60000
Figure 2-13. Comparison of intracellular expression and coumarin ligation by w37V LpIA and
W LpIA. (A) Expression level of W37vLpIA can be controlled through plasmid titration (similar results for
W3 7 LpIA). (B) Images show coumarin labeling specificities at different enzyme expression levels.
Coumarin labeling signal is shown with LAP2-YFP (specific labeling) and LAP2(ala)-YFP (non-specific
labeling). (C) Quantification of imaging data in (B). Coumarin labeling intensity was plotted against YFP
intensity (reflecting LAP2 or LAP2(ala) expression level). Data shown for >60 cells for each condition.
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Figure 2-14. Non-specific coumarin signal follows wa7vLpIA expression pattern when the enzyme is
overexpressed. HEK cells expressing whole-cell LAP2(ala)-YFP were labeled using overexpressedW37vLplA targeted to the nucleus or the cytosol. Non-specific coumarin labeling pattern follows enzyme
expression level as detected by anti-FLAG staining after fixation.
w37vLpLA w37LplA
LAP2-HP1 - - + - - -
Enzyme (pM) 30 15 15 30 15 30
Cournarin 4 + + + + + +
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Figure 2-15. In-gel coumarin fluorescence indicates covalent coumarin self-labeling with high enzyme
concentrations. In vitro reactions containing 15 or 30 [tM of the indicated coumarin ligase, 150 pM LAP2-
HP1 (where indicated), 500 pM coumarin 4, and ATP were incubated for 3 hours. Reactions were
quenched, boiled, and run on an SDS-PAGE gel. Coumarin signal on W37vLp1A persists after boiling,
indicating a covalent modification with coumarin probe.
We next set out to determine which LAP peptide works best for intracellular
protein labeling applications. Although we had already demonstrated that LAP2 could be
labeled as a fusion to YFP, we compared the coumarin labeling signal obtained with the
protein substrate E2p with the four best LAP peptides from yeast-display evolution:
LAP4. 1, LAP4.2, LAP4.3D, and LAP2 . We expressed each substrate as a fusion to YFP
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along with coumarin ligase and then performed a 10-minute coumarin labeling protocol.
We analyzed the imaging data and plotted coumarin labeling vs. substrate expression
level (Figure 2-16). LAP2 was the only peptide that gave improved coumarin labeling
signal over E2p. Therefore, for all future applications of coumarin labeling, we used
LAP2 as the peptide tag.
Coumarin labeling of LAPs compared to E2p
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Figure 2-16. LAP2 gives best coumarin labeling signal in intracellular coumarin labeling assay. Ten-
minute coumarin labeling was performed in HfEK cells expressing E2p or one of the evolved LAP peptides
fused to YFP. For at least 50 single cells for each condition, coumarin labeling intensity was plotted against
YFP expression level. LAP2 was the only evolved peptide that gave improved coumarin labeling over E2p.
Characterization of coumarin labeling inside mammalian cells
We characterized intracellular coumarin labeling with W37vLp1A in HEK cells
expressing LAP2-YFP. We performed the labeling using just 10 minutes of incubation
with coumarin-AM2 followed by probe washout over an hour. Negative controls where
we mutate the target lysine residue of LAP2 or replace the coumarin ligase with WTLp1A
show no coumarin labeling (Figure 2-17A). These controls demonstrate that the
intracellular labeling is site-specific and dependent on the activity of our engineered
coumarin ligase. We also demonstrated specific coumarin labeling of LAP2 fusions
targeted to the nucleus, cytosol, and plasma membrane as well as LAP2 fused to MAP2
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(microtubule-associated protein 2) and the cytoskeletal proteins vimentin and p-actin
(Figure 2-17B). The LAP2 peptide is also transposable, being efficiently labeled at N-
terminal, C-terminal, and internal fusion sites. We also estimated the intracellular
coumarin ligation yield and determined that, using the standard 10 minute labeling
protocol, 25 ± 13% of LAP2-YFP was labeled; extending the labeling time to 1 hour
increased labeling yield to 53 ± 25%. We call this robust and generalizable intracellular
protein labeling method PRIME (PRobe Incorporation Mediated by Enzymes).
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Figre 2-17. Characterization of intracellular coumarin labeling of LAP2-tagged substrates using
wa LplA. (A) PRIME labeling of LAP2-YFP in live HEK cells. Negative controls using an alanine mutant
of LAP2 and wild-type LpIA are also shown. (B) PRIME labeling of different LAP2-tagged proteins in
living cells. NES = Nuclear Export Sequence. CAAX = Farnesylation motif. NLS = nuclear localization
sequence. MAP2 = Microtubule-associated Protein 2.
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Comparison of coumarin PRIME and FlAsH labeling methods
After we fully characterized our new PRIME labeling method inside living
mammalian cells, we wanted to compare this new method to existing intracellular protein
labeling methods. We argue that best comparison would be to FlAsH, as it is the only
existing labeling method that uses a small peptide tag and works inside cells33 3 4 . We
wanted to compare the methods in terms of specificity, sensitivity, toxicity, and overall
labeling time. In order to perform a direct comparison of the labeling methods, we
prepared a single nuclear-targeted construct containing LAP2, the optimized 12-amino
acid tetracysteine peptide (FLNCCPGCCMEP)34 and mCherry for visualization (Figure
2-18). Since both recognition peptides are localized to the nucleus, we can easily
distinguish and quantify specific (nuclear) labeling and nonspecific (cytosolic) labeling.
.. CC GCC...Fls
SP0 coumarin
FLAsH
Q coumarin
Figure 2-18. Scheme for direct comparison of PRIME and FlAsH labeling. Both peptide tags are fused
to a nuclear localized mCherry protein for visualization. Because both substrates are nuclear, specific
labeling with either method will result in nuclear signal in either coumarin (PRIME) or fluorescein (FlAsH)
channels. Any cytosolic signal is the result of non-specific labeling or dye retention.
For the specificity comparison, we transfected HEK cells with this construct as
well as W37vLplA and performed the standard 10 minute coumarin labeling protocol,
followed by 30 minutes of FlAsH labeling (standard labeling protocol 34). We found that
coumarin labeling was very specific, giving primarily nuclear labeling signal that co-
localized with substrate expression (Figure 2-19). With FlAsH labeling, on the other
hand, we observed two types of nonspecific labeling: untransfected cells labeled by the
FlAsH biarsenical dye (Figure 2-19, red arrows) and cytosolic background in cells
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expressing the nuclear-targeted substrate (white arrow). Note that we also tried the
reverse labeling protocol where we first perform FlAsH followed by coumarin labeling
and noted no difference in specific labeling intensities. Unfortunately, we found that the
FlAsH background was much higher when we followed with coumarin labeling (data not
shown), which we suspect is due to endocytosis of excess FlAsH dye during the
coumarin labeling 37*C incubation steps. For quantitative comparison of these imaging
data, we plotted the coumarin and fluorescein nuclear vs. cytosolic fluorescence
intensities for n = 225 individual cells (Figure 2-19B). A high nuclear to cytosolic ratio
indicates a highly specific labeling method, and from the plot we concluded that
coumarin labeling is more specific than FlAsH labeling.
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Figure 2-19. PRIME labeling is more specific than FlAsH labeling. (A) HEK cells expressing the
LAP2-Cys4-mCherry NLS were labeled with coumarin followed by FlAsH labeling. Red arrows indicate
untransfected cells with FlAsH dye retention. White arrows indicate transfected cells with obvious
cytosolic background. (B) Imaging data from (A) was processed and the nuclear vs. cytosolic labeling
intensities plotted for both coumarin and FlAsH for -275 single cells. A steeper slope indicates a more
specific labeling method.
We used the same imaging data to determine the sensitivity of the two labeling
methods. First, we used the wedge method33 to calculate the substrate concentration in
individual cells. We then were able to plot the signal/background ratio (from data in 2-
19C) vs. the substrate concentration (Figure 2-20A). For both coumarin and FlAsH
labeling, we can detect as little as 10 gM target protein with signal to noise >2:1. Finally,
we compared the toxicity of the two labeling protocols using an assay for mitochondrial
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respiration and determined that FlAsH is more toxic than PRIME labeling (Figure 2-
20B).
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[LAP2-Cys 4-mCherry] in cells, pM
% Viability
Condition Untransfected Transfected
Untreated 100 6 94 ± 4
10 min of 20 pM
coumarin-AM2 98 ± 5 94 ± 7
6 hr of 20 pM
coumarin-AM2 93 ± 6 88 ± 1
30 min of 2.5 pM
FlAsH-EDT2 92 ± 5 80 ± 8
6 hr of 2.5 pM
FlAsH-EDT2 82±5 71±8
2 hr of 100 mM
NaNs 73 ±3 69 ± 3
Figure 2-20. FlAsH and PRIME methodologies are similarly sensitive, but FlAsH is more toxic to
cells. (A) Intracellular substrate concentrations were estimated using the wedge method. For -50 single
cells the coumarin and FlAsH nuclear/cytosolic intensity ratios were plotted against the absolute
concentration of the mCherry-fused substrates. When substrate levels are >10 pM, both methods produce
labeling signal >2:1. (B) An assay for mitochondrial respiration showed that FlAsH is more toxic than the
PRIME methodology.
LplA has decreased activity in oxidizing compartments of the cell
PRIME labeling is the first intracellular protein labeling method that combines a
peptide tag with high specificity and fast labeling. While we demonstrated effective
coumarin labeling in the cytosol, nucleus, and at the plasma membrane of living cells, we
also wanted to test labeling of proteins expressed in the secretory pathway. However,
when we targeted the w37vLplA to the endoplasmic reticulum (ER) we did not see any
labeling of LAP2-YFP-ER or of LAP2 fused to a number of transmembrane proteins
(data not shown). We initially suspected that the coumarin-AM 2 probe concentration is
not high enough inside the ER to achieve good labeling; but we did not observe coumarin
labeling in the ER with increased the probe concentration or when we expressed esterases
targeted to the endoplasmic reticulum (data not shown). To determine whether the lack of
activity in the ER was probe-specific, we attempted lipoylation of a LAP2-tagged surface
protein using WTLplA targeted to the endoplasmic reticulum. The LAP2-fusion gets
lipoylated by ER targeted enzyme as it is being trafficked through the ER, and we can
detect the lipoylation using immunofluorescence at the cell surface. The extent of
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lipoylation using an ER targeted enzyme (Figure 2-21, bottom) is extremely low
compared to lipoylation with enzyme supplied exogenously (Figure 2-21, top).
E2 - FP-TM anti-LA/AF568 DIC AF 8 seudo
Exogenous
wTLpIA
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Figure 2-21. Lipoylation activity of WTLpIA is decreased in the endoplasmic reticulum. Top, LAP2-
CFP is expressed on the mammalian cell surface. When the LAP2 is lipoylated using purified wTLpIA,
lipoylation signal is extremely strong (top). When the LAP2 is lipoylated using ER-targeted WTLpIA as it is
trafficked to the cell surface, lipoylation is barely detectable (bottom).
This tells us that the inherent activity of LplA is decreased in the endoplasmic
reticulum. Since WTLplA has 6 cysteine residues, we hypothesized that aberrant disulfide
formation or disulfide-induced misfolding could reduce activity in oxidizing
compartments like the ER. However, when we made mutants of WTLplA wherein the
cysteine residues were mutated to serines, we did not see any improvements in ER
activity (data not shown). Another potential problem could be the high calcium
concentration in the ER, which we found inhibits LplA activity in vitro (data not shown).
Without fully understanding why LplA has decreased activity in the ER, and without
clear avenues for rational design, we decided to move forward with in vitro evolution to
select for a probe ligase with increased activity in the endoplasmic reticulum and other
oxidizing cellular compartments (described in Chapters 6-8).
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Conclusions
In this chapter we have described the rational engineering of a coumarin
fluorophore ligase and the development of an intracellular protein labeling method
(PRIME). The method is based on E. coli lipoic acid ligase, which had previously been
used by the lab as a method for cell-surface protein labeling with an alkylazide probe. For
intracellular labeling, we envisioned using direct ligation of a small coumarin
fluorophore. We used rational mutagenesis to engineer a coumarin binding pocket in the
enzyme and then confirmed that the ligation was still highly sequence specific both in
vitro and on mammalian cell lysate. After optimization of coumarin probe delivery,
intracellular enzyme expression, and selecting the best peptide tag, we were able to
achieve site-specific coumarin labeling of intracellular proteins.
This method was robust and sufficiently generalizable that we were able to label
proteins in multiple subcellular compartments. When compared to existing labeling
methods, the PRIME method uniquely provides the combination of a peptide tag, high
labeling specificity, and compatibility with intracellular labeling. However, there are two
fundamental problems with this intracellular labeling method. First, the coumarin ligation
kinetics are not optimal when compared to the endogenous reaction or even the ligation
of other unnatural probes. Second, we do not see unnatural probe ligation activity in
oxidizing compartments such as the endoplasmic reticulum. Attempts at correcting these
problems through rational design and mutagenesis were not successful. Therefore, we
used in vitro evolution techniques to select for ligases with not only better ligation
kinetics, but also improved activity in the secretory pathway. This work is presented in
Chapters 6-8 of this thesis.
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Experimental
Protein expression and purification.
LplA, E2p, and LAP-Heterochromatin Protein 1 (HP1) fusion proteins were
expressed in BL21-DE3 bacteria with IPTG induction as previously described"2 1 . After
Ni-NTA purification, LplA enzymes were stored in 20 mM Tris pH 7.5, 1 mM DTT and
10% glycerol in aliquots at -80 'C. E2p and LAP-HP1 proteins were stored in PBS pH
7.4. Protein concentrations were determined using the bicinchoninic acid assay (Pierce).
In vitro coumarin ligation reactions (Figure 2-6, 2-7)
General reaction conditions using purified proteins were as follows: 100-150 tM
LAP or E2p substrate was incubated with 1-2 iM LplA, 500 tM coumarin probe, 5 mM
ATP, and 5 mM Mg(OAc) 2 in 25 mM Na2HPO 4 pH 7.2 at 30 'C for various lengths of
time. Reactions were quenched with EDTA (Cf 100 mM) and analyzed on a Varian
Prostar HPLC using a reverse-phase C18 Microsorb-MV 100 column (250 x 4.6 mm).
Chromatograms were recorded at 210 nm. For analysis of E2p and LAP4.3D-HP1
(LAP4.3D sequence: GFEHEKVWYDLDA), we used a 20-minute gradient of 40-57%
acetonitrile in water with 0.1% trifluoroacetic acid at 1 ml/minute flow rate. Both E2p
and LAP4.3D-HP1 had retention times of 12 minutes, which increased to 15-16 minutes
after ligation to coumarin probes. For analysis of reactions using the LAP2 synthetic
peptide (GFEIDKVWYDLDA), we used a 10-minute gradient of 30-60% acetonitrile in
water with 0.1% trifluoroacetic acid at 1 ml/minute flow rate. Retention times are shown
in Figure 2-7. Percent conversions were calculated by dividing the product peak area by
the sum of (product + starting material) peak areas.
Initial alanine scanning was performed using lysate from bacterial cells
transformed with LplA expression plasmids. 5 ml cultures at OD600 of 0.5 were induced
with 424 iM IPTG for 4 hours, before harvesting and lysis in 100 1d BPER reagent
(Thermo Scientific). 10 [d bacterial lysate was incubated overnight at 30'C with 100 tM
E2p, 500 [tM probe, 5 mM ATP, 5 mM Mg(OAc) 2 in 25 mM Na2HPO4, and LplA
mutant/probe pairs giving any product were identified from HPLC analysis.
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Secondary screening of W37 LplA mutants was performed as follows. 2 tM
purified enzyme was combined with 100 tM E2p and incubated overnight under the
general reaction conditions. Mutant/probe pairs showing activity under these conditions
were assayed in a tertiary screen using 1 1iM purified enzyme, 100 tM LAP4.3D-HPl,
and a shorter reaction time of 40 minutes to distinguish the activity of different mutants.
The data from the secondary and tertiary screens were used to generate the activity matrix
shown in Figure 2-6; the percent product conversions from the tertiary screen are
presented in the table in Figure 2-6.
For Figure 2-7 5 tM LplA (W37V, W371, or wild-type) was combined with 500
tM coumarin 4 and 150 1tM LAP2 peptide, which was synthesized by the Tufts Peptide
Synthesis Core Facility, under the general reaction condition. Reaction time was 2 hours
at 30 0C.
Mass spectrometric analysis (Figure 2-7)
Starred peaks from HPLC traces shown were manually collected and injected onto an
Applied Biosystems 200 QTRAP mass spectrometer. The flow rate was 10 tl/min and
mass spectra were recorded under the positive-enhanced multi-charge mode.
Kinetic measurements (Figure 2-8)
Km and kcat values were determined using coumarin 4 probe and LAP2 peptide. 2 [M
W37VLplA or W371LplA was combined with 150 ptM LAP2, 1 mM ATP, and 5 mM
Mg(OAc) 2 in 25 mM Na2HPO 4 pH 7.2. Coumarin 4 concentration was varied between
12.5 and 500 ptM for the W37vLplA measurement, and between 16 and 1600 pM for
W371LplA. Small aliquots were removed at different time intervals from the reaction
mixture at 30'C and quenched with 100 mM EDTA (final concentration). The time
intervals, ranging from 1-192 minutes, were determined empirically for each coumarin 4
concentration, such that the product conversion at the final initial rate measurement for
each coumarin 4 concentration did not exceed 10%. Samples were analyzed by HPLC
using a LAP2 peptide gradient as described under "In vitro coumarin ligation reactions".
To compensate for differences in extinction coefficients of LAP2 and LAP2-coumarin 4
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conjugate, a calibration curve was obtained that correlated the ratio of integrated HPLC
peak areas of LAP2:LAP2-coumarin 4 conjugate to the actual peptide concentration ratio.
The amount of product obtained at each time point was plotted against time to obtain the
initial velocity (Vo) for each concentration of coumarin 4. Vo values were then plotted
against coumarin 4 concentration and fit to the Michaelis-Menten equation (Vo = Vmax
[coumarin 4 ]/(Km + [coumarin 4])), using Origin 6.1 software. From the Vmax value, kcat
was calculated using the equation Vmax = kcat [E]total.
Mammalian cell culture
HEK, HeLa, and COS-7 cells were cultured in Dulbecco's modified Eagle medium
(DMEM; Cellgro) supplemented with 10% v/v fetal bovine serum (FBS; PAA
Laboratories) at 37'C and under 5% CO 2. CHO Ki cells were cultured in DMEM
supplemented with 10% v/v FBS, 70 mg/l L-proline and 220 mg/l sodium pyruvate. NIH-
3T3 cells were cultured in DMEM supplemented with 10% v/v newborn calf serum
(PAA Laboratories) at 37 'C and under 5% CO2. For imaging, cells were plated as a
monolayer on glass cover slips. Adherence of HEK cells was promoted by precoating the
coverslip with 50 pg/ml fibronectin (Millipore).
Coumarin labeling of mammalian cell lysate (Figure 2-9)
HEK cells expressing LAP2-YFP (or LAP2(K-,A)-YFP) were lysed under hypotonic
conditions in 1 mM HEPES pH 7.5 with 5 mM MgCl 2, 1 mM phenylmethylsulphonyl
fluoride, and protease inhibitor cocktail (Calbiochem). After three cycles of freeze-thaw,
cells were mixed by vortexing for 2 minutes. Lysate was cleared by centrifugation and
stored in aliquots at -80 'C. To label with coumarin or lipoic acid, lysates were incubated
with 200 nM LplA, 500 tM coumarin 4 or 250 [tM lipoic acid, 1.5 mM ATP, and 5 mM
Mg(OAc) 2 in 25 mM Na2HPO 4 pH 7.2. After overnight incubation at 30 'C, reactions
were boiled in protein loading buffer containing 2-mercaptoethanol for 7 minutes, then
separated on a 12% SDS-PAGE gel. Coumarin fluorescence was visualized on an Alpha
Innotech Chemilmager 5500 instrument using 365 nm UV light for excitation.
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Western blotting of mammalian cell lysate (Figure 2-9)
Lysates were labeled with coumarin 4 or lipoic acid as described in the Main Methods,
boiled, run on a 12% SDS-PAGE gel, and transferred onto a nitrocellulose membrane.
The membrane was blocked with 3% BSA solution in TBS + 0.5% Tween-20 (TBS-T)
for 1 hour. For anti-lipoic acid blotting, the membrane was incubated with rabbit
polyclonal anti-lipoic acid antibody (Calbiochem) in 3% BSA in TBS-T at 1:1000
dilution for 40 minutes, followed by three five-minute washes with TBS-T. The
membrane was then incubated with anti-rabbit horseradish peroxidase conjugate (Bio-
Rad) in 3% BSA in TBS-T at 1:20000 dilution for 40 minutes, followed by washes with
TBS-T. The blots were developed using Supersignal West Femto substrate (Pierce) and
visualized on an Alpha Innotech Chemilmager 5500 instrument.
Fluorescence imaging
Cells were imaged in Dulbecco's Phosphate Buffered Saline (DPBS) in epifluorescence
or confocal modes. For epifluorescence imaging, we used a Zeiss AxioObserver inverted
microscope with a 40x or 63x oil-immersion objective. Coumarin (400/20 excitation, 425
dichroic, 435/30 emission), YFP (493/16 excitation, 506 dichroic, 525/30 emission),
mCherry (570/20 excitation, 585 dichroic, 605/30 emission) and differential interference
contrast (DIC) images were collected and analyzed using Slidebook software (Intelligent
Imaging Innovations). For confocal imaging, we used a Zeiss Axiovert 200M inverted
microscope with a 40x oil-immersion objective. The microscope was equipped with a
Yokogawa spinning disk confocal head, a Quad-band notch dichroic mirror
(405/488/568/647), and 405 (diode), 491 (DPSS), and 561 nm (DPSS) lasers (all 50
mW). Coumarin (405 laser excitation, 445/40 emission), YFP (491 laser excitation,
528/38 emission), mCherry (561 laser excitation, 617/73 emission), and DIC images were
collected using Slidebook software. Fluorescence images in each experiment were
normalized to the same intensity ranges. Acquisition times ranged from 10-1000
milliseconds.
General protocol for coumarin PRIME labeling in living cells. (Figure 2-13, 2-16, 2-
17) HEK cells were transfected at ~70% confluency with expression plasmids for
73
W37VLplA (20 ng for a 0.95 cm 2 dish) and the E2p, LAP4.x or LAP2 fusion protein of
interest (400-600 ng) using Lipofectamine 2000 (Invitrogen). 8-24 hours after
transfection, cells were incubated with 20 pM coumarin-AM 2 in serum-free DMEM
(Dulbecco's modified Eagle medium, Cellgro) for 10 minutes at 37 'C. Note: 0.1% w/v
Pluronic F- 127 (Invitrogen) can be optionally added to the labeling solution to give more
even coumarin distribution in cells. The media was then replaced 3-4 times over 30-60
min at 37 'C, with DMEM supplemented with 10% FBS (Fetal Bovine Serum), to wash
out excess coumarin.
For Figure 2-16, HEK cells were transfected and labeled with coumarin as
described above. Using Slidebook software, the average mean fluorescence intensity for
each imaging channel was determined for >60 single cells for each condition. Plots show
coumarin labeling intensity plotted against YFP intensity (reflecting substrate-YFP
expression level) for >60 single cells.
Comparison of W37vLpIA and W371LplA labeling specificity in cells (Figure 2-13)
The indicated quantities of FLAG-W37vLplA or FLAG- W371LplA plasmid DNA (plus 400
ng LAP2-YFP DNA or LAP2(K-+A)-YFP) were transfected into HEK cells. Coumarin
labeling was performed as previously described. Epifluorescence images were taken at
40x magnification. Using Slidebook software, the average mean fluorescence intensity
for each imaging channel was determined for >60 single cells for each condition. Plots
show coumarin labeling intensity plotted against YFP intensity (reflecting LAP2-YFP or
LAP2(K-*A)-YFP expression level) for >60 single cells.
Determining source of background coumarin labeling (Figure 2-14)
HEK cells were transfected with either 200 ng of W37vLplA alone or co-transfected with
400 ng of LAP2-YFP or LAP2(K-*A)-YFP. Coumarin labeling was performed as
previously described. Plots show quantification of coumarin labeling vs. YFP expression
from average mean fluorescence intensities, which were collected using Slidebook
software as described above.
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Images show HEK cells that were transfected with 200 ng of W37vLplA targeted to
the nucleus or the cytosol. Where indicated, enzymes were co-transfected with
LAP2(K-A)-YFP. After coumarin labeling was performed, cells were fixed were fixed
using 3.7% formaldehyde in DPBS followed by cold precipitation with methanol.
Subcellular localization of FLAG-tagged LplA was confirmed using immunofluorescence
staining with 4 pg/ml anti-FLAG M2 antibody (Stratagene) in 1% BSA in DPBS for 30
minutes. After 15-minute washes, cells were incubated with 4 ptg/ml goat anti-mouse
antibody conjugated to Alexa Fluor 568 (Invitrogen) in 1% BSA in DPBS for 30 minutes,
then washed and imaged.
Quantification of labeling yield
HEK cells were transfected with w37vLplA or w371LplA and LAP2-YFP plasmids as
described. 12 hours after transfection, cells were labeled with coumarin-AM 2 as
described above for 10 or 60 minutes. After washing, epifluorescence images were
acquired in DPBS at 40x magnification. We used the "wedge method" 33 to estimate
absolute concentrations of coumarin and LAP2-YFP inside single cells. A wedge-shaped
microchamber was constructed from three glass coverslips. The length along the x
direction was 5 mm and the height of the chamber (z-direction) increased linearly from 0
to 150 pm. The chamber was filled with 9 [tM purified YFP and 12 ptM purified LAP2-
coumarin-4 conjugate in PBS pH 7.4. The fluorescence of the wedge was imaged under
conditions identical to those used for cellular imaging. We assumed an average cell
thickness of 5 pm and therefore interpolated to the region of the wedge with thickness of
5 pm and used YFP and coumarin fluorescence intensities measured there as reference
standards for their concentrations in single cells. The ratio [coumarin]/[LAP2-YFP]
represented coumarin ligation yield in cells. Data for each enzyme and coumarin
incubation time (10 or 60 minutes) were obtained from ~40 cells.
Intracellular FlAsH and coumarin labeling (Figure 2-19)
HEK cells were co-transfected with LAP2-Cys 4-mCherry-NLS and W37LplA. 24 hours
after transfection, cells were labeled with coumarin-AM 2 for 10 minutes as described
above. After five washes in growth medium, cells were cooled to room temperature, and
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labeled with 2.5 pM FlAsH-EDT2 (Invitrogen) for 30 minutes at 25 'C in serum-free
DMEM. The cells were rinsed twice with 250 pM BAL wash buffer (Invitrogen).
Labeled cells were imaged in epifluorescence mode, as described above (FlAsH filter set:
493/16 excitation, 488 dichroic, and 525/30 emission).
Comparison of labeling specificities (Figure 2-19)
Images obtained as described above were analyzed as follows. Cells with signal to
background ratio >2 (in the fluorescein or coumarin channel) were selected for analysis.
For each of these cells, two regions of interest (ROIs) were selected, one in the nucleus
and one in the cytosol. The background-corrected mean fluorescence intensity was
determined for each ROI using Slidebook. Excel was used to plot the nuclear versus
cytosolic fluorescence intensity for each cell, in the FlAsH or coumarin channel. We note
that background FlAsH labeling in the cytosol was still observed when we increased the
wash time from 30 minutes to 1.5 hours.
Quantification of labeling sensitivities (Figure 2-20)
Images obtained as described above were analyzed as follows. We used the "wedge
method"33 to estimate absolute concentrations of intracellular LAP2-Cys 4-mCherry-NLS.
A wedge-shaped microchamber was constructed from three glass coverslips. The length
along the x direction was 5 mm and the height of the chamber (z-direction) increased
linearly from 0 to 150 pm. The chamber was filled with 20 pM purified mCherry protein
in PBS pH 7.4. The fluorescence of the wedge was imaged under conditions identical to
those used for cellular imaging. We assumed an average cell thickness of 5 pm and
therefore interpolated to the region of the wedge with thickness of 5 pm and used
mCherry intensities measured there as reference standards for the concentration in single
cells. Intracellular LAP2-Cys 4-mCherry-NLS concentrations ranged from 3 pM to >1
mM. To analyze coumarin labeling, cells showing coumarin signal to background
(background from untransfected cells) >3:1 were selected for analysis. To analyze FlAsH
labeling, cells were selected with signal to background (from untransfected cells) >3:1 in
both the fluorescein and mCherry channels, to exclude untransfected cells that were non-
specifically labeled by FlAsH. For each cell, the background-corrected nuclear/cytosolic
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intensity ratio was calculated using Slidebook. Excel was used to plot these ratios as a
function of intracellular mCherry concentration.
Determination of labeling toxicity (Figure 2-20)
HEK cells were analyzed in 96-well plates. Transfected cells expressing W371Lp1A and
LAP2-Cys 4-mCherry-NLS were labeled 24 hours post-transfection using the protocols
described above. Sodium azide treatment was performed at 37 'C. After two washes in
fresh growth medium, cells were incubated with 0.5 mg/ml MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) for 40 minutes at 37 'C.
Medium was removed and precipitate was resuspended in 200 piL DMSO. Absorbance
measurements were taken at 570 nm (reference wavelength 670 nm) using a Tecan
SAFIRE platereader. Measurements were performed in triplicate. Errors, ± 1 s.d.
Comparison of LplA lipoylation activity in ER and on cell surface (Figure 2-21)
HEK cells were transfected with 600 ng of E2p-CFP-TM and 600 ng of either
WTLplA-NXN (for cis labeling) or WTLplA-ER (for ER labeling). 12 hours post-
transfection cells were labeled in three different ways for comparison: exogenous
lipoylation, cis lipoylation and ER lipoylation. For ER lipoylation, cells were incubated
with 250 pM lipoic acid for 1 hour, relying on endogenous ATP for lipoylation. For cis
lipoylation, cells were incubated with 250 pM lipoic acid, 5 mM Mg(OAC) 2, and 1 mM
ATP for 1 hour. For exogenous lipoylation, cells were incubated with 250 pM lipoic acid,
5 mM Mg(OAC) 2, 1 mM ATP, and 5 p.M WTLplA. For all samples, cells were washed 2 x
10 minutes with DMEM and then lipoylation was detected via live-cell antibody staining.
Live-cell immunofluorescence staining was performed with 4 ptg/ml anti-lipoic acid
antibody (CalBiochem) in 1% BSA in DPBS for 15 minutes. After three quick washes,
cells were incubated with 4 gg/ml goat anti-rabbit antibody conjugated to Alexa Fluor
568 (Invitrogen) in 1% BSA in DPBS for 15 minutes, then washed and imaged.
77
References
1. Fernandez-Suarez, M., et al. Redirecting lipoic acid ligase for cell surface protein
labeling with small-molecule probes. Nat Biotechnol 2007, 25, 1483-7.
2. Chen, I.; Howarth, M.; Lin, W.; Ting, A. Y. Site-specific labeling of cell surface
proteins with biophysical probes using biotin ligase. Nat Methods 2005, 2, 99-
104.
3. Lin, C. W.; Ting, A. Y. Transglutaminase-catalyzed site-specific conjugation of
small-molecule probes to proteins in vitro and on the surface of living cells. JAm
Chem Soc 2006, 128, 4542-3.
4. Green, D. E.; Morris, T. W.; Green, J.; Cronan, J. E., Jr.; Guest, J. R. Purification
and properties of the lipoate protein ligase of Escherichia coli. Biochem J 1995,
309 (Pt 3), 853-62.
5. Cronan, J. E.; Zhao, X.; Jiang, Y. Function, attachment and synthesis of lipoic
acid in Escherichia coli. Adv Microb Physiol 2005, 50, 103-46.
6. Fujiwara, K.; Okamura-Ikeda, K.; Motokawa, Y. Cloning and expression of a
cDNA encoding bovine lipoyltransferase. J Biol Chem 1997, 272, 31974-8.
7. Fujiwara, K.; Takeuchi, S.; Okamura-Ikeda, K.; Motokawa, Y. Purification,
characterization, and cDNA cloning of lipoate-activating enzyme from bovine
liver. JBiol Chem 2001, 276, 28819-23.
8. Fujiwara, K., et al. Crystal structure of bovine lipoyltransferase in complex with
lipoyl-AMP. JMol Biol 2007, 371, 222-34.
9. Fujiwara, K., et al. Molecular cloning, structural characterization and
chromosomal localization of human lipoyltransferase gene. Eur J Biochem 1999,
260, 761-7.
10. McManus, E.; Luisi, B. F.; Perham, R. N. Structure of a putative lipoate protein
ligase from Thermoplasma acidophilum and the mechanism of target selection for
post-translational modification. JMol Biol 2006, 356, 625-37.
11. Kim, D. J., et al. Crystal structure of lipoate-protein ligase A bound with the
activated intermediate: insights into interaction with lipoyl domains. J Biol Chem
2005, 280, 38081-9.
78
12. Posner, M. G.; Upadhyay, A.; Bagby, S.; Hough, D. W.; Danson, M. J. A unique
lipoylation system in the Archaea. Lipoylation in Thermoplasma acidophilum
requires two proteins. FEBS J2009, 276, 4012-22.
13. Christensen, Q. H.; Cronan, J. E. The Thermoplasma acidophilum LplA-LplB
complex defines a new class of bipartite lipoate-protein ligases. J Biol Chem
2009, 284, 21317-26.
14. Allary, M.; Lu, J. Z.; Zhu, L.; Prigge, S. T. Scavenging of the cofactor lipoate is
essential for the survival of the malaria parasite Plasmodium falciparum. Mol
Microbiol 2007, 63, 1331-44.
15. Gunther, S.; McMillan, P. J.; Wallace, L. J.; Muller, S. Plasmodium falciparum
possesses organelle-specific alpha-keto acid dehydrogenase complexes and
lipoylation pathways. Biochem Soc Trans 2005, 33, 977-80.
16. Kang, S. G.; Jeong, H. K.; Lee, E.; Natarajan, S. Characterization of a lipoate-
protein ligase A gene of rice (Oryza sativa L.). Gene 2007, 393, 53-61.
17. Zhao, X.; Miller, J. R.; Jiang, Y.; Marletta, M. A.; Cronan, J. E. Assembly of the
covalent linkage between lipoic acid and its cognate enzymes. Chem Biol 2003,
10, 1293-302.
18. Agard, N. J.; Baskin, J. M.; Prescher, J. A.; Lo, A.; Bertozzi, C. R. A comparative
study of bioorthogonal reactions with azides. ACS Chem Biol 2006, 1, 644-8.
19. Yao, J. Z., et al. Fluorophore targeting to cellular proteins via enzyme-mediated
azide ligation and strain-promoted cycloaddition. JAm Chem Soc, 134, 3720-8.
20. Lavis, L. D.; Raines, R. T. Bright ideas for chemical biology. ACS Chem Biol
2008, 3, 142-55.
21. Baruah, H.; Puthenveetil, S.; Choi, Y. A.; Shah, S.; Ting, A. Y. An engineered
aryl azide ligase for site-specific mapping of protein-protein interactions through
photo-cross-linking. Angew Chem Int Ed Engl 2008, 47, 7018-21.
22. Sun, W. C.; Gee, K. R.; Haugland, R. P. Synthesis of novel fluorinated
coumarins: excellent UV-light excitable fluorescent dyes. Bioorg Med Chem Lett
1998, 8, 3107-10.
23. Yang, T. T., et al. Improved fluorescence and dual color detection with enhanced
blue and green variants of the green fluorescent protein. J Biol Chem 1998, 273,
8212-6.
79
24. Puthenveetil, S.; Liu, D. S.; White, K. A.; Thompson, S.; Ting, A. Y. Yeast
display evolution of a kinetically efficient 13-amino acid substrate for lipoic acid
ligase. JAm Chem Soc 2009, 131, 1643 0-8.
25. Fujiwara, K., et al. Global conformational change associated with the two-step
reaction catalyzed by Escherichia coli lipoate-protein ligase A. JBiol Chem 2010,
285, 9971-80.
26. Fujiwara, K., et al. Crystal structure of lipoate-protein ligase A from Escherichia
coli. Determination of the lipoic acid-binding site. JBiol Chem 2005, 280, 33645-
51.
27. Fujiwara, K.; Okamura-Ikeda, K.; Motokawa, Y. Expression of mature bovine H-
protein of the glycine cleavage system in Escherichia coli and in vitro lipoylation
of the apoform. JBiol Chem 1992, 267, 20011-6.
28. Fujiwara, K.; Okamura-Ikeda, K.; Motokawa, Y. Lipoylation of acyltransferase
components of alpha-ketoacid dehydrogenase complexes. J Biol Chem 1996, 271,
12932-6.
29. Tsien, R. Y. Fluorescent probes of cell signaling. Annu Rev Neurosci 1989, 12,
227-53.
30. Miller, L. W.; Sable, J.; Goelet, P.; Sheetz, M. P.; Cornish, V. W. Methotrexate
conjugates: a molecular in vivo protein tag. Angew Chem Int Ed Engl 2004, 43,
1672-5.
31. Miller, L. W.; Cai, Y.; Sheetz, M. P.; Cornish, V. W. In vivo protein labeling with
trimethoprim conjugates: a flexible chemical tag. Nat Methods 2005, 2, 255-7.
32. Xu, Y.; Beckett, D. Kinetics of biotinyl-5'-adenylate synthesis catalyzed by the
Escherichia coli repressor of biotin biosynthesis and the stability of the enzyme-
product complex. Biochemistry 1994, 33, 7354-60.
33. Adams, S. R., et al. New biarsenical ligands and tetracysteine motifs for protein
labeling in vitro and in vivo: synthesis and biological applications. J Am Chem
Soc 2002, 124, 6063-76.
34. Martin, B. R.; Giepmans, B. N.; Adams, S. R.; Tsien, R. Y. Mammalian cell-
based optimization of the biarsenical-binding tetracysteine motif for improved
fluorescence and affinity. Nat Biotechnol 2005, 23, 1308-14.
80
Chapter 3. Application of coumarin PRIME to compartmentalized
labeling of intracellular proteins.
The work presented in this chapter has been published in part in C. Uttamapinant, K.A.
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for the MondoA shuttling assay.
The indicated data in Figure 3-3B is reproduced with permission from J. Dopie, K-P.
Skarp, E. K. Rajakyla, K. Tanhuanpaa, M. K. Vartiainen. Active maintenance of nuclear
actin by importin 9 supports transcription. Proc Natl Acad Sci U S A, 2012, 109, E544-
52.
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Introduction
In the previous chapter, we described the development of the coumarin PRIME
intracellular protein labeling methodology. This method uses an enzyme to site-
specifically label peptide-tagged proteins with a coumarin fluorophore. We demonstrated
that the method is fast, specific, and works in many subcellular compartments. One might
argue that one drawback of the PRIME labeling method is that labeling requires two
components: the enzyme and the LAP-tagged protein of interest. However, we see this
feature as a distinct advantage of our method that allows for more sophisticated
exploration of biology. A unique feature of PRIME labeling is the ability to use
genetically targeted ligases to selectively highlight protein subpopulations.
Protein translocation and selective labeling methods
Temporally-controlled protein translocation is a dynamic process that is involved
in many cellular functions- . Translocation of a single protein, such as an apoptotic
factor4'7 , a transcription factor8-12, or a signaling domain' 3-15, can produce a cascade of
downstream effects that have significant biological repercussions. The biology of some
protein translocation events has been heavily studied; for example, a good deal is known
about the effects of apoptotic factors shuttling between the mitochondria and nucleus and
gene regulation following the translocation of transcription factors from the cytosol to the
nucleus. However, recent results indicate that many proteins that were not previously
thought to have compartment-specific functions may behave differently based on
subcellular localization. Various labs have presented data that indicate cathepsins'6,17
kinasesi8-20, and even cytoskeletal proteins may each have nuanced biological
functions that are linked to their subcellular localization.
Scientists who want to study the link between a protein's subcellular localization
and function face significant challenges. One telling example is transglutaminase 2,
which has been found in the nucleus, cytosol, mitochondria, plasma membrane, and the
extracellular matrix26,27 . The nuclear pool of transglutaminase 2 plays a role in gene
regulation and histone modification, and these functions have interested groups for
years2 8 -3 0 . Cell fractionization followed by biochemical assays have been used to
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specifically study the nuclear population of transglutaminase 2. However, studying the
nuclear biology of transglutaminase 2 inside living cells using traditional imaging
methods is difficult, as the nuclear pool of transglutaminase 2 is estimated to be only
about 5-7% of the total population. Exploring the specific function, activity, and distinct
trafficking of such a small fraction of the entire protein population is extremely difficult
using traditional labeling and fluorescence imaging techniques 26. Since a simple
genetically encoded tag such as GFP or SNAP/CLIP would label the whole population,
researchers often combine these tools with advanced imaging techniques to study the
behavior of proteins in one area of the cell 31.
The most frequently used imaging methods to probe protein exchange or protein
trafficking are photobleaching techniques such as fluorescence loss in photobleaching
(FLIP) or fluorescence recovery after photobleaching (FRAP) 3 1,3 2 . In FLIP, one area of a
cell is illuminated with a high power laser, bleaching the fluorophores in that area;
concomitant loss of fluorescence in a non-illuminated area of the cell indicates proteins
are being rapidly exchanged between the two areas. In FRAP experiments, one area of a
cell is selectively photobleached and then subsequent recovery of fluorescence in that
area indicates exchange with another population outside the bleached area. However, the
bleached population cannot be visualized with these methods, making it impossible to
image all labeled proteins. To address this issue, several techniques employ the use of
photo-activatable or photo-switchable dyes or FPs33-37. These photo-activation techniques
allow for the simultaneous monitoring of fluorescence loss in one compartment and
associated fluorescence gain in another. By using photo-activatable techniques,
fluorophore populations can be specifically targeted and "turned-on" by a quick pulse of
light and their movement can be monitored, which is particularly useful for studying
proteins that traffic quickly and have short residences in multiple subcellular
35,38
compartments
While these advanced imaging methods allow for the study of a subpopulation of
a protein of interest (the subpopulation illuminated by light) there are three principal
limitations. First, each of these experiments is slow and time consuming and must be
performed individually on a large number of cells in order to get meaningful ensemble
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results about the target protein. Second, these methods require highly specific labeling
techniques; consequently, most FLIP/FRAP experiments rely on perfectly specific FP
fusions or highly specific protein-directed labeling methods. As previously discussed,
fusions to large tags have been shown to disrupt protein localization, trafficking, and
function and adverse effects have also been demonstrated in FLIP/FRAP studies39. In
order to obtain biologically relevant results, careful control experiments must be
performed to demonstrate proper behavior of the target protein-FP fusion. Finally, these
experiments are limited to studying cellular compartments that can be easily and
selectively illuminated by light. For example, it would be impossible using these methods
to specifically highlight proteins at the neuronal synapse, the inner mitochondrial
membrane, the ER, or the Golgi apparatus. This significant impediment is why most
examples of these techniques involve proteins that undergo nucleocytoplasmic
shuttling3 2 ,40 4 5 or receptors that can be selectively labeled and bleached at the cell
surface46 49.
Compartmentalized labeling as a method to probe biologicalfunction
In order to specifically highlight spatially defined subpopulations of a protein of
interest, we envisioned using genetically targeted ligases. Then we would be able to study
the biology of the labeled pool independently of the rest of the protein population. In this
chapter, we will summarize work towards this goal. We will first describe a proof-of-
principle experiment that will demonstrate that spatially defined subpopulations of a
protein of interest can be specifically labeled using targeted ligase. Then we will describe
the use of this method to label spatially distinct subpopulations of three biologically
relevant proteins: the cytoskeletal protein P -actin, the synaptic adhesion protein
neurexin- 1$ , and the transcription factor MondoA. Before introducing the experimental
results, we will provide a brief background on the physiological function of these proteins
and the previous investigations of the relationship between their subcellular localizations
and biological functions.
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Results
Proof of principle: Compartmentalized coumarin labeling
Before investigating biologically relevant proteins, we wanted to demonstrate the
concept of compartmentalized labeling in a controlled system. The first step is to
demonstrate that coumarin labeling is observed only when coumarin ligase and substrate
are co-localized, and not when they are expressed in separate compartments. We
proposed using targeted ligases to label subpopulations of LAP2-YFP. The general
scheme for this proof-of-principle experiment is shown in Figure 3-1. In this scheme,
nuclear labeling should only label the nuclear population of LAP2-YFP, while cytosolic
ligase should label only the cytosolic population of LAP2-YFP (Figure 3-1, top).
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Figure 3-1. Scheme for proof-of-principle compartmentalized labeling experiment. HEK cells that are
expressing LAP2-YFP across the whole cell, when labeled with nuclear- or cytosolic-targeted ligase should
show only nuclear or cytosolic labeling, respectively (top). As control experiments, when using targeted
substrate, we should only observe coumarin labeling when ligase and substrate are co-localized (bottom).
In practice, we transfected HEK cells with both nuclear LAP2-YFP and cytosolic
LAP2-YFP. When using cytosolic ligase, we observed labeling of the cytosolic
subpopulation (Figure 3-2A, left, top row), and when using nuclear ligase we observed
specific labeling of the nuclear subpopulation of LAP2-YFP (Figure 3-2A, right, top
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row). Positive controls are shown where individual enzyme and substrate are co-localized
and strong labeling signal is observed (Figure 3-2A, middle rows). Negative controls
show that when enzyme and substrate are not co-localized, no coumarin labeling was
observed (Figure 3-2A, bottom rows). Antibody staining for enzyme in Figure 3-2B
shows nuclear and cytosolic w37vLplA expression.
A FLAG-mNLpA-NES FLAG-vvLpLA-NLS
Coun arin +C Coumarin LAP2- LAP2-YFP + DIC
LAP2-YFP-NLS LAP2-YFP-NLS
LAP2-YFP-NES LAP2-YFP-NES
LAP2-YFP-NES LAP2-YFP-NLS
LAP2-YFP-NLS LAP2-YFP-NES
B Coumarin LAP2-YFP anti-FLAG Coumarin LAP2-YFP anti-FLAG
LAP2-YFP-NLS LAP2-YFP-NLS
LAP2-YFP-NES LAP2-YFP-NES
Figure 3-2. Proof-of-principle: compartmentalized PRIME labeling with genetically targeted ligase.
(A) HEK cells that are expressing both LAP2-YFP-NLS (nuclear) and LAP2-YFP-NES (cytosolic) were
labeled with either cytosolic (NES, left) or nuclear-targeted (NLS, right) w3 7vLp1A. Controls where
individual substrates are co-localized with enzyme (middle row) or not co-localized (bottom row)
demonstrate the specificity of this method. (B) Anti-FLAG staining of fixed cells shows the expression
pattern of the targeted W37 vLpIA enzymes.
This was an encouraging result, but in this experiment we used spatially defined
proteins that are not actively exchanging. It was not clear whether this technique would
allow the compartmentalized labeling of real proteins that may be undergoing constant
dynamic trafficking and exchange. To probe the abilities of this technique, we moved
forward in stages. We first investigated p-actin, whose sub-cellular localization and
trafficking has been studied in a variety of ways, including fluorescence imaging
techniques 40,so- 52 . We then demonstrated compartmentalized labeling of the synaptic
adhesion protein neurexin 1 P, which has not been extensively studied intracellularly but
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has a well-defined trafficking pattern to the surface of neurons53 . Finally, we attempted
compartmentalized labeling of the transcription factor MondoA. Although MondoA is
known to be present in multiple subcellular compartments under different conditions, its
dynamic trafficking behavior is virtually unknown 4 .
Biology of fi-actin
Cytosolic p-actin is a major component of the cytoskeleton and its essential roles
in cell migration, cell morphology, and intracellular trafficking have been extensively
studied. Since it was proposed over 30 years ago, the existence of a nuclear pool of actin
has been a topic of heated debate in the literature5 0 . Primarily because of improvements
in protein labeling techniques and fluorescence microscopy, the last ten years have
produced an overwhelming consensus that p-actin is present in the nucleus 2 3 ,2 4 . The
potentially distinct biological roles of nuclear actin are now an active area of
research 2 1,25,
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Nuclear actin has been identified as a component of chromatin remodeling
complexes 24 , associates with RNA polymerases5 7 , and binds to transcription factors22 and
proteins involved in mRNA export58 . Thus, nuclear actin may have structural or even
regulatory roles in the nucleus that are distinct from the traditional cytosolic functions of
the protein. Since the roles of the spatially segregated actin populations seem to be very
different, many groups have investigated whether the two pools of actin are segregated or
actively exchanging. While the 42 kDa actin monomer is small enough to pass through
the nuclear pore (generally accepted size-cutoff of ~50 kDa5 9,60, although conflicting data
exist6 1 ), it is not clear whether nuclear actin is actively imported or exported. Recent
work by Dopie and colleagues has demonstrated using both FLIP and FRAP on GFP-
tagged p-actin that the pools of nuclear and cytosolic actin seem to be exchanging
quickly40 . For the FLIP study, the authors performed continuous cytosolic photobleaching
of GFP-p-actin, and observed concurrent photobleaching of nuclear actin, indicating that
at least a portion of the nuclear pool of actin exchanges with the cytosolic population. In
the FRAP study, the authors photobleached the nuclear GFP-p-actin and they observed
gradual nuclear fluorescence recovery. This experiment suggests that the cytosolic pool
of actin is either passively diffused or actively transported into the nucleus. Using RNAi
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knockdowns of nuclear import/export proteins, Dopie and colleagues were able to
demonstrate that, at least for the 69kDa GFP-f-actin chimera, active import is required.
While the study described above indicates that the two actin subpopulations are
exchanging, there are several issues with the experimental design. First, GFP-p-actin
almost doubles the size of the native actin, and likely prohibits passive diffusion through
the nuclear pore. So while the GFP-p-actin chimera required active transport into and out
of the nucleus, it is not prudent to conclude from this result that endogenous actin
monomers also require active transport. Second, previous work has shown that nuclear
export of p-actin requires actin binding factors that maintain the protein in its monomeric
form25 62. This is another indication that the size and polymeric state of actin is critical to
its transport and exchange. If even actin dimers cannot be exported from the nucleus, the
export of a GFP-actin fusion is probably not the best model for biologically relevant
export of monomeric actin. Third, previous studies 40 ,52,63 (including our own work) have
demonstrated that fusions of actin to FPs such as mApple or GFP prohibit or decrease the
nuclear accumulation of actin under basal conditions, a phenomenon which is not seen
when using antibody staining for endogenous actin or live-cell imaging with small tags
2357(Figure 3-3A). Dopie and colleagues do not address this obvious issue in their paper,
even though their GFP-actin control cells clearly show significant nuclear exclusion of
their GFP-actin chimera (Figure 3-3B). We thought the PRIME technology would be a
good fit for studying nuclear p-actin. The method uses a small tag that minimally perturbs
actin monomers and hopefully closer mimics endogenous p-actin. In the subsequent
section, we demonstrate how we have used genetically targeted ligases to label spatially
defined subpopulations of LAP2-actin.
Demonstration of compartmentalized labeling of nuclear actin
We first made a LAP2-p-actin fusion and performed coumarin PRIME labeling
using untargeted ligase. The coumarin labeling signal of LAP2-p-actin has overlapping
localization to antibody staining or phalloidin staining, two traditional methods of
imaging actin in fixed cells (Figure 3-3A). We therefore concluded that the LAP2-tagged
p-actin has similar localization as endogenous actin and would likely be a good mimic of
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the behavior of monomeric actin. We next proposed to label actin subpopulations using
both nuclear and cytosolic coumarin ligase (W37vLplA).
A
Coumarin Phalloidin anti-HA Coumarin + DIC rmApple-acUn
Live-cell labeling Fixed-cell labeling Fixed-cell labeling
B
U.Of
Figure 3-3. Actin localization pattern depends on detection method. (A) Comparison of methods for
actin visualization. Coumarin PRIME labeling of HA-LAP2-p-actin was performed in live cells. Cells were
then fixed and actin detected via two traditional methods: phalloidin staining for filamentous actin and
antibody staining. These three methods all show a nuclear pool of p-actin. These methods are compared to
the effect of a large FP tag (mApple), where significant nuclear exclusion is observed (B) Localization
pattern of the GFP- p-actin fusion as reported in Dopie et. al. (reprinted here with permission). Note that
the localization pattern of this FP chimera is also nuclear excluded.
Figure 3-4 shows coumarin labeling of LAP2-p-actin in COS-7 cells when using
untargeted, cytosolic, and nuclear ligases. We initially did not see any labeling signal
using the nuclear-targeted coumarin ligase. We hypothesized that this was due to nuclear
actin being bound in complexes or not sterically accessible to the nuclear enzyme. This
result also indicates that the nuclear actin we observe when using untargeted ligase is
probably the result of coumarin labeling of actin monomers in the cytosol, followed by
translocation to the nucleus. The observation that labeling with cytosolic coumarin ligase
produces nuclear labeling signal supports this idea that nuclear translocation follows
cytosolic labeling of accessible LAP2-p-actin monomers (Figure 3-4, middle panels).
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H2B-YFP + H2B-YFP +
Coumarin Coumarin DIC
FLAG-w37vLpA
FLAG- wa7vLplA-NES
FLAG-w 7 vLpIA-NLS
Figure 3-4. Compartmentalized labeling of LAP2-p-actin. COS-7 cells expressing LAP2-p-actin are
labeled with untargeted, cytosolic (NES), or nuclear-targeted (NLS) coumarin ligase.
To test this hypothesis, we performed coumarin labeling using nuclear targeted
ligase in the presence of the drug leptomycin-B (LMB), a selective inhibitor of Crml
nuclear exporter, which has been previously demonstrated to cause nuclear accumulation
of p-actin23 ,62. Under these conditions, we observed specific labeling of the nuclear pool
of LAP2-p-actin using nuclear-targeted coumarin ligase (Figure 3-5). When labeling in
the presence of leptomycin-B, we saw nuclear actin structures that included filaments and
nucleolar clusters. We suspect that leptomycin-B may cause an increase in nuclear actin
such that endogenous actin-binding proteins are saturated, producing free actin that is
accessible to the nuclear coumarin ligase, which is not the case under basal conditions.
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Figure 3-5. Compartmentalized labeling of nuclear actin in the presence of leptomycin B. COS-7 cells
expressing LAP2-p-actin were labeled with coumarin using untargeted or nuclear-targeted W37vLpIA.
Where indicated, labeling was performed after treatment with 2 ng/ml leptomycin B (LMB) to inhibit
nuclear export. LMB is required to see coumarin labeling when using nuclear-targeted ligase.
The behavior of LAP2-p-actin in the presence of LMB closely matches previous
results using either antibody staining of endogenous actin post-fixation or live-cell
imaging with microinjected fluorescently labeled actin, which all indicate nuclear
accumulation of the actin23,62. However, these results stand in stark contrast to the
observations from Dopie and colleagues, who found no difference in the level of nuclear
GFP-actin in the presence or absence of LMB. While the authors claim that this indicates
nuclear export of actin is not Crml dependent and is instead associated with another
exporter (Exp6), it could simply be that GFP-p-actin does not behave, traffic, or interact
with nuclear actin binding proteins in the same way as LAP2-p-actin or endogenous
actin. The only other instance of reported p-actin insensitivity to LMB was seen with
YFP-fused actin , which supports the theory that this insensitivity may be an artifact of
the large FP fusions.
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Biology of neurexin-ifi
Neurexins are pre-synaptic transmembrane adhesion proteins that have been
linked to synaptogenesis and synapse maturation. The broad class of neurexin proteins is
extremely heterogeneous due to the large number of alternative splice sites, with the
theoretical number of isoforms approaching that of the immunoglobulin family 4'64.
Neurexins were discovered in the early 1990s and quickly rose to the forefront of
neurobiology after initial experiments indicated these proteins trigger post-synaptic
differentiation and thus may be involved in synapse modulation. Soon after neuroligin
was identified as the post-synaptic binding partner of neurexin, these two proteins
became the subject of intense study by the neuroscience community. Subsequent
experiments indicated that neurexin-neuroligin trans-synaptic interactions appear to
control the balance of GABAergic and glutamatergic inputs and thus may have huge
implications in the understanding of not only the formation of the synapse but also signal
transduction, synapse classification, and even clinical manifestations of neurological
diseases such as autismi4 65 ,66
The process of synapse formation is divided into several distinct steps. First,
axons and dendrites must grow towards each other and form initial contacts. Second, a
synaptic junction is established with subsequent (or perhaps concomitant) recruitment of
pre-and post-synaptic scaffolding proteins and cellular machinery. Finally, the synapse
matures and, through modification of protein-protein interactions at the synapse and
within the pre and post-synaptic busons, synapse specification is achieved. Through
various in vitro and in vivo experiments, neurexin and neuroligin have been implicated in
every step of this process14'67-69. However, investigation into the biological relevance of
these results has so far been limited by the live-cell techniques available. While all areas
of synapse formation are being actively researched, groups studying synapse maturation
are particularly interested in exploring the membrane implantation and subsequent
53,70-72turnover of neurexin and neuroligin '-. The ability to specifically highlight the
intracellular pool of neurexin before it is trafficked to the cell surface and then follow
protein recruitment to maturing synapses would be extremely beneficial. We describe in
the subsequent section the application of coumarin PRIME to the compartmentalized
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labeling of LAP2-tagged neurexin- 1P. While labeling in neurons is the end goal of
neurexin imaging, here we demonstrate labeling of neurexin- 1f in fibroblasts.
Demonstration of compartmentalized labeling of neurexin-1fi
For these experiments, we cloned a double LAP2 fusion to neurexin- 1P (LAP2-
neurexin 1p-LAP2). This construct geometry would allow us to perform labeling on both
sides of the membrane. We performed three experiments to label distinct subpopulations
of neurexin- 1fP as it is trafficked through the secretory pathway and implanted in the
membrane. First, using exogenously applied enzyme, we labeled only the LAP2-
neurexinl p-LAP2 that is accessible on the cell surface (Figure 3-6, left). This produced
clearly defined rings with no labeling of intracellular LAP2-neurexinl p-LAP2. Second,
using ligase targeted to the inner leaflet of the plasma membrane, we labeled the
intracellular face of the implanted neurexin-lp (Figure 3-6, middle). This produced a
clear ring at the plasma membrane, and also a low level of signal in the cell interior,
corresponding to sites where the enzyme and LAP2-neurexin1 p-LAP2 came into contact
before membrane implantation. It is likely that shorter labeling times would eliminate this
aberrant signal. Finally, we used untargeted ligase to label the entire intracellular pool of
LAP2. This produced not only a clear ring at the plasma membrane from labeling of the
intracellular face of the implanted neurexin 11 but also strong signal corresponding to
labeling of accessible LAP2 at the cytosolic face of the endoplasmic reticulum and Golgi
apparatus as the protein is trafficked to the cell surface (Figure 3-6, right).
We also considered labeling of LAP2-tagged neurexin as it is trafficked through
the endoplasmic reticulum using an ER-targeted ligase. However, as we discussed in
Chapter 2, coumarin labeling using ER-targeted ligases is not possible. Chapter 7
summarizes the evolution of a cell-surface and ER-active probe ligase and includes a
demonstration of ER labeling of neuroligin, neurexin's interacting partner.
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Figure 3-6. Compartmentalized labeling of neurexin-Ip. The double-tagged neurexin-1P construct,
LAP2-neurexinlp-LAP2 (LAP2-NRX-LAP2 in the diagram) was transfected into HEK cells. Coumarin
labeling was performed using W37VLpIA applied exogenously (left), W37vLpIA targeted to the inner-leaflet
of the plasma membrane (right), and untargeted W37vLpIA (middle).
Biology of MondoA
Glucose is a fundamental metabolite and the biochemical pathways of glucose
metabolism are among the best understood in biochemistry. For decades scientists have
known that altered glucose homeostasis is a characteristic of human diseases such as
cancer, diabetes, and Alzheimer's disease73'74 . However, most of the molecular
mechanisms for how cells sense and respond to changes in extracellular glucose
concentrations are not well understood. Several proposed pathways for glucose sensing
involve cytosolic proteins that sense intracellular glucose levels and then respond through
regulation of glycolytic enzymes or by initiating insulin secretion75-77. About ten years
ago, a new family of transcriptional regulators of glucose homeostasis was discovered.
These protein complexes sense glucose metabolism and then trigger a transcriptional
response that induces expression of glycolytic target genes78 . The most intriguing of these
glucose sensors is the MondoA:Mlx dimeric transcription factor.
MondoA:Mlx is a functional heterodimer that is localized to the outer
mitochondrial membrane when intracellular glucose concentrations are low. When
intracellular levels of glucose increase, MondoA:Mlx translocates to the nucleus and
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induces transcription of several key proteins involved in glucose regulation, including
thioredoxin-interacting protein (TXNIP), which is a potent down regulator of glucose
uptake. Previous work demonstrated that MondoA:Mlx is associated with hexokinase on
the outer mitochondrial membrane and that the translocation is dependent on hexokinase
activity (hexokinase phosphorylates glucose to glucose-6-phosphate). This result, coupled
with the fact that MondoA does not sense glucose directly but instead responds to levels
of glucose-6-phosphate (G6P), indicates that MondoA:Mlx translocation may respond to
a conformational change upon catalysis of glucose by hexokinase".
Recent work on MondoA:Mlx translocation has revealed intriguing results. While
it has been clearly established that high intracellular glucose concentrations result in
translocation of MondoA and TXNIP transcription, little is known about how the system
resets itself. In many cases, TXNIP transcription remains high even after glucose levels
have returned to normal (personal communication, Vamsi Mootha). This is what we call
"metabolic memory"; the cells remember that they were in a high glucose environment
and need to be reset in order to return to the basal state. An influx of insulin will erase the
metabolic memory of the cell and finally reduce TXNIP transcription after it has begun.
The mechanism of the erasure is not known, but seems to be dependent on insulin as
TXNIP levels remain high until an influx of insulin drops expression to basal levels
(Vamsi Mootha, personal communication).
The mechanism by which insulin erases the metabolic memory of the cell is
unknown. One hypothesis is that insulin directly affects MondoA:Mlx localization; by
disrupting the MondoA:Mlx/DNA interaction, for example, insulin would result in the
loss of TXNIP transcription and the return to the cell's basal state. Another theory is that
perhaps insulin serves to activate export of MondoA:Mlx from the nucleus to the outer
mitochondrial membrane where the heterodimer is able to re-associate with hexokinase;
this would also "erase" metabolic memory as the translocation would result in the loss of
TXNIP transcription. Our PRIME technology is uniquely suited to investigating these
two hypothesis. By specifically labeling the nuclear pool of MondoA:Mlx, we would then
be able to monitor the localization of this population and follow any trafficking events
after the addition of insulin to erase metabolic memory. Although we were not able to
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directly address these issues using our coumarin PRIME technology, what follows is a
description of the considerable progress towards this goal.
Progress towards compartmentalized labeling of MondoA
MondoA-LAP2 and MondoA -E2p fusions exhibit proper translocation
The first goal of this project was to simply produce a fusion to MondoA that does
not disrupt the protein's translocation behavior. Although MondoA is over 1000 amino
acids long, it is exquisitely susceptible to disruption via genetic fusions. This sensitivity
to modification is unsurprising considering that proper function of MondoA requires at
least two known protein-protein interactions (with both Mlx and hexokinase) along with
unimpeded DNA binding by the basic helix-loop-helix leucine zipper domain of
MondoA. While small epitope tags (V5 and HA) had been fused to the C-terminus of
MondoA without interfering with MondoA:Mlx translocation, FPs at the N-terminus, C-
terminus or even internal fusion sites did not produce proper MondoA shuttling behavior
(Donald Ayer, personal communication). These FP fusions all resulted in improper
nuclear localization under low-glucose conditions, indicating that they likely disrupt
binding to the mitochondrial membrane or perhaps hexokinase.
We made fusions of E2p and LAP2 to the both the N- and C-termini of MondoA.
We then tested the behavior of these fusions in a standard MondoA glucose shuttling
assay (for details, see Experimental). This assay reproduces both a glucose-starved (Low
Glucose) and a high G6P (High Glucose) state. Under the glucose-starved (Low Glucose)
conditions, there is very little G6P inside the cells, so the MondoA-Mlx heterodimer is
localized to the mitochondria (Figure 3-7, left). Under high G6P (High Glucose)
conditions, the MondoA:Mlx heterodimer is localized to the nucleus (Figure 3-7, right).
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Figure 3-7. Scheme of the subcellular localization patterns for MondoA:Mlx under both high and low
intracellular glucose concentrations.
We performed the glucose shuttling assay in live HeLa cells expressing the
MondoA fusions and then fixed the cells and compared the subcellular localization
pattern to that of MondoA-V5. The MondoA-V5 construct from the Ayer lab traffics
properly in HeLa cells, as demonstrated in the top panel of Figure 3-8. The N-terminal
fusions of E2p and LAP2 to MondoA localize primarily to the nucleus regardless of
intracellular glucose levels. This indicates that even very small tags can disrupt the
function of MondoA when fused at the N-terminus of the protein. The C-terminal fusions
of E2p and LAP2 to MondoA both traffic normally in the shuttling assay (Figure 3-8).
This was the first demonstration of the proper trafficking of a MondoA fusion to tags that
can be used for live-cell protein labeling.
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Figure 3-8. C-terminal LAP2 and E2p fusions to MondoA traffic as wild-type MondoA. The glucose
shuttling assay (see experimental) was performed in HeLa cells expressing the indicated MondoA fusions.
Fusion expression patterns were determined by antibody staining after cell-fixation. While N-terminal
fusions were mis-localized under low glucose conditions, the C-terminal fusions of LAP2- and E2p- to
MondoA traffic properly.
Expression level must be controlled for proper shuttling of MondoA-E2p and MondoA-
LAP2
We quickly determined that MondoA localization is highly sensitive to not only to
fusions, but also overexpression. In cells expressing MondoA-V5 construct,
overexpression induced whole-cell localization of the protein when treated with high
glucose, although we always observed mitochondrial MondoA under low glucose
conditions regardless of expression level (data not shown). Similar mislocalization effects
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were seen with E2p and LAP2 fusions when expressed at high concentrations (Figure 3-
9). These data suggest that perhaps the nuclear import mechanism or unknown MondoA
nuclear binding partners become saturated when MondoA is overexpressed, resulting in
cytosolic background accumulation of the protein under high glucose conditions.
MondoA-
High
expression
of MondoA-
HA-E2p
MondoA-
HA-LAP2
High
expression
of MondoA-
HA-LAP2
Figure 3-9. MondoA-LAP2 and MondoA-E2p nuclear localization is disrupted at high expression
levels. HeLa cells were prepared with the indicated MondoA fusion at either high or low expression
conditions (normal expression is identical to levels in Figure 3-8, high expression is twice that level).
After much optimization of MondoA expression conditions, attempts at co-
transfecting additional hexokinase or Mlx, and even adding nuclear export inhibitors
under high glucose conditions, we determined that MondoA fusions simply must be
expressed at concentrations less than 15 pM in order to localize properly in the shuttling
assay.
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Coumarin labeling is not sensitive enough to achieve coumarin labeling of MondoA-E2p
and MondoA-LAP2 at low expression levels
Since MondoA expression levels must be limited to less than 15 ptM in order to
exhibit proper localization, we were concerned that our coumarin PRIME technology
(which has a sensitivity limit of about 10 pM) would not be applicable to labeling the
MondoA in live cells. Unfortunately, even with untargeted coumarin ligase, we were not
able to see any labeling of the MondoA at the mitochondria (Low Glucose) or in the
nucleus (High Glucose) (Figure 3-10A). However, we did observe labeling of MondoA
when it was over-expressed and improperly localized (data not shown).
+DIC
High Contrast
MondoA-HA-E2p
LOW GLUCOSE
MondoA-HA-E2p
HIGH GLUCOSE
MondoA-HA-LAP2
LOW GLUCOSE
MondoA-HA-LAP2
HIGH GLUCOSE
Figure 3-10. No coumarin labeling of MondoA fusions when properly localized. HEK cells expressing
the indicated MondoA fusion and W37 VLplA were subjected to the Mondo shuttling assay. Coumarin
labeling was then performed under both high and low glucose conditions. No coumarin labeling was
observed, although we did see coumarin labeling of the positive control plasmid (top panels).
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At low expression, the MondoA is at the cusp of what we could detect using the
PRIME methodology. Keeping that in mind, we were still concerned that perhaps the
phenomenon we were seeing was not the result of low labeling sensitivity but actually the
result of the LAP2 or E2p being sterically inaccessible when the MondoA fusions were
properly localized. To test this theory, we decided to try intracellular lipoylation using
targeted WTLp1A. Since the wild-type lipoylation reaction is more sensitive than the
coumarin ligation, we hoped that we could observe labeling of MondoA-LAP2 or
MondoA-E2p under the low expression conditions required for proper localization.
Demonstration of compartmentalized lipoylation of MondoA-E2p and MondoA-LAP2
For lipoylation, we needed to perform tetracycline-controlled expression WTLp1A,
as described in Chapter 2. We first confirmed that all of our shuttling assays were
functioning properly in the HeLa cell line stably expressing the tetracycline repressor
(data not shown). We then performed lipoylation of MondoA-LAP2 and MondoA-E2p
under low glucose conditions using untargeted ligase and under high glucose conditions
using nuclear-targeted LplA. We detected lipoylation post-fixation and found that
labeling of the properly-localized proteins using targeted WTLplA was successful(Figure
3-11).
Low glucose, mitochondrial High glucose, nuclear
+DIC +DIC
MondoA-
HA-E2p
MondoA-
HA-LAP2
Figure 3-11. MondoA fusions can be lipoylated when properly localized. HeLa cells expressing the
indicated MondoA fusion and WTLpIA were subjected to the Mondo shuttling assay. The cells were then
treated with lipoic acid, and lipoylation was detected post-fixation.
This allowed us to conclude that while the coumarin PRIME method was not
sensitive enough to probe the biology of the MondoA subcellular shuttling, the MondoA
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system is amenable to an enzyme mediated labeling method at both the mitochondria and
the nucleus. This biological system can be investigated further after the development of a
more sensitive probe ligase.
Conclusion
In this chapter, we have introduced a new method that uses genetically targeted
coumarin ligase to achieve labeling of a subpopulation of a protein of interest. We first
demonstrated this technique in a proof-of-principle experiment wherein we were able to
selectively label either the nuclear or cytosolic population of a LAP2-YFP fusion. We
then demonstrated the use of this method on three biologically relevant proteins:
neurexin- 1p , p-actin, and MondoA. All of these proteins have been demonstrated to have
distinct functions depending on subcellular localization or dynamic shuttling events.
Using our compartmentalized labeling method, we were able to label nuclear p-
actin and demonstrate that most of the nuclear p-actin labeling signal we see using
untargeted ligase is the result of actin monomers being labeled in the cytosol and then
translocated to the nucleus. We were also able to demonstrate that nuclear levels of actin
rise in the presence of leptomycin B, which agrees with previous literature studying
endogenous actin, but conflicts with recent results with large actin-FP fusions. Next, we
demonstrated labeling of three subpopulations of neurexin- 1p as it was trafficked through
the secretory pathway. Finally, we demonstrated steps toward labeling of MondoA:Mlx
heterodimer. We were able to demonstrate the first instance of proper MondoA
trafficking when fused to a useful live-cell protein labeling tag (both E2p and LAP2).
While coumarin labeling was not sensitive enough to label spatially distinct
subpopulations, we were able to achieve compartmentalized lipoylation of MondoA-E2p
and MondoA-LAP2 fusions.
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Experimental
Fluorescence imaging.
Cells were imaged in Dulbecco's Phosphate Buffered Saline (DPBS) in epifluorescence
or confocal modes. For epifluorescence imaging, we used a Zeiss AxioObserver inverted
microscope with a 40x or 63x oil-immersion objective. Coumarin (400/20 excitation, 425
dichroic, 435/30 emission), YFP (493/16 excitation, 506 dichroic, 525/30 emission),
mCherry (570/20 excitation, 585 dichroic, 605/30 emission) and differential interference
contrast (DIC) images were collected and analyzed using Slidebook software (Intelligent
Imaging Innovations). For confocal imaging, we used a Zeiss Axiovert 200M inverted
microscope with a 40x oil-immersion objective. The microscope was equipped with a
Yokogawa spinning disk confocal head, a Quad-band notch dichroic mirror
(405/488/568/647), and 405 (diode), 491 (DPSS), and 561 nm (DPSS) lasers (all 50
mW). Coumarin (405 laser excitation, 445/40 emission), YFP (491 laser excitation,
528/38 emission), mCherry (561 laser excitation, 617/73 emission), and DIC images were
collected using Slidebook software. Fluorescence images in each experiment were
normalized to the same intensity ranges. Acquisition times ranged from 10-1000
milliseconds.
General protocol for coumarin PRIME labeling in living cells. (Figure 3-3)
HEK cells were transfected at ~70% confluency with expression plasmids for W3 vLplA
(20 ng for a 0.95 cm2 dish) and the E2p, LAP4.x or LAP2 fusion protein of interest (400-
600 ng) using Lipofectamine 2000 (Invitrogen). 8-24 hours after transfection, cells were
incubated with 20 pM coumarin-AM 2 in serum-free DMEM (Dulbecco's modified Eagle
medium, Cellgro) for 10 minutes at 37 'C. Note: 0.1% w/v Pluronic F-127 (Invitrogen)
can be optionally added to the labeling solution to give more even coumarin distribution
in cells. The media was then replaced 3-4 times over 30-60 min at 37 'C, with DMEM
supplemented with 10% FBS (Fetal Bovine Serum), to wash out excess coumarin.
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Intracellular coumarin labeling (Where protocol differs from that described above)
For Figure 3-2, to obtain equal expression of LAP2-YFP-NES and LAP2-YFP-
NLS, a 2:1 (NES:NLS) ratio of plasmid DNA was used. Labeling was performed for 30
minutes when using w37vLplA-NLS (or W371LplA-NLS). After labeling and live-cell
imaging, samples were fixed using 3.7% formaldehyde in DPBS followed by cold
precipitation with methanol. Subcellular localization of FLAG-tagged LplA was
confirmed using immunofluorescence staining with 4 pig/ml anti-FLAG M2 antibody
(Stratagene) in 1% BSA in DPBS for 30 minutes. After 15-minute washes, cells were
incubated with 4 pg/ml goat anti-mouse antibody conjugated to Alexa Fluor 568
(Invitrogen) in 1% BSA in DPBS for 30 minutes, then washed and imaged.
For Figure 3-6, cell-surface labeling was performed for 30 minutes at room
temperature with 10 pM W37vLplA or W3 LplA, 50 pM coumarin 4, 1 mM ATP, and 2
mM Mg(OAc) 2 in 50 mM Na2HPO 4 pH 7.2.
For Figure 3-4 and 3-5, COS-7 cells were labeled for 30 minutes. Where noted, 2
ng/ml leptomycin B was added to the labeling and washout media. Fixed samples were
prepared as described above.
MondoA Shuttling Assay (Figure 3-8, 3-9, 3-10, 3-11)
HEK cells were transfected at -70% confluency with 0.3 pg MondoA-V5 or the
indicated LAP2 or E2p fusion to MondoA, 0.3 jig pME1 8 Flag-Mlx, and 0.2 g
Hexokinase II. Transfected duplicates for both high and low glucose states. After 24
hours, media was exchanged for glucose-free MEM (Cellgro). After 12 hours of
incubation in glucose-free media, a "high glucose" state was induced where required by
adding 20 mM 2-deoxyglucose to the glucose-free MEM and incubating with cells for an
additional 6 hours. Note: Glucose-free media is required to observe strong nuclear
shuttling of wt Mondo. Cells were then fixed and the MondoA was detected via V5
antibody while the MondoA fusions were detected via HA staining.
MondoA coumarin labeling (Figure 3-10)
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MondoA glucose shuttling assay is performed as described above, except
W37VLp1A is co-transfected with the plasmids listed. Coumarin labeling was performed in
the indicated glucose-free or 2-deoxy-glucose supplemented media by adding 20 pM
coumarin-AM2 and incubating for 30 minutes followed by washing steps.
Cells were imaged live for coumarin. Where indicated in legends, cells were fixed (see
protocol above) and then stained for MondoA-HA-E2p or MondoA-HA-LAP2
expression before imaging.
MondoA Lipoylation (Figure 3-11)
MondoA glucose shuttling assay is performed as described above but in TREX-
HeLa cell lines and with pcDNA4/TO-WTLplA untargeted or targeted to the nucleus.
Lipoylation was performed in the indicated glucose-free or 2-deoxy-glucose
supplemented media by adding 250 pM lipoic acid and incubating for 4 hours. The cells
were then rinsed and fixed using 3.7% Paraformaldehyde in DPBS, followed by cold
methanol permeabilization. Cells were blocked for 1 hour in 3% BSA in DPBS at room
temperature. Lipoylation was detected by incubating with 1:300 dilution of anti-lipoic
acid antibody (CalBiochem) in 1% BSA in DPBS for 20 minutes at room temperature.
After two washes, a 1:300 dilution of anti-rabbit AlexaFluor488 antibody (Invitrogen) in
1% BSA in DPBS was added to cells for 20 minutes at room temperature. Cells were
washed twice and then imaged.
Wedge-method approximation of MondoA expression levels
Mondo-HA-LAP2 was expressed in HEK cells at varying levels. Antibody
staining for HA was performed post-fixation as described above with AlexaFluor488
secondary antibody used. In a side-by-side assay, HA-LAP2-mCherry was expressed and
imaged live and then fixed and antibody staining for HA was performed with
AlexaFluor488 secondary antibody used. Using the wedge method, we approximated the
concentrations of HA-LAP2-mCherry and then correlated expression level to HA
staining. Using this approximate ratio of HA staining to concentration, we calculated the
approximate concentration of MondoA-HA-LAP2 at various transfection amounts based
on HA staining levels.
106
References
1. Chu, C. T.; Plowey, E. D.; Wang, Y.; Patel, V.; Jordan-Sciutto, K. L. Location,
location, location: altered transcription factor trafficking in neurodegeneration. J
Neuropathol Exp Neurol 2007, 66, 873-83.
2. Lemberg, M. K. Intramembrane proteolysis in regulated protein trafficking.
Traffic, 12, 1109-18.
3. Szul, T.; Sztul, E. COPII and COPI traffic at the ER-Golgi interface. Physiology
(Bethesda), 26, 348-64.
4. Yoshida, K. Nuclear trafficking of pro-apoptotic kinases in response to DNA
damage. Trends Mol Med 2008, 14, 305-13.
5. Crabtree, G. R.; Graef, I. A. Bursting into the nucleus. Sci Signal 2008, 1, pe54.
6. Shahbabian, K.; Chartrand, P. Control of cytoplasmic mRNA localization. Cell
Mol Life Sci, 69, 535-52.
7. Lindenboim, L.; Borner, C.; Stein, R. Nuclear proteins acting on mitochondria.
Biochim Biophys Acta, 1813, 5 84-96.
8. Billin, A. N.; Eilers, A. L.; Queva, C.; Ayer, D. E. Mlx, a novel Max-like
BHLHZip protein that interacts with the Max network of transcription factors. J
Biol Chem 1999, 274, 36344-50.
9. Billin, A. N.; Eilers, A. L.; Coulter, K. L.; Logan, J. S.; Ayer, D. E. MondoA, a
novel basic helix-loop-helix-leucine zipper transcriptional activator that
constitutes a positive branch of a max-like network. Mol Cell Biol 2000, 20, 8845-
54.
10. Chan, Y. M.; Jan, Y. N. Roles for proteolysis and trafficking in notch maturation
and signal transduction. Cell 1998, 94, 423-6.
11. Gordon, W. R.; Arnett, K. L.; Blacklow, S. C. The molecular logic of Notch
signaling--a structural and biochemical perspective. J Cell Sci 2008, 121, 3109-
19.
12. Hill, C. S. Nucleocytoplasmic shuttling of Smad proteins. Cell Res 2009, 19, 36-
46.
13. Ebinu, J. 0.; Yankner, B. A. A RIP tide in neuronal signal transduction. Neuron
2002, 34, 499-502.
107
14. Craig, A. M.; Kang, Y. Neurexin-neuroligin signaling in synapse development.
Curr Opin Neurobiol 2007, 17, 43-52.
15. Giese, B., et al. Long term association of the cytokine receptor gp 130 and the
Janus kinase JakI revealed by FRAP analysis. JBiol Chem 2003, 278, 39205-13.
16. Turk, V., et al. Cysteine cathepsins: from structure, function and regulation to
new frontiers. Biochim Biophys Acta, 1824, 68-8 8.
17. Reiser, J.; Adair, B.; Reinheckel, T. Specialized roles for cysteine cathepsins in
health and disease. J Clin Invest, 120, 3421-3 1.
18. Gould, G. W. IKKepsilon: a kinase at the intersection of signaling and membrane
traffic. Sci Signal, 4, pe30.
19. Wortzel, I.; Seger, R. The ERK Cascade: Distinct Functions within Various
Subcellular Organelles. Genes Cancer, 2, 195-209.
20. Zehorai, E.; Yao, Z.; Plotnikov, A.; Seger, R. The subcellular localization of
MEK and ERK--a novel nuclear translocation signal (NTS) paves a way to the
nucleus. Mol Cell Endocrinol, 314, 213-20.
21. Visa, N.; Percipalle, P. Nuclear functions of actin. Cold Spring Harb Perspect
Biol, 2, a000620.
22. Miralles, F.; Visa, N. Actin in transcription and transcription regulation. Curr
Opin Cell Biol 2006, 18, 261-6.
23. Kwak, I. H.; Kim, H. S.; Choi, 0. R.; Ryu, M. S.; Lim, I. K. Nuclear
accumulation of globular actin as a cellular senescence marker. Cancer Res 2004,
64, 572-80.
24. Olave, I. A.; Reck-Peterson, S. L.; Crabtree, G. R. Nuclear actin and actin-related
proteins in chromatin remodeling. Annu Rev Biochem 2002, 71, 755-81.
25. Vartiainen, M. K. Nuclear actin dynamics--from form to function. FEBS Lett
2008, 582, 2033-40.
26. Kuo, T. F.; Tatsukawa, H.; Kojima, S. New insights into the functions and
localization of nuclear transglutaminase 2. FEBSJ, 278, 4756-67.
27. Belkin, A. M. Extracellular TG2: emerging functions and regulation. FEBS J,
278, 4704-16.
28. Shimizu, T., et al. Structure of a covalently cross-linked form of core histones
present in the starfish sperm. Biochemistry 1997, 36, 12071-9.
108
29. Mishra, S.; Saleh, A.; Espino, P. S.; Davie, J. R.; Murphy, L. J. Phosphorylation
of histones by tissue transglutaminase. JBiol Chem 2006, 281, 5532-8.
30. Boehm, J. E.; Singh, U.; Combs, C.; Antonyak, M. A.; Cerione, R. A. Tissue
transglutaminase protects against apoptosis by modifying the tumor suppressor
protein p110 Rb. JBiol Chem 2002, 277, 20127-30.
31. Ishikawa-Ankerhold, H. C.; Ankerhold, R.; Drummen, G. P. Advanced
Fluorescence Microscopy Techniques-FRAP, FLIP, FLAP, FRET and FLIM.
Molecules, 17, 4047-132.
32. Koster, M.; Frahm, T.; Hauser, H. Nucleocytoplasmic shuttling revealed by FRAP
and FLIP technologies. Curr Opin Biotechnol 2005, 16, 28-34.
33. Chudakov, D. M., et al. Photoswitchable cyan fluorescent protein for protein
tracking. Nat Biotechnol 2004, 22, 143 5-9.
34. Lummer, M., et al. Reversible photoswitchable DRONPA-s monitors
nucleocytoplasmic transport of an RNA-binding protein in transgenic plants.
Traffic, 12, 693-702.
35. Sturgill, J. F.; Steiner, P.; Czervionke, B. L.; Sabatini, B. L. Distinct domains
within PSD-95 mediate synaptic incorporation, stabilization, and activity-
dependent trafficking. JNeurosci 2009, 29, 12845-54.
36. Diaspro, A., et al. 3D localized photoactivation of pa-GFP in living cells using
two-photon interactions. ConfProc IEEE Eng Med Biol Soc 2006, 1, 389-91.
37. Lippincott-Schwartz, J.; Patterson, G. H. Fluorescent proteins for photoactivation
experiments. Methods Cell Biol 2008, 85, 45-61.
38. Lippincott-Schwartz, J.; Altan-Bonnet, N.; Patterson, G. H. Photobleaching and
photoactivation: following protein dynamics in living cells. Nat Cell Biol 2003,
Suppl, S7-14.
39. Meyer, T.; Begitt, A.; Vinkemeier, U. Green fluorescent protein-tagging reduces
the nucleocytoplasmic shuttling specifically of unphosphorylated STAT 1. FEBS J
2007, 274, 815-26.
40. Dopie, J.; Skarp, K. P.; Rajakyla, E. K.; Tanhuanpaa, K.; Vartiainen, M. K.
Active maintenance of nuclear actin by importin 9 supports transcription. Proc
Natl Acad Sci U S A, 109, E544-52.
109
41. Howell, J. L.; Truant, R. Live-cell nucleocytoplasmic protein shuttle assay
utilizing laser confocal microscopy and FRAP. Biotechniques 2002, 32, 80-2, 84,
86-7.
42. Birbach, A.; Bailey, S. T.; Ghosh, S.; Schmid, J. A. Cytosolic, nuclear and
nucleolar localization signals determine subcellular distribution and activity of the
NF-kappaB inducing kinase NIK. J Cell Sci 2004, 117, 3615-24.
43. Akoumianaki, T.; Kardassis, D.; Polioudaki, H.; Georgatos, S. D.;
Theodoropoulos, P. A. Nucleocytoplasmic shuttling of soluble tubulin in
mammalian cells. J Cell Sci 2009, 122, 1111-8.
44. Roth, D. M.; Harper, I.; Pouton, C. W.; Jans, D. A. Modulation of
nucleocytoplasmic trafficking by retention in cytoplasm or nucleus. J Cell
Biochem 2009, 107, 1160-7.
45. Drake, K. R.; Kang, M.; Kenworthy, A. K. Nucleocytoplasmic distribution and
dynamics of the autophagosome marker EGFP-LC3. PLoS One, 5, e9806.
46. Hildick, K. L.; Gonzalez-Gonzalez, I. M.; Jaskolski, F.; Henley, J. M. Lateral
diffusion and exocytosis of membrane proteins in cultured neurons assessed using
fluorescence recovery and fluorescence-loss photobleaching. J Vis Exp.
47. van Royen, M. E.; Dinant, C.; Farla, P.; Trapman, J.; Houtsmuller, A. B. FRAP
and FRET methods to study nuclear receptors in living cells. Methods Mol Biol
2009, 505, 69-96.
48. Lillemeier, B. F.; Koster, M.; Kerr, I. M. STATI from the cell membrane to the
DNA. EMBO J2001, 20, 2508-17.
49. Yu, W.; Kawasaki, F.; Ordway, R. W. Activity-dependent interactions of NSF
and SNAP at living synapses. Mol Cell Neurosci, 47, 19-27.
50. Schindler, M.; Jiang, L. W. Nuclear actin and myosin as control elements in
nucleocytoplasmic transport. J Cell Biol 1986, 102, 859-62.
51. Oma, Y.; Harata, M. Actin-related proteins localized in the nucleus: from
discovery to novel roles in nuclear organization. Nucleus, 2, 38-46.
52. Hofmann, W. A., et al. SUMOylation of nuclear actin. J Cell Biol 2009, 186, 193-
200.
53. Yamagata, M.; Sanes, J. R.; Weiner, J. A. Synaptic adhesion molecules. Curr
Opin Cell Biol 2003, 15, 621-32.
110
54. Stoltzman, C. A.; Kaadige, M. R.; Peterson, C. W.; Ayer, D. E. MondoA senses
non-glucose sugars: regulation of thioredoxin-interacting protein (TXNIP) and the
hexose transport curb. JBiol Chem 2011, 286, 3 8027-34.
55. Sans, C. L.; Satterwhite, D. J.; Stoltzman, C. A.; Breen, K. T.; Ayer, D. E.
MondoA-Mlx heterodimers are candidate sensors of cellular energy status:
mitochondrial localization and direct regulation of glycolysis. Mol Cell Biol 2006,
26, 4863-71.
56. Percipalle, P.; Visa, N. Molecular functions of nuclear actin in transcription. J
Cell Biol 2006, 172, 967-7 1.
57. Hofmann, W. A., et al. Actin is part of pre-initiation complexes and is necessary
for transcription by RNA polymerase II. Nat Cell Biol 2004, 6, 1094-101.
58. Percipalle, P.; Raju, C. S.; Fukuda, N. Actin-associated hnRNP proteins as
transacting factors in the control of mRNA transport and localization. RNA Biol
2009, 6, 171-4.
59. Elad, N.; Maimon, T.; Frenkiel-Krispin, D.; Lim, R. Y.; Medalia, 0. Structural
analysis of the nuclear pore complex by integrated approaches. Curr Opin Struct
Biol 2009, 19, 226-32.
60. Allen, T. D.; Cronshaw, J. M.; Bagley, S.; Kiseleva, E.; Goldberg, M. W. The
nuclear pore complex: mediator of translocation between nucleus and cytoplasm.
J Cell Sci 2000, 113 (Pt 10), 1651-9.
61. Wang, R.; Brattain, M. G. The maximal size of protein to diffuse through the
nuclear pore is larger than 60kDa. FEBS Lett 2007, 581, 3164-70.
62. Wada, A.; Fukuda, M.; Mishima, M.; Nishida, E. Nuclear export of actin: a novel
mechanism regulating the subcellular localization of a major cytoskeletal protein.
EMBOJ1998, 17, 1635-41.
63. Uttamapinant, C., et al. A fluorophore ligase for site-specific protein labeling
inside living cells. Proc Natl Acad Sci US A, 107, 10914-9.
64. Graf, E. R.; Kang, Y.; Hauner, A. M.; Craig, A. M. Structure function and splice
site analysis of the synaptogenic activity of the neurexin- 1 beta LNS domain. J
Neurosci 2006, 26, 4256-65.
65. Graf, E. R.; Zhang, X.; Jin, S. X.; Linhoff, M. W.; Craig, A. M. Neurexins induce
differentiation of GABA and glutamate postsynaptic specializations via
neuroligins. Cell 2004, 119, 1013-26.
111
66. Cline, H. Synaptogenesis: a balancing act between excitation and inhibition. Curr
Biol 2005, 15, R203-5.
67. Scheiffele, P.; Fan, J.; Choih, J.; Fetter, R.; Serafini, T. Neuroligin expressed in
nonneuronal cells triggers presynaptic development in contacting axons. Cell
2000, 101, 657-69.
68. Graff, J. M.; Stumpo, D. J.; Blackshear, P. J. Molecular cloning, sequence, and
expression of a cDNA encoding the chicken myristoylated alanine-rich C kinase
substrate (MARCKS). Mol Endocrinol 1989, 3, 1903-6.
69. Chen, S. X.; Tari, P. K.; She, K.; Haas, K. Neurexin-neuroligin cell adhesion
complexes contribute to synaptotropic dendritogenesis via growth stabilization
mechanisms in vivo. Neuron, 67, 967-83.
70. Paraoanu, L. E.; Becker-Roeck, M.; Christ, E.; Layer, P. G. Expression patterns of
neurexin-1 and neuroligins in brain and retina of the chick embryo: Neuroligin-3
is absent in retina. Neurosci Lett 2006, 395, 114-7.
71. Levinson, J. N.; El-Husseini, A. A crystal-clear interaction: relating
neuroligin/neurexin complex structure to function at the synapse. Neuron 2007,
56, 937-9.
72. Chen, X.; Liu, H.; Shim, A. H.; Focia, P. J.; He, X. Structural basis for synaptic
adhesion mediated by neuroligin-neurexin interactions. Nat Struct Mol Biol 2008,
15, 50-6.
73. Peterson, C. W.; Ayer, D. E. An extended Myc network contributes to glucose
homeostasis in cancer and diabetes. Front Biosci 2011, 17, 2206-23.
74. Cardoso, S., et al. Insulin is a two-edged knife on the brain. JAlzheimers Dis
2009, 18, 483-507.
75. Fridlyand, L. E.; Ma, L.; Philipson, L. H. Adenine nucleotide regulation in
pancreatic beta-cells: modeling of ATP/ADP-Ca2+ interactions. Am JPhysiol
Endocrinol Metab 2005, 289, E839-48.
76. Fridlyand, L. E.; Philipson, L. H. Glucose sensing in the pancreatic beta cell: a
computational systems analysis. Theor Biol Med Model, 7, 15.
77. Gao, Z. Y.; Li, G.; Najafi, H.; Wolf, B. A.; Matschinsky, F. M. Glucose
regulation of glutaminolysis and its role in insulin secretion. Diabetes 1999, 48,
1535-42.
112
78. Stoltzman, C. A., et al. Glucose sensing by MondoA:Mlx complexes: a role for
hexokinases and direct regulation of thioredoxin-interacting protein expression.
Proc Natl Acad Sci U S A 2008, 105, 6912-7.
113
114
Chapter 4. Considerations for the directed evolution of LplA and
introduction to evolution methods
The work described in this chapter is unpublished.
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Introduction
Using LplA as a platform for labeling both intracellular and cell surface proteins
has proven very advantageous, and the extension of the PRIME methodology to
interaction-dependent labeling (ID-PRIME) has increased the range of biological
problems that can be studied with this method. However, a major limitation of PRIME is
that LplA and its mutants have low activity in the secretory pathway. The remaining
chapters of this thesis focus on the use of directed evolution techniques to produce LplA
variants with improved activity in the secretory pathway and cell surface.
Before beginning the directed evolution of LplA, considerable effort was made to
rationally engineer the enzyme. While these efforts were not successful in producing
LplA variants with improved catalytic activity in the endoplasmic reticulum, they did
inform the approaches used for the directed evolution of the enzyme. In this chapter, we
first present a condensed summary of the rational design efforts and outline the goals for
the directed evolution of LplA. Next, we introduce common methods of directed
evolution and the criteria used to select methods for LplA evolution. Finally, we will
present the initial experiments that were performed before focusing on the yeast-display
directed evolution strategies summarized in Chapters 5, 6, and 7.
Rational engineering of LplA
LplA oxidation and stability
One of the first valuable observations we made about LplA is that storage in
reducing buffer improves and preserves the activity of the purified enzyme. These results
are supported by data from Green and colleagues, who noted that LplA activity declined
during storage to ~15% of original activity after 3 months2 . LplA has six surface
cysteines, none of which are oxidized in the native form of the protein2. Green and
colleagues hypothesized that this inactivation was due to oxidation of the protein,
creating an intramolecular disulfide. This was supported by the determination that, while
active LplA had six reactive thiol groups per molecule, the storage-inactivated LplA had
just four reactive thiol groups per molecule. Interestingly, we found that some mutants of
LplA are more susceptible to storage inactivation, but that storage in buffer containing
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Figure 4-1. Structural homology of LpIs. (A) Crystal structure of apo E. coli LpIA (cyan, PDB IX2G)
aligned with crystal structure of apo Lpl from S. Pneumoniae (magenta, PDB IVQZ). Note that both
enzymes have a large N-terminal and a smaller C-terminal domain. (B) Crystal structure of apo E. coli
LplA (cyan) aligned with apo T. acidophilum LplA (magenta PDB 2ARS, left) and with apo S. agalactiae
(magenta, PDB 2POL, right). (C) Crystal structures of lipoyltransferases aligned with LpIA. Crystal
structure of apo E. coli LpIA (cyan) aligned with apo M. tuberculosis lipoyltransferase (magenta, PDB
1W66, left) and with apo T thermophilus (magenta, PDB 2HQV, right). All structure figures and
alignments were generated in PyMol.
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Another interesting result from the attempts to rationally engineer LplA is that C-
terminal truncations of LplA increase enzyme stability and solubility. When we made
truncations of LplA at Pro249 (removing the entire C-terminal domain, vide infra) and
expressed the protein in . coli, the soluble fraction of the protein increased; this effect
was even more pronounced for mutants of LplA that were difficult to express (data not
shown). When we assayed the activity of the Pro249 LplA truncation, we observed that,
while lipoyltransferase activity was unaffected, the truncated enzyme had severely
decreased adenylation activity. Intrigued by this, we wanted to explore the potential for
engineering the activity of the N-terminal domain of LplA to achieve site-specific
labeling with this smaller enzyme.
As previously discussed, LplA catalyzes the ligation of lipoic acid in a two-step
reaction: an adenylation step, where lipoic acid is activated with ATP to form lipoyl-
AMP, then a lipoyltransferase step, where the lipoate is transferred to the protein
substrate. While E. coli LplA can perform both steps of the lipoylation reaction, some
species require a separate enzyme for each step. Many bacterial Lpls have two domains,
one large N-terminal domain and a small C-terminal domain. Examples of this are E. coli
LplA (PDB lX2G)3 and Lpl from Streptococcus pneumoniae, (PDB lVQZ) which are
structurally homologous (Figure 4-1). These enzymes are capable of catalyzing both steps
of the reaction. On the other hand, several species have Lpls with just one domain that is
structurally homologous to the N-terminal domain of E. coli LpIA. Examples of this are
Lpls from Thermoplasma acidophilum (PDB 2ART and 2C8M)4'5 and Streptococcus
agalactiae (PDB 2POL) (Figure 4-1B). Only the Lpl from T acidophilum has been
characterized in terms of lipoylation activity and can catalyze only the adenylation step of
the reaction5 . This information leads to the natural hypothesis that the N-terminal domain
of E. coli LplA is responsible for the adenylation step and the C-terminal domain is
responsible for the transfer step. However, when we consider the structures of various
bacterial lipoyltransferases that have been solved (Mycobacterium tuberculosis, PDB
1W66; T thermophilus, PDB 2QHV)6'7 , these enzymes do not have adenylation activity,
but their structures also align with just the N-terminal domain of LplA (Figure 4-1 C).
Based on the structures available, the relationship between the multi-domain LplA
enzyme and its two-step enzymatic activity was not clear.
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Figure 4-1. Structural homology of Lpls. (A) Crystal structure of apo E. coli LpIA (cyan, PDB IX2G)
aligned with crystal structure of apo Lpl from S. Pneumoniae (magenta, PDB IVQZ). Note that both
enzymes have a large N-terminal and a smaller C-terminal domain. (B) Crystal structure of apo E. coli
LpIA (cyan) aligned with apo T. acidophilum LpIA (magenta PDB 2ARS, left) and with apo S. agalactiae
(magenta, PDB 2POL, right). (C) Crystal structures of lipoyltransferases aligned with LpIA. Crystal
structure of apo E. coli LplA (cyan) aligned with apo M tuberculosis lipoyltransferase (magenta, PDB
IW66, left) and with apo T. thermophilus (magenta, PDB 2HQV, right). All structure figures and
alignments were generated in PyMol.
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Soon after starting this project, a crystal structure of K coli LplA with the bound
lipoyl-AMP intermediate was published that provided insight into the interaction and
functions of the N- and C-terminal domains8 . This crystal structure demonstrated that
LplA undergoes a global conformational change between the apo form of the protein and
the lipoyl-AMP-bound form of the protein (Figure 4-2). In the apo form of the protein,
the N-terminal and C-terminal domains are linked by a short loop (red). Upon formation
of the adenylate ester, LplA undergoes three conformational changes. The adenylate
binding loop (magenta) and the lipoate binding loop (yellow) close down on the lipoyl-
AMP (cyan), shielding the activated intermediate from solvent. The third conformational
change is a huge 180 rotation of the C-terminal domain (green). The rotation of this
domain is thought to be required for proper protein substrate binding and lipoyltransfer.
This hypothesis is supported by the observation that bovine lipoyltransferase is
structurally homologous to the activated stretched conformation of . coli LplA (Figure
4-3). However, it is not known if flipping of the C-terminal domain is required for LAP2
binding.
121
90:
substrate binding
and
adenylation
90:
substrate binding
and
adenylation
Figure 4-2. E. coli LpIA undergoes a global conformational change. Top structure is of apo E. coli
LplA. The N-terminal domain (grey) and C-terminal domain (green) are connected by a loop (red). The
lipoate-binding loop (blue) and adenylate binding loop (magenta) both close over the lipoyl-AMP (cyan)
upon adenylate formation (bottom structures, PDB 3A7R) and the C-terminal domain rotates 180 degrees.
All structure views created using PyMol.
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Figure 4-3. Comparison of bovine lipoyltransferase and lipoyl-AMP bound E. coli LpIA. E. coli LplA
with lipoyl-AMP bound (PDB 3A7R) is aligned to the apo form of bovine lipoyltransferase (PDB 3A7U).
All structure views were created using PyMol.
This data helps explain the results we observed with truncated LplA. With the
truncated LplA, we observed lipoyltransferase activity similar to wild type. We
hypothesize that since the C-terminal domain is deleted, and therefore not blocking or
controlling protein binding, the transfer step is not affected. The decrease in adenylation
activity may have several sources. First, it could be that the 1800 rotation of the C-
terminal domain comes before the chemistry step for lipoyl-AMP formation and is
required for efficient adenylation. Little data exists to support this hypothesis, and the
truncated LplA does have some adenylation activity; however, as we discuss in Chapters
6 and 7, full-length LplA variants with improved catalytic activity have highly mutated
C-terminal regions, which may indicate a relationship between adenylation and the C-
terminal domain. Second, we noticed that in the lipoyl-AMP bound form of LplA, part of
the adenylation loop interacts with residues 250-255 in the C-terminal domain (Figure 4-
4). It may be that when these residues are not present, the adenylation loop has fewer
interactions to induce closure over the small-molecule binding pocket and lipoyl-AMP
formation is inhibited by solvent exposure. This hypothesis is supported by the fact that a
truncation of LplA at Glu256 has increased adenylation activity compared to the Pro249
truncation, although is not as robust as full-length LplA (see Chapter 5). Attempts at
improving adenylation activity by adding mutations or further adjusting the extent of
LplA truncation were not successful (data not shown).
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Figure 4-4. Residues 250-256 of LpIA may be necessary for closing adenylation loop. Crystal structure
of E. coli LpIA with lipoyl-AMP bound (PDB 3A7R). The region depicted in red corresponds to residues 1-
249, and represents the first truncated LpIA tested. The lipoate-binding loop (blue) and adenylate-binding
loop (magenta) both close over the lipoyl-AMP (cyan) upon adenylate formation and the adenylate-binding
loop interacts with residues 250-256 (yellow) in the C-terminal domain. These residues were added on to
the second truncated LplA tested (LpIA-NTD, see Chapter 5). Structure view created in PyMol.
We determined that directed evolution of LplA might produce more promising
results than the moderate successes obtained from rational design. Based on the exciting
results obtained using the N-terminal domain of LplA, we decided to proceed with a two-
pronged directed evolution approach. One arm of the project focused on the evolution of
LplA-NTD and the other arm was geared towards the evolution of full-length LplA. The
overarching goal for the evolution projects was to produce LplA variants with improved
activity in the endoplasmic reticulum and cell surface. However, there were additional
preliminary goals for the evolution of LplA-NTD. The first goal was to simply develop
an LplA-NTD variant with adenylation activity as good or better than full-length LplA.
The second goal was to then select for LplA-NTD mutants that were capable of ligating
unnatural probes. With these goals in mind, we explored potential avenues for directed
evolution of enzymatic activity.
Methods of directed protein evolution
Directed protein evolution is a powerful technique for improving existing
properties of proteins and has even been used to produce new protein function. While
rational design can be a valuable tool, it requires extensive knowledge about the
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functional, structural, and mechanistic properties of an enzyme. Directed enzyme
evolution, on the other hand, does not require a priori knowledge about the protein's
properties in order to produce the desired characteristics. The general strategy for
directed evolution is to first create a diverse library of genes that encode the expression of
a collection of protein variants. Then, using a phenotype selection strategy, the proteins
with the desired attributes are isolated from the library and the genes encoding that
population of proteins are amplified. Through iterative rounds of gene expression,
phenotype selection, and gene amplification, the library becomes enriched in genes that
encode for proteins with the desired properties. The crux of directed evolution is that
there must be a stable link between phenotype and genotype.
In Darwinian evolution, the membranes of the living cell serve to encapsulate
proteins and thus connect genotype and phenotype. There are various in vivo directed
evolution methods that mimic nature and use cells to preserve this link. With in vivo
directed evolution, the gene diversification, protein selection, and gene amplification
steps all occur inside living cells9 . In addition, there are methods that we will call semi-in
vitro that perform the gene diversification step outside of living cells, but then the
diversified library is introduced into living cells via transformation or transfection. All
subsequent selection and gene amplification steps occur inside cells. Finally, there are
also several in vitro directed evolution methods that work outside of the confines of the
living cell and thus require different methods of linking genotype and phenotype. We will
briefly discuss existing in vivo directed evolution methods and then present the semi-in
vitro and in vitro directed evolution methods that are most frequently used in the
literature.
In vivo directed evolution
In vivo methods require mutation and gene diversification to occur within the cell,
which is usually achieved by using E. coli strains that have introduced error-prone
polymerases or have knocked-down DNA repair pathways 0 . Controlling the error rate in
the target gene is very difficult using these methods. When the repair pathways are
knocked down, only low mutation rates (~A mutation per 2kb) are achievable'"' and
endogenous genes will be mutated as well. The use of error-prone polymerases increases
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the target gene error rate, but still presents the issue of introducing mutations into
endogenous genes as well as target genes. To circumvent this problem, the Loeb lab
developed a method that uses an error-prone Poll polymerase . Since Poll is primarily
involved in replication of the ColEl plasmid, this technique leaves most endogenous
proteins unaffected. This method produces error rates of approximately 2 mutations per
2kb, but because Poll is primarily involved in transcription initiation, these mutations are
maximal in the first 700bp from the origin of replication9 12
After library diversification, E. coli can be selected using either drug resistance
markers or screened for engineered manifestations of the desired property. In general,
prokaryotic evolution methods are desirable because genome engineering is
straightforward, culturing is simple, doubling time is fast, and libraries can be made and
selected in a short time9. Recent work has even demonstrated that entire prokaryotic
pathways can be adjusted using in vivo directed evolution13 ; including pathways to
produce chiral drug intermediates14 and useful alcohol-based fuels 5 . However, the
prokaryotic methods are limited to proteins that express well inside prokaryotic cells.
Any targets that require eukaryotic-specific post-translational modifications or folding
pathways will not be amenable to this method. Since the goal for the directed evolution is
to produce an LplA variant with improved activity in the secretory pathway, prokaryotic
directed evolution is not an appropriate platform for LplA evolution.
When evolving eukaryotic proteins, an in vivo eukaryotic method is ideal since
the protein can evolve in a natural environment, with all of the folding and post-
translational modification machinery in place. Some eukaryotic in vivo evolution
methods use modified yeast strains where the methods of gene diversification are similar
to those used in prokaryotic methods, such as using repair-deficient yeast strains9 . These
methods have the same limitations in terms of genetic diversity as their prokaryotic
counterparts. To address this issue of genetic diversity, researchers can take advantage of
the somatic hypermutation that occurs in B-cells' 6-8 . Somatic hypermutation is used in
the immune response to randomize the variable regions of immunoglobulin (Ig) light and
heavy chains. By inserting the target gene into regions flanking the hypermutable Ig
genes, mutation rates of up to 2 mutations per 1kb can be achieved. However, delivery at
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the target locus flanking the Ig site is difficult to achieve specifically; most examples use
random integration using viruses and then subsequent screening for proper transgene
integration at the desired locus. To address this issue of low ratio of targeted to random
transgene delivery, labs have turned to B cells from chicken or swine, which are able to
undergo homologous recombination and thus can be used to achieve targeted transgene
integration19,20. Eukaryotic in vivo methods have been used to evolve antibodies 20,21 and
fluorescent proteins 16. However, when working with living cells it is difficult to control
selection conditions for improving enzyme activity, and even then, the organism may
accommodate selective pressure through the effects of off-target proteins or pathways.
While this is a problem for the evolution of specific activity in a single protein, this
feature is one of the reasons these in vivo methods are perfect platforms for evolving
metabolic pathways or complex protein networks.
Semi-in vitro directed evolution
A significant drawback to using an in vivo method is the difficulty in controlling
the mutation rate and diversification of the target genes. This is why many directed
evolution methods utilize a semi-in vitro approach where genetic library design and
diversification are performed in vitro, but cells are used for the selection and gene
amplification steps. For example, powerful error-prone PCR or DNA shuffling
techniques can be used to generate a large library of gene variants, which can then be
transformed into E coli or yeast or transfected into mammalian cells for intracellular
expression and subsequent downstream selections and amplification. Unlike in vivo
methods, where gene diversification occurs simultaneously with gene amplification,
when using semi-in vitro methods the gene library must be isolated from the host and re-
diversified in vitro, if desired. One significant limitation to most semi-in vitro methods is
that the selection strategy must be cell-compatible (selections using phage display are the
exception).
One benefit of performing the gene diversification process in vitro is that the
mutation rate can be exquisitely controlled. In vitro library generation techniques also
allow researchers to focus mutations in specific areas of the protein of interest, which can
be extremely valuable when evolving enzyme activity. Moreover, techniques such as
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error-prone PCR can produce very high mutation rates: up to 15 mutations per 1 kb when
only altered salt concentrations are used'0 , and rates as high as 200 mutations per 1kb
when dNTP analogues are included. While gene libraries generated by in vitro
techniques can easily have >1011 unique members' 0, the overall library size using a semi-
in vitro method is limited by the delivery efficiencies into the cells being used (bacteria,
<1010; yeast, (<108) ; mammalian cells (<108)24-27.
In addition to intracellular methods, there are various semi-in vitro directed
evolution methods that use displayed protein for selections. Existing display strategies are
phage display, bacterial display, yeast-display, and mammalian display. The most
frequently used of these methods is M13 phage display28 ,29 . In this method, the protein to
be evolved is displayed on the surface of the M13 filamentous phage particle, and the
gene encoding the protein is packaged within the phage particle. Phage-display is semi-in
vitro because the phage must be amplified within infected E. coli and there is an in vivo
selection against proteins that are unstable or poorly exported. Phage-display has most
frequently been used to evolve new antibodies 0'3 and binding or substrate peptides32 34
Unfortunately, the use of phage-display to select for enzyme catalysis has been limited.
Some groups have used phage to display enzyme variants and select for binding to
transition-state analogues or known mechanism-based inhibitors29, with limited success.
Others have used a strategy where the substrate is covalently attached to the phage and
product is monitored by intra-molecular reaction of the enzyme and substrate on the
phage particle itself3 6,37 . However, reported enrichment factors in model selections are
very low (<10-fold), indicating this strategy has limited dynamic range and does not
adequately discriminate between active and inactive library members.
Bacterial-display, yeast-display and mammalian cell display are all related
methods that have been used for protein evolution. These methods display the proteins on
the cell surface by making library fusions to surface proteins or to transmembrane
domains38-40. Through technology developments, the issue of library delivery and
expression control has been solved for both bacterial39 and yeast surface display4'
through technology developments. However, library delivery is still problematic for
mammalian cell surface display. For example, stable transfection of foreign DNA
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produces multiple integrations into the host cell genome, often resulting in multiple
library members expressed in the same cell 42. To address this issue, viral infection has
frequently been used in an attempt to control multiplicity of plasmid delivery43 44.
Recently, Amgen has published a method that uses homologous recombination to achieve
defined integration at a single site in the genome4 7. This is a considerable technological
advance, which should make mammalian surface display more amenable to enzyme
evolution. Still, there have been several reports of directed enzyme evolution using
bacterial display45 and yeast display25,46, yet there have been no such examples of enzyme
evolution using mammalian cell display.
In-vitro directed evolution
When using in vitro directed evolution methods, all steps of the evolution process:
gene diversification, protein translation and selection, and gene amplification, are
performed in vitro. These methods require specific techniques to link genotype and
phenotype. Two of the most frequently used in vitro methods for providing this link are
mRNA display and ribosome display24 ,48 . Ribosome display uses mRNA sequences that
have been engineered without a stop codon. When performing translation of these
engineered sequences, the ribosome stalls on the mRNA producing a complex of
translated protein and mRNA linked via the halted ribosome. Ribosome display has been
used to evolve peptide binders49' 50, antibodies5 - , and proteins with improved stability 54.
The Szostak group developed a conceptually similar approach called mRNA display. In
mRNA display, the ribosomal inhibitor puromycin is conjugated to the mRNA; when
proteins are translated from the mRNA and when the puromycin terminator is reached, a
covalent link between the newly translated protein and the mRNA is formed.
In vitro compartmentalization (IVC) is a technique that mimics the cell by
encapsulating the genetic library in aqueous droplets of an oil-water emulsion*4 ' 56. This is
done at concentrations such that, at most, only one DNA copy exists per compartment.
This method allows very large libraries to be screened; for example, a library of 1010
members can be effectively compartmentalized in just 50 ptL of an emulsion8 . This
method is often combined with mRNA or ribosome display to improve control of
reaction conditions, concentrations, and protein expression. Compartmentalization serves
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to prevent product or protein diffusion and to standardize protein expression by ensuring
equal distribution of in vitro translation components5 6 . This technique has been used to
evolve several binding proteins57, including an RNA-binding protein with altered
specificity 58, and p53 variant with improved recognition of low-response elements59.
Enzyme activity is more difficult to evolve; but in vitro compartmentalization has been
used to change and improve the substrate specificity of a methyltransferase6 0 and change
the substrate recognition of endonucleases 1 . It is telling that the majority of these
successes are for enzymes or proteins that directly bind DNA or RNA. This is due to the
limited methods to link product to DNA using a completely in vitro system. Recently
Griffiths and colleagues have combined IVC with FACS to circumvent this issue and
have been able to evolve improved activity of a phophotriesterase62 . This result and other
similar approaches are discussed in detail in Chapter 7.
One benefit of using a purely in vitro directed evolution method is that larger
libraries can be created and selected than what are feasible using semi-in vitro methods.
In theory, library sizes as large as 1015 can be generated and screened, although in
practice library sizes usually range from 1010o13 48,63-65. Therefore, these libraries can be
102-104 times larger than those practically obtained using the previously described
methods. Moreover, since in vitro evolution methods utilize in vitro protein translation,
difficult targets can be evolved, such as extremely unstable or even toxic proteins. In
vitro methods are also advantageous because selection conditions can be easily modified
and selection strategies that are incompatible with living cells are possible. One
drawback, however, is that without the encapsulating membranes of a cell, the method of
linking genotype-phenotype must be carefully considered. More importantly, if enzyme
activity is the goal of the selection, the enzymatic product must somehow be associated
with the resulting DNA or encapsulated using IVC.
Criteria for a directed evolution method
The goal for these projects is to evolve an LplA variant that has increased activity
in the secretory pathway of the living cell. Using eukaryotic cells would allow us to
evolve LplA in the environment where we will later be applying the enzyme. The ability
to use powerful in vitro library generation methods such as error-prone PCR or DNA
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shuffling is also desirable, particularly because the mechanism for LplA activity loss in
the secretory pathway is not understood. For these two reasons, a semi-in vitro eukaryotic
cell-based method would be ideal for LplA evolution. The final question is whether to
use a method that displays the enzyme on the surface of a cell or to rely on intracellular
labeling and detection. We decided to investigate the use of yeast-display and
mammalian cell-display since a display method permits us to monitor enzyme expression
level by antibody staining while using a variety of methods to detect labeling signal.
Moreover, since the enzymes displayed on the cell surface have been trafficked through
the endoplasmic reticulum, these methods allow for the selection of activity in the
secretory pathway.
In the results section of this chapter, we describe our initial attempts at using
mammalian-cell based FACS to evolve improved full-length LplA activity. While model
selections in mammalian cells looked promising, we will discuss the various issues that
made this evolution route untenable.
Results
Demonstration of cis labeling of E2p by LplA when co-expressed on HEK cell surface.
For this evolution strategy, we decided to use HEK cells since these cells are
small, have high transfection efficiencies, and fast doubling times. We proposed using a
selection platform where the ligase and peptide substrate are co-displayed on the
mammalian cell surface. Using this platform, enzymatic activity can be assayed by
incubating cells with probe and ATP and monitoring the cis labeling of the substrate by
the co-expressed enzyme.
Our lab has previously demonstrated that LplA substrates can be highly expressed
on the mammalian cell surface as fusions to CFP with the inclusion of a single
transmembrane domain (LAP2-CFP-TM and E2p-CFP-TM). Unfortunately, when
WTLplA was fused to an FP-TM in an identical geometry, the fusion had extremely poor
surface delivery and formed aggregates along the secretory pathway (data not shown). To
address this issue, we tested the surface delivery of WTLplA fusions to other surface
proteins (neurexin-lp, LDLR, and neuroligin-1). Of all the constructs tested, WTLplA-
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neurexinlp fusion gave the best surface expression (data not shown). For this reason, all
subsequent mammalian cell-surface optimizations and testing use LplA-neurexin-1p
fusions. While the downstream goal of this evolution is to evolve LplA activity for the
labeling of LAP2 fusions, LplA has higher cis lipoylation activity with E2p on the cell
surface (data not shown). For this reason, model selections and initial optimizations of
mammalian cell labeling use co-displayed E2p-CFP-TM
The first step in the development of a HEK cell evolution platform was to
determine whether the cis labeling strategy described above could effectively distinguish
between highly active and moderately active or inactive ligases. As proof-of-principle,
we first performed the simplest experiment using a cis lipoylation assay (Figure 4-5A). In
this assay, we determined the cis lipoylation activity of WTLplA and compared this to the
cis lipoylation activity of two less active variants (W3 7vLplA or W3 7ALplA) or an inactive
variant (K133RLpIA). After labeling and performing antibody staining for lipoylation and
for enzyme expression level, we analyzed the samples by fluorescence imaging and
fluorescence activated cell sorting (FACS) (Figure 4-5B-C). From these data it is clear
that the proposed selection scheme can effectively distinguish between active and less
active ligases using both fluorescence imaging and fluorescence activated cell sorting.
Interestingly we were even able to distinguish between the cis lipoylation activity of
W37vLplA and the slightly more active W37ALplA mutant.
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Figure 4-5. Cis lipoylation on mammalian cell surface is robust and discriminating. (A) Scheme for cis
labeling on the mammalian cell surface. E2p-CFP-TM and LpIA-neurexin-lp (NRX) are co-expressed on
the mammalian cell surface. Cells are incubated with lipoic acid and ATP and the enzyme is capable of
lipoylating the E2p substrate. The lipoylation is detected by antibody staining (yellow) and FLAG staining
reports on the enzyme expression level. (B) Fluorescence imaging of cis lipoylation on HEK cell surface.
Cells were prepared and labeled as described in (A). Top row shows extent of lipoylation using WTLpIA.
Middle rows show extent of lipoylation with less-active mutants, W3 7 LplA and w3 7vLpIA. Bottom row
shows that when a dead mutant of LplA is used (KI33RLplA) there is no lipoylation observed. (C) HEK cells
prepared identically to those described in (B) were analyzed by FACS. Each dot in the scatter plot
corresponds to an individual cell. Lipoylation level is on x-axis, while enzyme expression is on the y-axis.
Row designations correspond to rows in (B).
Model selection of LplAs displayed on HEK cell surface
The next step was to determine whether active ligases could be enriched from a
heterogeneous population of cells using FACS. To do this, we performed one round of
model selection on mixtures of WTLpLA and W37vLplA HEK. For the model selections,
transfected HEK cells were mixed in 1:1, 1:10, and 1:100 ratios of WTLplA: W37VLplA
yeast and then labeled with lipoic acid. After fluorophore staining, HEK cells that
exhibited a high ratio of labeling to enzyme expression were sorted out (Figure 4-6). The
FACS plots demonstrate that the population of highly labeled HEK cells decreased with
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increasing dilution of WTLp1A. DNA was recovered from both the unsorted mixtures and
the sorted cells for subsequent analysis of the enrichment factor of this selection strategy.
1:1 1:10 1:10
wTLplA: "LpIA wLplA : w3vLpA wLplA: w"VLplA
Lipoytation Lipoylation Lipoylation
Figure 4-6. Model selection for enrichment of lipoylation activity. HEK cells expressing E2p-CFP-TM
and either WTLplA-neurexin-1p or w37vLplA-neurexin-1p were labeled in cis as in Figure 4-5 and then
mixed in ratios of 1:1, 1:10, or 1:100 w LpIA:W37vLpIA expressing cells. The cells were then sorted via
FACS using the gate shown. This gate was designed to select out highly labeled HEK cells.
Two strategies to determine enrichment factor were tested. First we attempted to
analyze the DNA directly using a PCR assay. We had previously modified the WTLp1A-
neurexin- 1p DNA by adding 200 base pairs to the non-coding region of the plasmid. This
modification allowed the use of identical primers to amplify the plasmid mixture and
distinguish between the wTLplA and wnvLplA populations based on amplicon size.
Unfortunately, it became clear that the PCR assay was introducing a bias, selectively
amplifying the w37vLp1A insert over the WTLp1A insert (Figure 4-7A). This bias was
present even when using known ratios of purified plasmid DNA. This approach was
therefore abandoned in favor of direct sequencing analysis of the isolated DNA samples.
By analyzing the sequencing chromatogram at the W37 residue, the ratio of wTLplA and
W37VLp1A can be determined accurately (Figure 4-7B). From this data, we calculated that
this selection strategy gives 50-fold enrichment of WTLp1A over the less-active W37V
mutant.
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Figure 4-7. Methods for determining model selection enrichment. (A) PCR amplification assay for
enrichment. WTLplA-neurexin-lb has an additional 200 base pairs added to the non-coding region of the
DNA, so that it can be distinguished from W37vLplA-neurexin-lb using identical primers. The PCR
reactions were performed and products run on a gel. When using either DNA isolated from HEK cells
(Lanes 1-4, left), or simply template DNA mixed in vitro (Lanes 1-4, right), there is a bias in the PCR
amplification. (B) Sequencing assay for enrichment. HEK cells were lysed after sorting and the plasmid
DNA isolated and sent for sequencing. By analyzing the sequencing chromatograms at residue 37 of LpIA,
the ratio of WTLpIA: W37vLpIA can be determined. After comparison of DNA mixtures before and after
sorting it was determined using this assay that one round of selection can produce -50x enrichment.
These results demonstrate that the mammalian cell based selection strategy can
give good enrichment using transiently transfected cells. Before we began actual library
selections, however, two points must be addressed. First, since the FACS selections gate
on substrate labeling and enzyme expression only, the amount of substrate needs to be
consistent across all library members. For this, we created HEK cell lines stably
expressing LAP2-CFP-TM and E2p-CFP-TM (data not shown). Second, the issue of
library delivery needs to be addressed. We determined that we would use error-prone
PCR to create a library of LplA mutants (see Chapter 5 for protocol details). However, as
previously mentioned, one of the problems with using mammalian cell-based evolution
platforms is the difficulty of achieving delivery of <I library member per cell. At the time
we were working on this project, the best option was to use viral delivery of library
members 47. Since then, a group has reported use of a FLIP-IN system which stably
integrates plasmid DNA at a single locus using CHO cells stably expressing Flp
recombinase38 . This is a fantastic development, because stable integration at a single
locus eliminates potential variations in expression levels of library members from gene
silencing that are common when using random genomic integration.
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Viral infection gives poor LplA surface expression in HEK cells
Since viral delivery was the most promising technique available at the time of
these experiments, we proceeded to test viral transduction and expression of WTLplA-
neurexin-IP. The commercial RetroMax viral delivery system was used to prepare
viruses and expression plasmids. Using this system, we were able to achieve fantastic
viral delivery and expression of a cytosolic WTLplA-GFP control plasmid (Figure 4-8,
top). However, no surface expression was observed when using W LplA-neurexin-IP
(Figure 4-8, middle). Antibody staining after cell fixation demonstrated that viral delivery
of the plasmid was successful and the protein was being expressed, but it was not
trafficked properly to the cell surface under these conditions (Figure 4-8, bottom). Further
optimization of the viral plasmid (such as adjusting the linker between wTLplA and the
neurexin) did not recover the level of surface expression we observe when the plasmid is
transiently transfected.
GFP/anti-FLAG DIC Mer e
wTLpLA-GFP
FLAG-wTLplA-NRX
Live cells
surface antibody staining
FLAG-wLpA-NRX
Fixed cells
Whole-cell antibody staining
Figure 4-8. Viral infection of WTLpIA-neurexin-1p gives poor surface expression. HEK cells were
infected using packaged retrovirus prepared using the RetroMax kit (Imgenex). When infecting using
WTLpIA fused to cytosolic GFP (WTLplA-GFP) expression is good and transduction efficiency is ~10% (top
row). When infecting using wTLplA-neurexin-1p (NRX), there is no labeling when performing surface
antibody staining for enzyme expression (FLAG, middle row). However, when the infected HEK cells are
fixed and then stained for enzyme expression, signal is observed (bottom row), indicating good expression
but poor surface delivery.
When this result was obtained, it had just been determined that HEK cell viability
after FACS sorting was less than 20%. With viability this low, the HEK cells could not
be propagated through rounds without drastically reducing library diversity due to cell
death. Instead the cells would need to be lysed after sorting followed by DNA recovery,
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new virus preparation, and infection of fresh HEK cells for the next round of selections.
As the technological difficulties associated this approach became increasingly apparent,
we abandoned mammalian cell surface display in favor of yeast-display. While
mammalian display is in its infancy with no examples of evolved catalytic activity, there
are several examples of using yeast-display to evolve enzymatic activity. The literature
precedence for enzyme evolution 25,46, combined with the improved recovery of yeast
cells from FACS were the most important factors in our decision to switch to a yeast-
display platform. The yeast-display evolution of LplA will be discussed in Chapters 5-7
of this thesis.
Conclusions
This chapter summarizes the results of the rational engineering of LplA. While we
were able to determine that LplA activity in the secretory pathway and cell surface is
affected by enzyme oxidation state, there are additional pathways of enzyme inactivation
that we were not able to identify directly. These factors could be general enzyme stability
or enzyme misfolding. We also demonstrated that truncation of LplA improves enzyme
stability and LplA-NTD retains full lipoyltransferase activity and partial adenylation
activity. Since rational engineering of LplA was largely unsuccessful in restoring activity
in the secretory pathway, and the source of enzyme inactivation is not entirely clear, we
determined that directed evolution of the enzyme might produce better results.
We decided that a semi-in vitro directed evolution method be ideal for the
selection of LplA variants. It would simultaneously allow the use of powerful in vitro
library generation techniques while permitting selection for activity along the secretory
pathway of living cells. We identified two routes of enzyme evolution, one focused on
evolving LplA-NTD for protein labeling and one focused on evolving full-length LplA
for improved activity in the secretory pathway.
We first tested a mammalian cell surface display evolution platform on full-length
LplA. While this platform produced ~50x enrichment of active ligases in a model
selection, there were two significant problems that led to the abandonment of this
approach. First, the recovery of mammalian cells after sorting was very poor. As a result,
preventing the loss of library diversity due to cell death would require that the library
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DNA be isolated between each round of selection, which would complicate this strategy.
Second, the viral delivery of our target gene produced extremely poor surface expression
and infection was difficult to achieve reproducibly over several batches of virus. This
issue, combined with the need to perform viral delivery at each round to deal with poor
cell recovery, made continuing with this directed evolution platform untenable. We
therefore turned to yeast-display evolution which is a much more established method of
directed evolution. The remaining chapters of this thesis focus on the efforts to use yeast-
display evolution to improve various properties of LplA. The results of the yeast-display
evolution of LplA-NTD are summarized in Chapter 5 and the results of the yeast-display
evolution of full-length LplA are discussed in Chapter 6 and Chapter 7.
Experimental
Cis lipoylation on mammalian cell surface (Figure 4-5, Table 4-1)
HEK cells were transfected with 600 ng of E2p-CFP-TM and 600 ng of WTLplA-
NRX or the indicated LplA mutant using Lipofectamine 2000 (Invitrogen) per
manufacturer's protocol. 12 hours post-transfection cells were labeled with 500 piM lipoic
acid, 5 mM Mg(OAc) 2, and 1 mM ATP for 6 hours at 30C. For all samples, cells were
washed 2 x 10 minutes with DMEM and then lipoylation was detected via live-cell
antibody staining. Live-cell immunofluorescence staining was performed with 4 ptg/ml
anti-lipoic acid antibody (CalBiochem) and 4 pig/ml anti-FLAG antibody (Stratagene) in
1% BSA in DPBS for 15 minutes. After three quick washes, cells were incubated with 4
pg/ml goat anti-rabbit antibody conjugated to AlexaFluor 488 and 4 pg/ml goat anti-
mouse AlexaFluor 568 (both Invitrogen) in 1% BSA in DPBS for 15 minutes, then
washed and imaged.
For FACS analysis, HEK cells plated into T25 flasks were transfected with 4 jig
of E2p-CFP-TM and 4 ptg of WTLplA-NRX or the indicated LplA mutant. Labeling was
performed identically to above and then the adherent HEK cells were mechanically lifted
from the flasks and resuspended in DMEM at 1 x 106 cells/ml for FACS analysis.
Model selection for lipoylation on HEK cell surface (Figure 4-6, 4-7)
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For FACS analysis, HEK cells plated into T25 flasks were transfected with 4 ig
of LAP2-CFP-TM and 4 tg of WTLplA-NRX or W3 7ALplA-NRX using Lipofectamine
2000 (Invitrogen) per manufacturer's protocol. Labeling was performed as described
above in cis lipoylation on mammalian cell surface and then the adherent HEK cells
were mechanically lifted from the flasks and resuspended in DMEM at 1 x 106 cells/ml.
The two pools of HEK cells were then combined in 1:1, 1:10, or 1:100 ratios of WTLplA:
W37VLplA. Approximately 250 tL of each mixed sample was removed and saved for
subsequent DNA isolation and sequencing, the remaining sample was sorted via FACS
and using the indicated sort gates.
Pre-mixed HEK samples and sorted HEK cells were pelleted, lysed and the
plasmid DNA isolated. Isolated DNA was then sequenced and sequencing
chromatograms were analyzed to determine enrichment factors for the model selection.
Viral transduction of LplA-NRX (Figure 4-8)
Viral transduction was performed according to the RetroMax Retroviral system
(Imgenex). HEK cells were transfected with the viral expression gene: pCLNCX
WTLplA-NRX or pCLNCX WTLplA-GFP and the viral packaging gene: pCLAmpho. 2
hours post-transfection, change media. 24 hours after media change, collect virus-
containing supernatant from the cells. Virus was filter-sterilized and stored in aliquots at -
80C. Virus was used in 1:10 or 1:20 titres in conditioned media with 8 ig/ml Polybrene
and incubated with cells for 24 hours.
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Chapter 5. Yeast-display evolution of a truncated LplA for site-specific
protein labeling
The work discussed in this chapter is unpublished. The first model selections and first-
generation selections for LplA-NTD variants with both adenylation and lipoyltransferase
activity were performed by Dr. Sujiet Puthenveetil. Philip Zegelbone assisted with the in
vitro characterization of WTLplA-NTD and T 7ILplA-NTD.
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Introduction
We describe in this chapter the efforts to use yeast-display to evolve the N-
terminal domain (NTD) of E coli Lp1A. The first goal of this evolution project was to
improve the ability of LplA-NTD to catalyze the adenylation step of the natural reaction.
The second and more ambitious goal is to evolve LplA-NTD variants that can catalyze
the adenylation and ligation of unnatural probes. The development of such an enzyme
would have two far-reaching benefits for the PRIME methodologies. First, reducing the
size of the ligase by almost 30% (~36kDa to ~26kDa) would make LplA labeling more
attractive for applications such as ID-PRIME. When performing intracellular PRIME
labeling, the large size of LplA is not a factor. However, enzyme size is a significant
issue in ID-PRIME. Because the enzyme is fused to a protein of interest in ID-PRIME
applications, fusions to full-length LplA may interfere with biology as is observed with
GFP and other protein-based labeling methods. Second, since yeast-display will be used
to evolve the truncated LplA-NTDs, any evolved variants selected for increased catalytic
activity would be concomitantly selected for improved activity when expressed on the
cell surface. Therefore, the ligases would also address the original overarching goal of
these LplA-based selections: produce a ligase with better activity in oxidizing
compartments of the cell.
This chapter is divided into two sections. In the first section, we present the
directed evolution of an LplA-NTD variant with better lipoylation activity than WTLp1A.
We first compare the lipoylation activity of the original WTLplA-NTD and full-length
WTLplA on the mammalian cell surface and in vitro. Then we briefly describe the general
yeast-display platform and the selection strategy that produced LplA-NTD variants
capable of catalyzing both the adenylation and transfer steps of the lipoylation reaction.
The lipoylation activities of the resulting ligases are characterized on mammalian cells
and in vitro and the contributions of the consensus mutations are investigated. These
consensus mutations informed and focused the second generation of LplA-NTD
selections, which we describe in the second section. The second-generation libraries and
selections were directed at the evolution of LplA-NTD variants with unnatural probe
ligation activity.
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Results
Evolution of LpIA-NTD variants capable of catalyzing both steps of lipoylation
reaction
Truncation of LplA and cis lipoylation tests
As introduced in Chapter 4, we had discovered that LplA retained some catalytic
activity when the C-terminal domain was truncated. Based on the apo E. coli structure,
we had initially performed truncation of the enzyme at position 249 (Figure 5-lA)'. This
enzyme had full lipoyltransferase activity but drastically reduced adenylation activity.
When we considered the structure of the activated lipoyl-AMP bound form of LplA, we
noticed that a previously disordered adenylation loop becomes ordered and the resulting
beta sheet interacts with the first beta-sheet of the C-terminal domain, corresponding to
residues 250-255 (Figure 5-1, right)2. We therefore also tested a truncation of the enzyme
at Glu256. We hoped that this enzyme might have better adenylation activity compared to
the Pro249 truncation. We found that LplA truncated at Glu256 had adenylation activity
that was approximately 70% higher than the Pro249 truncation in an in vitro assay (data
not shown). Therefore, it was determined that the Glu256 truncation (hereafter referred to
as LplA-NTD) would be the basis for future experiments and evolution.
148
A90:
B
90:
Figure 5-1. Structural comparison of the two truncated LpIA variants. (A) Crystal structure from apo
E. coli LplA (PDB IX2G). Adenylate-binding loop and lipoate binding loop are in pink and blue,
respectively. C-terminal domain is colored grey. Residues 1-249, corresponding to Pro249 truncate, are
colored in red. Residues 250-255 are colored in yellow and represent the extension to make Glu256
truncate. (B) Crystal structure from Lipoyl-AMP bound E. coli LplA (PDB 3A7R). All colors are
maintained as in (A).
We next wanted to test the lipoylation activity of LplA-NTD in a mammalian
cell-surface assay, to do this we made a fusion of LplA-NTD to neurexin-1p. This is a
fusion that, as previously described in Chapter 4, gives good cell-surface expression of
the enzyme. We then expressed this fusion in HEK cells along with a surface LAP2
fusion (LAP2-CFP-TM). The cells were incubated with lipoic acid and ATP and the
activity of the enzyme was determined by monitoring cis lipoylation of the LAP2-CFP-
TM. Figure 5-2 shows that when lipoyl-AMP is added to the cells, the cis lipoylation of
LAP2 by LplA-NTD is equivalent to that observed with full-length WTLplA. However,
when the cells are incubated with lipoic acid and ATP, the cis lipoylation of LAP2 by
WTLplA-NTD is barely detectable, while full-length WTLp1A gives very strong cis signal.
These results suggest that the lipoyltransferase activity of WTLplA-NTD is unaffected by
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the truncation of the C-terminal domain, but that the adenylation activity of WTLplA-NTD
is markedly lower than that of WTLp1A.
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Figure 5-2. Comparison of adenylation and lipoyltransferase activity using LpIA-NTD and full length
LpIA. Scheme shows cis lipoylation assay. The indicated enzyme and LAP2-CFP-TM are co-expressed on
the surface of HEK cells. Transfected cells are incubated with lipoyl-AMP or lipoic acid and ATP for 1
hour. Cis lipoylation is detected by antibody staining and cells are imaged live.
Evolution of LpLA-NTD variants capable of performing adenylation and ligation of
lipoic acid
Yeast-display evolution schemes generally express the protein libraries fused to a
yeast mating protein, Aga2p 3. Aga2p is attached to the yeast cell surface via a disulfide
interaction with the Agalp mating protein. This scaffold produces consistently high
expression of target libraries, reducing variability in selections4 . In order to use yeast-
display to evolve improved Lp1A activity, we need to also express the LAP2 peptide on
the surface of the yeast (Figure 5-3). Chen and colleagues recently introduced a method
for yeast-display evolution where enzyme and substrate are co-displayed on the yeast cell
surface5 . We proposed using a similar technique where the LAP2 peptide is constitutively
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expressed on the yeast cell surface as a fusion to Agalp.The enzyme library can then be
induced in a subset of these cells as a fusion to Aga2p.
LpIA
Aga2p- .
SS +NH3
II
Agaip LAP
Yeast Cell
Figure 5-3. Yeast-display platform. Yeast cells constitutively express LAP2 as a fusion to the mating
protein AgaIp. A subset of the cells inducibly express LplA as a fusion to Aga2p. Enzyme expression level
can be monitored by HA epitope staining. LplA can catalyze the enzymatic ligation of probes onto the
LAP2.
The general scheme for yeast-display evolution can be found in Figure 5-4A.
Sujiet Puthenveetil made a first-generation library of LplA-NTD variants using error-
prone PCR with dNTP analogues and Taq polymerase6. The resulting library was
transformed into yeast cells constitutively expressing LAP2. The enzyme library is
induced, and each yeast cell expresses a unique library member on the surface. The yeast
pool is then labeled using lipoic acid and ATP and the lipoylation level of LAP2 can be
detected using antibody staining (Figure 5-4B). Active ligases produced highly labeled
yeast cells that were sorted out by FACS and then propagated to the next round. This
scheme is then repeated iteratively with more stringent rounds of labeling and selection.
Sujiet performed the selection as outlined above for lipoylation activity, by the
fourth round the best clone was identified as T57'LplA-NTD. To verify that the increase in
labeling signal obtained with T57 ILplA on the yeast cell surface is not context dependent,
we tested the lipoylation activity of these clones on the mammalian cell surface in a cis
labeling assay using lipoic acid and ATP (Figure 5-5). We compared this activity to
FI47 LLplA-NTD and WTLplA-NTD as well as full-length WTLplA. The F14 7LLp1A-NTD
mutant originated from a first-generation LplA-NTD library that was subjected to
selection for the ability to ligate an azidoalkanoic probe, although it didn't possess this
activity on the mammalian cell surface (data not shown).
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Figure 5-4. Yeast display selection strategy. (A) A library of LplA mutants is made using error-prone
PCR. The library is transformed into yeast cells constitutively expressing LAP2-Agalp. Each yeast cell is
expressing a unique library member. The library of yeast cells is labeled and then highly labeled yeast cells
are selected out via fluorescence activated cell sorting (FACS). This process is then repeated in
increasingly stringent iterations of enzyme induction, labeling, and sorting. (B) Yeast cells are incubated
with lipoic acid and ATP, allowing enzymatic lipoylation of the LAP2 by the LplA. Lipoylation is detected
by live-cell antibody staining on the yeast cell surface. Enzyme expression level is also monitored by HA
staining.
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Figure 5-5. Evolved LpIA-NTD variants have improved adenylation activity. HEK cells co-expressing
LAP2-CFP-TM and the indicated enzyme fused to neurexin-lp (NRX) were incubated with lipoic acid and
ATP. Cis lipoylation of the LAP2 was detected by antibody staining. High signal indicates both adenylation
and lipoyltransferase activity.
From the cis lipoylation assay, it is clear that both T"'LplA-NTD and Fl 4 7LLplA-
NTD have improved adenylation activity compared to WTLplA-NTD. More importantly,
the lipoylation activity of the evolved LplA-NTD variants rivals that observed with full-
length WTLplA under these conditions. While the lipoylation activity was increased, no
cis labeling was observed on the mammalian cell surface when using the azidoalkanoic
probes (data not shown). Given this result, we were concerned that perhaps the original
error-prone library based on the WTLplA-NTD template did not produce many active
clones. We therefore decided to perform a second round of directed evolution with two
fundamental changes. First, we biased the library towards improved adenylation activity
by using the lipoylation-improving mutations in the template for error-prone PCR.
Second, instead of selecting for lipoylation activity, the second-generation evolution
scheme would select for unnatural probe ligation.
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Evolution of LplA-NTD variants capable of performing adenylation and ligation of an
unnatural probe
Selection scheme for LplA-NTD directed evolution for bromoalkanoic probe ligation
The first step in the second-generation evolution was to determine the target probe
for the selection platform. The first option is to select for coumarin fluorophore ligation.
However, this was not feasible for three reasons. First, coumarin is very sticky on the
yeast cell and the resulting background is high. Second, the cell sorters we have access to
do not have optimized lasers and filter sets for coumarin fluorescence, and the suboptimal
settings available did not produce very high signal, even when yeast were labeled
exogenously with purified enzyme (data not shown). Finally, while a direct fluorophore
ligation is ideal for intracellular applications, a two-step labeling scheme would be best
for enzyme evolution. A two-step scheme would evolve an LplA variant to ligate the
functional group handle and then detect that label with a variety of fluorophore or probe
conjugates (Figure 5-6).
Blo-orthogonal Dervtize functional group handle
functional group handle with fluorophore conjugate
ATP kOA-. _-%
AP
Figure 5-6. Two-step labeling strategy using LpIA. In the first step, LplA is used to perform enzymatic
ligation of a functional group handle or affinity handle. In the second step, the functional group or affinity
handle is detected by chemoselective derivatization or affinity probe.
There was already precedence in the lab for performing two-step labeling on the
yeast cell surface. For the evolution of the LAP2 peptide, Sujiet Puthenveetil had
successfully performed labeling and enrichment using a two-step labeling method, and
we proposed using a similar selection scheme in the second-generation selection. In the
proposed scheme we use LplA to ligate an 1 1-bromoundecanoic acid probe (11-Br) onto
the LAP2 peptide. The ligated probe is detected using a two-step method with HaloTag7
conjugated to biotin followed by streptavidin fluorophore conjugate (Figure 5-7A). This
scheme gives an effective fluorescent readout of the enzymatic activity of LplA-NTD
library members.
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Once we had determined a selection scheme, the next step was to generate a
library of LplA-NTD mutants. The library was generated using error-prone PCR with
dNTP analogues. Both 8-oxo-deoxyguanosine-5'-triphosphate (8-oxo-GTP) and 2'-
deoxy-P-nucleoside-5'-triphosphate (dPTP) were used to induce point mutations in the
template DNA 6,8 . The 8-oxo-GTP analogue induces A to C and T to G mutations in the
DNA with T to G mutations being slightly over-represented (1:1.5 ratios). The dPTP
analogue induces A to G, T to C, G to A, and C to T mutations, with A-G mutations
being very over-represented (5:4:1:1 ratios). By controlling the concentrations of dNTP
analogues added to the PCR and by controlling the number of PCR cycles performed in
the presence of the analogues, the mutation rate of the library can be exquisitely
controlled. The libraries were made using a 1:1:1 ratio of WTLplA:T5"7 LplA-NTD:
F147LLplA-NTD. Using this mix of DNA templates would incorporate additional diversity
and we hoped bias the library towards incorporation of mutations that increased the
lipoylation activity of WTLplA-NTD would improve the initial activity of the library
members.
Because we were not sure whether a highly mutated library would be beneficial or
deleterious to LplA-NTD activity, three libraries were made with various mutation rates
(see Experimental). Error rates ranged from just one amino acid mutation per library
member to eight amino acid mutations per library member. The libraries were
transformed into yeast using electroporation9 and library sizes ranged from 6.0 x 106 to
3.0 x 107 members (see Experimental). The resulting yeast libraries were pooled and
selections were performed on the pooled library, which had a combined diversity of 5 x
107.
The pooled library was subjected to four rounds of selection for ligation of the 11-
bromoundecanoic acid (11-Br); yeast pools were amplified between rounds but no further
library diversification was performed. Evolutionary pressure for improved catalytic
activity was introduced by decreasing the labeling times (from 5 hours to 1 hour) and by
collecting a smaller fraction of cells in each successive round (Figure 5-7B). By round 4,
the pooled library of 5 x 107 unique members had been reduced to just four consensus
members (Table 5-1). All consensus clones contained the T571 mutation, indicating that
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this mutation increases labeling activity when combined with a variety of additional
mutations. We hypothesize that T571 may be improving LplA-NTD surface stabilization.
T571 is located at the end of a short alpha helix that is more solvent exposed in the apo
form of LplA compared to the lipoyl-AMP bound form of the protein (Figure 5-8). We
wonder whether the mutation of a polar threonine residue to a more hydrophobic
isoleucine residue may help bury the loop and stabilize the N-terminal domain when it is
expressed alone.
'plA
Aga2pm.
NH O Br
+ ATP
Yeast Cell
HN 1Br HNI HaloTag-Biotin I Detect with
streptavidin
phycoerythnin (PE)
Round 2
0.9%
Enzyme, AF488
Round 3
Enzyme, AF488
Round 4
.8
Enzyme, AF488
Figure 5-7. Selection for 11-Br probe ligation using LpIA-NTD library. (A) Selection strategy. The
prepared yeast library is incubated with 11-Br probe and ATP, active enzymes are able to catalyze the
covalent attachment of the 1 1-Br probe to the LAP2 peptide. The ligated 11-Br can then be detected using
HaloTag-biotin conjugate followed by streptavidin-PE. This gives an effective fluorescent readout of
enzymatic activity. (B) 11-Br activity selection on LplA-NTD library. Sort windows from increasingly
stringent labeling and selection rounds. All rounds used 500 sM I1-Br probe. Round 1- 5 hour incubation
with 11-Br and ATP. Round 2- 2.5 hour incubation with 11-Br and ATP. Round 3-1.5 hour incubation with
11-Br and ATP. Round 4- 1 hour incubation with 1 1-Br and ATP.
Table 5-1. Consensus clones from round 4 of 11-Br selection on LpIA-NTD library. 20 clones from
round 4 were randomly selected and sent for sequencing. The table depicts the relative frequencies of each
consensus clone.
156
A
B
w0.
C,,
0
.5
I
Enzyme, AF488
Figure 5-8. Position of T571 on LplA crystal structures. Apo E. coli LpIA is shown in green,
lipoyl-AMP bound LpIA is shown in grey. Position of T57I at the end of a helix is shown in red. Structure
view created in PyMol.
The next step was to test the 11-Br ligation activity of the consensus clones on the
mammalian cell surface. To do this, the various consensus clones were expressed as
fusions to neurexin- 1p on the surface of HEK cells co-expressing LAP2-CFP-TM. These
cells were incubated with 11-Br and ATP for 1 hour. After labeling, the 11-Br ligation
onto LAP2 was detected by HaloTag-fluorophore conjugate (HT-AlexaFluor647) (Figure
5-9). In this assay, three of the consensus clones produced high cis labeling that was
almost equivalent to labeling with exogenous enzyme (Figure 5-9, top row).
LpIA LAP
.AIF ~ Halo egdy
LAP2-CFP-TM DIc HT-AF647
exogenous
enzyme
T571/Y139H/F147L LplA-NTD
-NRX
TS71/A76SLplA-NTD
-NRX
T571/S159GLp]A-NTD
-NRX
TS71/
2
47RLpIA-NTD
-NRX
Figure 5-9. Evolved LpIA-NTDs have increased 11-Br cis labeling activity on mammalian cell
surface. Consensus clones from 11-Br selections on LplA-NTD library were co-expressed on the HEK cell
surface with LAP2-CFP-TM. Cis 11-Br ligation is detected using a HaloTag-AlexaFluor647 conjugate.
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To test the specificity of these active clones, we performed a side-by-side assay
where specific labeling (determined using cis ligation of 11-Br onto LAP2-CFP-TM) was
compared to the nonspecific labeling (determined using cis ligation of 11-Br onto
LAP2(ala)-CFP-TM) (Figure 5-10). For each enzyme, the ratio of specific to nonspecific
signal was approximated by determining the average labeling signal to noise for cells
expressing LAP2 and comparing to that obtained when labeling cells expressing
LAP2(ala) (Table 5-2). We hereafter refer to the ratios of specific to nonspecific labeling
signal as "specificity ratios"; a non-specific enzyme will have a lower specificity ratio.
LAP2-CFP-TM HT-AF647 DIC LAP2(ala)-CFP-TM HT-AF647 DIC
LpIA
-NRX
wTLpA-NTD
-NRX
T571/A76SLpIA-NTD
-NRX
T571IS159GLpIA-NTD
-NRX
T571IQ247RLpA-NTD
-NRX
Figure 5-10. Evolved LpIA-NTDs exhibit various degrees of non-specific 11-Br labeling. Consensus
clones that were active in initial cis 11-Br ligation assays (see Figure 5-9) were co-expressed as fusions to
neurexin-11B (NRX) on HEK cells expressing either LAP2-CFP-TM or LAP2(ala)-CFP-TM. Any labeling
of LAP2(ala)-CFP-TM is nonspecific. Evolved ligases are compared to WTLpLA-NTD and full-length
"VLplA. Cis 11-Br ligation is detected using a HaloTag-AlexaFluor647 conjugate.
11-Br-OH ligation
SpecificitZ ratio
"TLplA-NTD 1.5
nMu3W1LA-NTD ND
unansLpWANTD 4
"ususLpIA-NTD 6
unoamLpA-NTD 5.5
Table 5-2. Specificity ratios for cis ligation of 11-Br using LpIA-NTD variants. For the imaging data in
Figure 5-10, AlexaFluor647 fluorescence intensities were quantified for -50 transfected cells for each
condition. The ratio of labeling to background fluorescence was calculated for each cell. Then, for each
enzyme, specificity ratios were calculated by dividing the average signal to noise observed with LAP2 by
the average signal to noise observed with LAP2(ala). Values are rounded to the nearest 0.5.
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There were two observations that were surprising in this experiment. First, while
full-length WTLplA produces no cis 11-Br ligation labeling, WTLpA-NTD produces a low
level of cis 11-Br labeling using this assay; and this signal is mostly nonspecific as the
specificity ratio is approaching 1. Second, all of the evolved consensus clones exhibit
some nonspecific labeling signal. However, in contrast to WTLpA-NTD, the evolved
clones have improved specific 11-Br ligation activity, as all clones have specificity ratios
>1. Because of the multi-step detection method, the nonspecific signal on the cell surface
could have several sources: nonspecific probe sticking, nonspecific enzymatic labeling,
or nonspecific HaloTag fluorophore conjugate. Each of these issues was explored
individually.
First, the 11-Br probe could be sticky to the cell surface, producing nonspecific
signal that isn't enzyme-dependent. The long hydrophobic probe may stick in
membranes, producing background that is detected using HT-fluorophore conjugates. To
address the issue of probe sticking we performed cis labeling specificity comparison
identically to that described above, but using a 10-Br-AMP probe (Figure 5-11,
quantification Table 5-3). We hypothesized that if probe sticking is the source of the
problem, the more hydrophilic 10-Br-AMP would have reduced nonspecific background
sticking. We discovered that a more hydrophilic probe decreased the background we
observed, but did not completely eliminate the nonspecific signal. Also, the reduction in
background was not consistent across all mutants.
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LAP2(aia)
wTLpA-NTD
-NR:
T57'LpIA-NT
-NRX
T571/A76SLpA-NT
-NRX
T571/S159GLpIA-NTD
-NRX
T571/Q247RLpIA-NTD
-NRX
Figure 5-11. Evolved LpIA-NTDs exhibit better specificity with 10-Br-AMP labeling. Consensus
clones that were active in initial cis 11-Br ligation assays (see Figure 5-9) were co-expressed as fusions to
neurexin-1p (NRX) on HEK cells expressing either LAP2-CFP-TM or LAP2(ala)-CFP-TM. Cells were
incubated with 10 pM 10-Br-AMP for 20 minutes. Any labeling of LAP2(ala)-CFP-TM is nonspecific.
Evolved ligases are compared to wLpA-NTD and full-length WTLpIA. Cis 10-Br ligation is detected using
a HaloTag-AlexaFluor568 conjugate.
10-Br-AMP ligation
Specificity ratio
"
TLpIA-NTD 2
""LplA-NTD 10
7nnpIA-NTD 4
naSuM'"pA-NTD 8
"""""'Lpl1A-NTD 15
Table 5-3. Specificity ratios for cis ligation of 10-Br-AMP using LpIA-NTD variants. For the imaging
data in Figure 5-10, AlexaFluor647 fluorescence intensities were quantified for -50 transfected cells for
each condition. The ratio of labeling to background fluorescence was calculated for each cell. Then, for
each enzyme, specificity ratios were calculated by dividing the average signal to noise observed with LAP2
by the average signal to noise observed with LAP2(ala). Values are rounded to the nearest 0.5.
Second, the enzymatic ligation of the evolved LplA-NTDs may be nonspecific,
producing covalently labeled proteins that are not LAP-tagged. To address this, we used
two independent assays to judge specificity of the enzymatic ligation. First, we tested cis
lipoylation on the mammalian cell surface, all of the clones exhibited low levels of
specific lipoylation of LAP2, and no observable lipoylation of LAP2(ala) (data not
shown). However, because the specific lipoylation activity was so low with these evolved
mutants, we were not sure if lack of observable LAP2(ala) labeling was due to true
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specificity or an artifact of low lipoylation activity. We therefore attempted an additional
assay testing for specificity on the yeast cell surface. In this assay we prepared yeast that
were expressing the LplA-NTD variant without any LAP2 co-expressed. These yeast
cells were incubated with 11-Br probe and ATP and any non-specific labeling was
detected using the previously described detection protocol (Figure 5-12).
Aga2MLplA
0
0)Y Br
Agaip H HaloTag-Biotin Detect with
+ ATP streptavidin-Yeast phycoerythrin (PE)
Cell
WLpIA wLpA-NTD T57ILpLA-NTD F147LLpLA-NTD
Enzyme, AF488 Enzyme, AF488 Enzyme, AF488 Enzyme, AF488
T571/A76SLplA-.NTD 757I/s59GLplANTD T571/Q247RLplA-NTD
_ C*~.1 1."7
Enzyme, AF488 Enzyme, AF488 Enzyme, AF488
Figure 5-12. Some LpIA-NTD enzymes exhibit nonspecific signal on the yeast cell surface. The
indicated LpIA variant is expressed as a fusion to Aga2p in yeast with no substrate present. The yeast cells
are then incubated with 11-Br probe and ATP and any non-specific ligation is detected with HaloTag-biotin
conjugate followed by streptavidin-PE. Yeast populations were analyzed by FACS. Any SA-PE signal
indicates nonspecific labeling.
Using this assay, two of the evolved LplA-NTD variants demonstrated no non-
specific labeling. However, wTLp1A-.NTD, T57 ILplA-NTD, F14 7 LLplA-NTD, and
T57 /A76SLplA-.NTD all produced some non-specific labeling signal. While suggestive that
some enzymes may be nonspecifically ligating the probe, this result is not conclusive
since the same potential issues with hydrophobic 11-Br probe sticking to the displayed
proteins could be an issue in this assay.
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Finally, it could be that the HaloTag protein detection is nonspecific due to
HaloTag sticking independent of the presence of the probe. To test this, we expressed the
LplA-NTD variants in HEK and then applied HaloTag-AlexaFluor647 directly to the
cells without any probe incubation (Figure 5-13). What we found was surprising. When
HEK cells were expressing full-length WTLpIA, there was almost no sticking of the
HaloTag fluorophore conjugate; however, with WTLpA-NTD and T7'LplA-NTD there
was a significant amount of background sticking.
wTpAHT-AF647 
M
-NRX
wTLpA-NTD
-NRX
T57ILpLA-NTD
-NRX
Figure 5-13. HaloTag-fluorophore conjugates give higher background on cells expressing LpIA-
NTDs. HEK cells were transfected with LAP2-CFP-TM and the indicated enzyme fused to neurexin-1B
(NRX). Cells were treated with HaloTag-AlexaFluor647 without any prior probe incubation. Any AF647
signal represents non-specific sticking.
What we hypothesize is that the LplA-NTD variants have more exposed
hydrophobic surfaces due to the truncation. These exposed hydrophobic surfaces may
then be more sticky to the HaloTag protein, resulting in background. Analysis of the
crystal structure shows that a truncation at Glu256 will expose an extensive hydrophobic
patch on the protein (Figure 5-14, in green). However, this hypothesis does not explain
why the level of HaloTag sticking varies depending on the NTD variant being used.
Figure 5-14. Analysis of hydrophobic surfaces of LplA-NTD. Crystal structure of LpIA (PDB 3A7R)
with truncation at Glu256. Hydrophobic surfaces are colored in green, hydrophilic surfaces in grey.
Truncation exposes the hydrophobic core of the protein. All structure views created in PyMol.
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Based on these experiments, we concluded that performing 11-Br ligation with
the LplA-NTD variants followed by HaloTag-fluorophore conjugate does not produce
clean labeling signal on the cell surface. Because ligation of the 11-Br probe was so
problematic on the mammalian cell surface, and the evolved LplA-NTD mutants also had
very low ligation activity with lipoic acid and no ligation activity with the alkyl azide
probes (data not shown), we did not continue with further characterization of these
mutants.
Conclusion
This chapter describes efforts towards the directed evolution of the N-terminal
domain of LplA (LplA-NTD). In first-generation library selections, we were able to
evolve two LplA-NTD variants with improved adenylation activity (T 71LplA-NTD and
F147LLplA-NTD). When lipoic acid and ATP were applied to the cell surface, these LplA-
NTD variants demonstrated better cis lipoylation activity onto LAP2 fusions than full-
length WTLplA. In an in vitro assay, we determined that both T171LPA-NTD and
F147LLplA-NTD had improved activity compared to WTLplA-NTD, although the in vitro
activity of these enzymes was not equivalent to wTLp1A.
We describe second-generation library selections for cis ligation activity with an
unnatural 11-Br probe. These selections produced four consensus clones, three of which
had improved activity over WTLplA-NTD on the mammalian cell surface. However,
further investigation demonstrated that the cis 11-Br ligation assay produced moderate
levels of nonspecific background labeling. A series of experiments were performed to
ascertain the source of the nonspecific signal that we observed. Based on these
experiments, we concluded that the nonspecific labeling on the mammalian cell surface is
partially explained by probe sticking, but sticking of the HaloTag-fluorophore conjugates
or nonspecific enzymatic ligation cannot be completely ruled out.
While we were successful in producing LplA-NTD variants with improved
lipoylation activity on the cell surface, we were not able to evolve LplA-NTD variants
capable of site-specific labeling using unnatural probes. The reason for this is likely due
to the detection method we used. The use of a sticky probe (11-Br) and a protein-based
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detection method (HaloTag-fluorophore) likely both contribute to the background
observed on the cell surface. From the work in this chapter, we concluded that future
evolution schemes and cell-surface ligation assays should rely on more specific detection
chemistries or methods and employ small molecules whenever possible.
Experimental
Cis lipoylation on mammalian cell surface (Figure 5-2, 5-5)
HEK cells were transfected with 600 ng of LAP2-CFP-TM and 600 ng of either
WTLplA-NRX, wTLplA-NTD-NRX, or indicated mutants using Lipofectamine 2000
(Invitrogen) per manufacturer's protocol. 12 hours post-transfection cells were labeled.
For labeling with lipoic acid: cells were incubated with 500 1 M lipoic acid, 5 mM
Mg(OAc) 2, and 1 mM ATP for 1 hour at 30'C. For labeling with lipoyl-AMP: cells were
incubated with 100 nM lipoyl-AMP and 5 mM Mg(OAc) 2 for 1 hour at 30'C. For all
samples, cells were washed 2 x 10 minutes with DMEM and then lipoylation was
detected via live-cell antibody staining.
Live-cell immunofluorescence staining was performed with 4 pig/ml anti-lipoic
acid antibody (CalBiochem) and 4 ptg/ml anti-FLAG antibody (Stratagene) in 1% BSA in
DPBS for 15 minutes. After three quick washes, cells were incubated with 4 tg/ml goat
anti-rabbit antibody conjugated to AlexaFluor 488 and 4 tg/ml goat anti-mouse
AlexaFluor 568 (both Invitrogen) in 1% BSA in DPBS for 15 minutes, then washed and
imaged.
General Yeast methods
Growth and induction
Unless otherwise noted, cells were grown in SDCAA growth media [2% dextrose,
0.67% yeast nitrogen base without amino acids (BD Difco), 0.5% Casamino acids (BD
Difco), 0.54% Disodium phosphate, 0.86% Monosodium phosphate] at 30'C with
shaking for 20 hours. To induce protein expression, the cultures were diluted to a cell
density of ~10 6 cells/ml in SGCAA media (identical to SDCAA above but with 2%
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galactose as the carbon source). Induction in SGCAA was performed at 30'C for 20
hours.
Transformation
For single clones, L2-YIP yeast cells were transformed with DNA using the
Frozen-EZ Yeast Transformation II kit (Zymo Research). The transformed yeast cells
were plated on selective plates (SDCAA -W, -U) and single yeast colonies were selected
for amplification.
For the libraries, L2-YIP yeast cells were electroporated with the error-prone PCR
library (see library construction below) using a BioRad GenePulser Xcell.
Long-term storage
For individual clones, glycerol stocks were made. Isolated colonies were grown in 5
mL SDCAA overnight at 30'C. 812 tL of saturated overnight yeast culture was
combined with 188 tL of 80% glycerol (sterile) and placed into a 2 mL cryo-vial, stored
at -800C.
For libraries and rounds, frozen stocks were made. At least 1010 freshly grown cells
from each library were inoculated into 1 L low-dextrose SDCAA [as above but with
0.5% dextrose] and grown at 300 C for approximately 3 days. Cells were pelleted and then
resuspended in freezing solution (2% glycerol, 0.67% yeast nitrogen base) to a final
concentration of ~6 x 1010/mL. Cells were divided into 1 mL aliquots in cryovials. The
tubes were then put into a Mr. Frosty (Nalgene) and allowed to slow-freeze overnight -
80'C. The next day, cells were moved to liquid nitrogen for long-term storage.
Sorting and Scanning Instrumentation
All fluorescence activated cell sorting was performed on a BD FACSAria (BD
Biosciences). For all analysis where sorting was not required, a BD LSRII-HTS (BD
Biosciences) was used. Both of these instruments are located in the Flow Cytometry Core
Facility at the Koch Institute for Integrative Cancer Research at MIT.
Preparation of Yeast cells constitutively expressing LAP2-Agalp
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The LAP2-Agalp yeast integrating plasmid was cloned from the YIPlac2 11-GPD-
Avitag-Agalp plasmid which was a gift from Irwin Chen at Harvard University. First,
two restriction sites, AflII/NheI were introduced on either side of the Avitag to create
YIPlac2l1-GPD-AflII-Avitag-NheI-Agalp. The LAP2 tag was then introduced by pre-
annealing LAP2 primers with AflII/Nhel sticky ends and ligating into AflII/NheI digested
YIPlac2 11 -GPD-AflII-Avitag-NheI-Agal p. This produced the yeast integrating plasmid
YIPlac2 11 -GPD-AflII-LAP2-NheI-Agalp.
To integrate the plasmid into the yeast genome, YIPlac2 11 -GPD-AflII-LAP2-NheI-
Agalp was linearized by digestion with BsiWI and transformed into Saccharomyces
cerevisiae strain BJ5465 using the protocol described above and plated on SDCAA plates
lacking uracil. Colonies were picked and grown in SDCAA lacking uracil. A yeast
colony with the LAP2-Agalp construct correctly inserted and with good expression was
designated "LAP2-YIP" yeast and displays the LAP2 peptide sequence constitutively on
the cell surface as a fusion to the N-terminus of Agalp.
Creating LplA-NTD libraries
The round zero (RO) LplA-NTD library was made of a mixture of libraries created
with varying mutation rates. These libraries were made by error-prone PCR and cloned
into LAP2-YIP S. cerevisiae using gap repair homologous recombination.
For all libraries, a 1:1:1 mixture of T57 LplA-NTD:F14 7LLplA-NTD:wTLplA-NTD
was used as a template for the error-prone PCR.
For Library A, the PCR reaction contained 2 iM 8-oxo-2'deoxyguanosine (8-oxo-
dGTP), 2 tM 4-dihydro-8H-pyrimido-[4,5-C][1,2]oxazin-7-one (dPTP), 200 M each
dNTP, and 0.2 M each of primers IF and IR and reactions were thermocycled 10 times.
For Library B, the PCR reaction was assembled as above but with 2 [tM dNTP
analogues and was thermocycled 20 times.
For Library C, the PCR reaction was assembled as above but with 20 M dNTP
analogues and was thermocycled 10 times.
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For all libraries, mutagenized genes were further amplified in PCR reactions
without mutagenic dNTP analogs using primers IF and 1 R. The pCTCON2-Aga2p vector
was prepared by digestion with NheI and BamHI, and gel-purified. The PCR-amplified
inserts and digested pCTCON2 vector were mixed in 1:3 ratios and transformed together
into LAP2-YIP S. cerevisiae by electroporation as described previously (cite Colby et al).
Homologous recombination occurred inside the yeast, giving the desired product. Serial
dilutions of transformed yeast were plated on SDCAA plates and colonies were counted,
to determine transformation efficiencies for each library. A total of ~108 cells from each
fully grown library culture were mixed together and then the pooled library was pelleted
and induced as described above.
11-Br probe labeling and selections on yeast cell surface (Figure 5-7, Figure 5-12)
Yeast cells constitutively displaying the LAP2 peptide and either the induced LplA
libraries or individual clones (see General yeast methods for Lp1A induction details) were
pelleted and washed twice with Tris-buffered saline (pH 7.5) with 1 mg/ml bovine serum
albumin (TBS-B). Cells were resuspended to a cell density of 2 x 108 cells/ml in TBS-B
with 500 1 M 11-Br-OH, 5 mM Mg(OAc) 2 and 3 mM ATP and incubated on a rotator at
30'C for 1-5 hours. Labeling time for Round 1 was 5 hours, for Round 2 was 2.5 hours,
for Round 3 was 1.5 hours, and for Round 4 was 1 hour. The reactions were stopped by
pelleting the cells and washing with ice-cold TBS-B containing 100 mM EDTA. Cells
were washed twice with ice-cold TBS-B.
The ligated 11-Br probe was detected by incubating with 1 pM HaloTag-biotin for 1 hour
at 30C. Yeast cells were then pelleted and washed twice with TBS-B. The biotin was
detected using phycoerythrin-conjugated streptavidin (SA-PE; Jackson Immunoresearch)
in TBS-B at 1:50 dilution. The LplA surface-expression level was detected using mouse
monoclonal anti-myc antibody (Roche) in TBS-B at 1:150 dilution. Incubation with SA-
PE and anti-myc occurred simultaneously at 4'C for 40 minutes. Cells were pelleted and
washed twice with ice-cold TBS-B. Then the yeast cells were incubated with anti-chicken
AlexaFluor-488 secondary antibody (AF488; Invitrogen) in TBS-B at 1:100 dilution for
40 minutes at 4'C. Cells were pelleted and washed twice with ice-cold TBS-B then
resuspended in TBS-B to a density of 1 x 107 /mL for FACS.
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For the libraries, sorted cells were cultured until saturation in SDCAA growth
media with 50 tg/mL penicillin, 25 tg/mL kanamycin, and 50 tg/mL streptomycin.
After the culture was saturated, -109 yeast cells were pelleted and induced in SGCAA
and prepared for the next round of selection.
For testing of the ligation specificity of individual clones, EBY100 yeast were
transformed using the Frozen-EZ Yeast Transformation II kit (Zymo Research). The
transformed yeast cells were plated on selective plates (SDCAA -W, -U) and single
yeast colonies were selected for amplification. Enzyme expression was then induced, and
cells were labeled as described above.
Testing cis 11-Br-OH and 10-Br-AMP ligation on mammalian cell surface (Figure 5-
9, 5-10, 5-11)
HEK cells were transfected with 600 ng of LAP2-CFP-TM or LAP2(K-+A)-CFP-
TM and 600 ng of the indicated LplA-NTD-NRX variant using Lipofectamine 2000
(Invitrogen) per manufacturer's protocol. 12 hours post-transfection cells were labeled
with 11-Br-OH or 10-Br-AMP. For labeling with 11-Br-OH: cells were incubated with
500 tM 1 1-Br-OH, 5 mM Mg(OAc) 2, and 3 mM ATP for 1 hour at 30'C. For labeling
with 10-Br-AMP: cells were incubated with 10 [tM 10-Br-AMP and 5 mM Mg(OAc) 2 for
20 minutes hour at 30'C. For all samples, cells were washed 3 x 3 minutes with DMEM
and then the ligation of the bromo-probe was detected using HaloTag-dye conjugates.
Cells were incubated with HaloTag-AlexaFluor647 or HaloTag-AlexaFluor568 for 10
minutes, then washed 3 x 3 min with DMEM and imaged live.
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Chapter 6. In vitro evolution of full-length LplA for improved activity in
the endoplasmic reticulum and cell surface
The work described in this chapter is being prepared for publication. Tao Uttamapinant
synthesized the pAz probe and the acetoxymethyl ester protected pAz probe (pAz-AM).
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Introduction
The goal of this project is to produce a full-length LplA variant that exhibits
improved probe ligation activity both in the secretory pathway and when expressed on
the mammalian cell surface. We envisioned that this improved ligase could be applied to
PRIME labeling of proteins in the endoplasmic reticulum as well as extend ID-PRIME to
the labeling of inter-cellular protein-protein interactions.
As previously discussed, using LplA to directly ligate a fluorophore or probe is
preferable for intracellular applications over the two-step labeling protocol, which
requires two distinct incubation and washout steps. However, the two-step labeling
scheme is ideal for an evolution project; it allows us to evolve one LplA variant to ligate
the general functional group handle which can then be chemoselectively derivatized with
a variety of probes (Figure 6-1). Using this strategy, one enzyme evolution step can
enable us to label proteins with virtually any fluorophore or probe.
Bio-orthogonal Derivatize functional group handle
functional group handle with fluorophore conjugate
ligase
ATP HO)-
LP y_*C HLV
Figure 6-1. Proposed two-step labeling method for enzyme evolution strategy. In the two-step labeling
scheme, LpIA is first used to enzymatically ligate a bio-orthogonal functional group handle onto the LAP
peptide. In the second step, the bio-orthogonal functional group handle is chemoselectively derivatized with
any fluorophore- or reporter-conjugate
Unfortunately, our first attempts at using a two-step labeling strategy to evolve
LplA-NTD, as described in Chapter 6, produced ligases that were non-specific. This
strategy used enzymatic ligation of a bromoalkanoic acid followed by detection using
HaloTag conjugates. Not only was the enzymatic ligation of the 11-Br probe non-
specific, we also observed significant background sticking of the HaloTag-fluorophore
conjugates (Chapter 5). Another drawback of that labeling scheme was its dependence on
a HaloTag detection method, which is protein-based and thus not cell-permeable. This
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detection method would thus be restricted to cell surface proteins or fixed cells. Because
of these issues, we wanted to find a new target probe for the two-step labeling strategy
for the evolution of full length LplA
In order to accurately reflect the relative activity of the first enzymatic step in
these selections, the second derivatization step needs to be fast and high yielding. LplA
has been demonstrated to ligate alkyl azides"2 , aryl azides 3 , and, more recently, picolyl
azides 4 with good yield inside cells. Azides can be chemoselectively derivatized via
alkynes in a variety of ways, some of which are high yielding and compatible with living
cells (Figure 6-2). The traditional [3 + 2] cycloaddition of azides and alkynes was
developed by Huisgen; but required high temperatures and pressures in order to produce
high yields5 . Sharpless and colleagues created a Cu(I)-catalyzed version of the reaction
that can be performed at room temperature and physiological pH with fast kinetics and
high yield6-8 (Figure 6-2, top). However, these conditions require high concentrations of
Cu(I), resulting in cytotoxicity when used on cells9 . To overcome this limitation, a Cu-
free method that uses strain-promoted [3 + 2] cycloaddition with a transcyclooctyne was
developed by the Bertozzi group' 0"' (Figure 6-2, middle). This method eliminates the
need for copper by relying on the increased reactivity induced by the strain of a
transcyclooctyne. The reaction kinetics of this method can be further enhanced by using
mono- or di-fluorinated transcyclooctynes. While we have successfully used this
method of azide derivatization to label intracellular proteins2 , the kinetics using strain-
promoted click (kapp = 10-3 to 10-1 M-1 sec-1) are still 103- 106 -fold slower than the copper
catalyzed versions (kapp = 102 to 103 M~1 sec-1). To address the issue of slow kinetics, Tao
Uttamapinant in our lab recently developed a new protocol for cell-compatible copper
click chemistry using a copper-chelating picolyl azide probe 4 (Figure 6-2, bottom). This
approach allows for the reduction of Cu(I) catalyst but, because the azide probe has a
high affinity for copper, there is no concomitant loss in reaction kinetics. Tao's new
method reduces the required copper concentration 100 to 1,000-fold compared to the
Sharpless protocol, but has similar ligation kinetics 4'7 .
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Figure 6-2. Methods for chemoselectively derivatizing azides with alkynes. Copper-catalyzed [3 + 2]
cycloaddition developed by Sharpless and Finn is fast at physiological pH, but cytotoxic (top). Copper-free
[3 + 2] cycloaddition using strained cyclooctynes developed by Bertozzi lab can be performed in living
cells, but the kinetics are slow. Finally, the cell-compatible copper-catalyzed [3 + 2] cycloaddition using
copper chelating azides developed by our lab is both fast and nontoxic to cells (bottom).
Tao Uttamapinant demonstrated that when cell-surface proteins were labeled
using the picolyl azide probe, the signal obtained following the cell-compatible copper
click step was 5- to 20-fold higher than when using alkyl azide probes 4 under identical
labeling conditions. We confirmed this result, demonstrating that labeling with the
picolyl azide probe (pAz) produced higher labeling signal than with an alkyl azide probe
(Az9) when using exogenous w37vLp1A on both the mammalian and yeast cell surface
(Figure 6-3). This increase in labeling signal has huge implications for our application.
We were previously unable to detect cis ligation on the yeast cell surface when using
alkyl-azide probes even with long incubation times (data not shown). After we switched
to the picolyl-azide probe, we could detect low cis labeling with an LplA mutant (Results
section). Moreover, because both the picolyl azide and the alkyne conjugates are small
molecule probes, this detection method is more versatile than the HaloTag detection
strategy used for LplA-NTD selections (Chapter 5)
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Figure 6-3. Comparison of pAz and Az9 labeling using exogenous W37vLplA. Top images show labeling
of HEK cells expressing E2p on the cell surface using W37vLpIA and either alkyl azide (Az9, left) or picolyl
azide (pAz, right). Fluorescent activated cell sorting (FACS) was used to generate the lower plots which
show labeling of yeast cells expressing LAP2 on the cell surface using w LplA and either alkyl azide
(Az9, left) or picolyl azide (pAz, right).
In this chapter, we describe the in vitro directed evolution of a full-length PRIME
ligase with improved ligation activity in vitro, in the secretory pathway, and on the cell
surface. First, we describe how we performed yeast-display of an LplA enzyme library
and selected for LplA variants with improved picolyl azide (pAz) probe ligation activity.
Second, we present the characterization of the isolated LplA variants in vitro and on the
surface of yeast and mammalian cells. Finally, we demonstrate how the optimized pAz
ligase can be applied to label intercellular neurexin and neuroligin interactions on live
cells.
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Results
Selection platform based on co-display of ligase and peptide on yeast cell surface
We proposed using a yeast-display system identical to what we previously used
for evolution of the truncated LplA (Chapter 5) and pioneered by Chen and colleagues 3.
To briefly reiterate, in this system the enzyme and substrate are co-displayed on the yeast
cell surface. The LAP2 peptide (GFEIDKVWYDLDA) is constitutively expressed as a
fusion to the Agalp mating protein. We can then induce the expression of the LplA
enzyme library, which is displayed as a fusion to Aga2p (Figure 6-4A). After applying
labeling reagents to the cells, we can measure the amount of cis labeling of LAP2 peptide
catalyzed by the tethered enzyme. Although labeling is performed at the cell surface, this
strategy allows us to select for LplA variants that have high activity after being processed
through the secretory pathway.
The main concern with this evolution platform is the potential for artificially low
turnover when using a surface-tethered ligase, which may restrict access to surface-
expressed peptide. This is particularly problematic on the yeast cell surface, which is not
as fluid as the mammalian cell surface' 4 . To first demonstrate that cis labeling is possible
with the full-length ligase, yeast displaying WTLplA and the LAP2 peptide were
incubated with lipoic acid and ATP for three hours. After washing, lipoylation of the
LAP2 peptide was detected by anti-lipoic acid antibody (phycoerythrin (PE) signal) and
enzyme expression level was detected by anti-HA antibody (AlexaFluor488 signal). After
antibody staining, the fluorescently labeled yeast pools were analyzed by fluorescence-
activated cell sorting (FACS) (Figure 6-4B). When yeast cells displaying WTLp1A were
analyzed, LAP2 cis lipoylation was observed, but the signal was not as high as identically
prepared yeast cells lipoylated with exogenously applied enzyme (Figure 6-4C). This
control is consistent with our previous observations that full-length WTLplA has
decreased activity when expressed on the cell surface compared to when it is expressed
and purified from K coli. We also observed lower lipoylation signal when we performed
cis lipoylation using yeast cells expressing w37 ALplA, which has about 30% the activity
of wild-type in vitro, although enzyme expression level was similar (Figure 6-4C, right-
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most panel). This result demonstrates that the cis labeling assay is capable of
distinguishing between homogeneous populations of a highly active ligase (WTLplA) and
a less-active ligase (W37ALplA). This platform faithfully reflects the observed activity
disparities between various LplA mutants.
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Figure 6-4. Demonstration of cis lipoylation activity using LpIA and LAP2 co-displayed on yeast cell
surface. (A) Diagram of co-display. Yeast cells constitutively express LAP2 as a fusion to the Agalp
mating protein, and a subset transiently express LpIA as a fusion to Aga2p. The HA epitope tag can be used
to monitor LpIA expression levels. (B) Scheme for cis lipoylation protocol. Yeast cells are treated with
lipoic acid and ATP and lipoylation is detected by antibody staining and fluorescence activated cell sorting
(FACS). (C) FACS analysis of yeast cells treated with lipoic acid and ATP for 3 hours. Lipoylated LAP2
was detected by anti-lipoic acid antibody (phycoerythrin (PE), y-axis) and enzyme expression was
quantified using anti-HA antibody (AlexaFluor488, x-axis). Each dot in the scatter plot represents a single
yeast cell. Yeast cells expressing wTLpIA have higher cis lipoylation signal (27.5%) than yeast cells
expressing W37ALpIA (8.1%). Lipoylation of LAP2 yeast with exogenous WTLpIA is shown as a control.
We next wanted to demonstrate that this selection strategy can enrich for high
turnover ligases from a heterogeneous population. To do this, we performed one round of
model selection on mixtures of WTLpIA and w3 7ALplA yeast. For the model selections,
yeast cells were mixed in 1:1, 1:10, and 1:100 ratios of WTLplA: W37ALplA yeast and then
labeled with lipoic acid. After fluorophore staining, cells that exhibited a high ratio of PE
to AlexaFluor488 were sorted out via FACS (Figure 6-5). The FACS plots show that
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before sorting the population of highly labeled yeast decreased with increasing dilution of
WTLplA but that after sorting, the population of highly labeled yeast was enriched. In this
model selection experiment, we observed -50-fold enrichment of WTLplA over W37 ALplA
(Figure 6-5, chromatograms). These results demonstrate that the detection of LAP2 cis
labeling is an effective readout of enzyme activity and that the selection strategy enriches
for ligases with high ligation activity.
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Figure 6-5. Model selection enriches for highly active ligase over less active ligase. Samples were
mixed in 1:10 or 1:100 ratios of WTLplA-expressing yeast to W37ALp1A-expressing yeast. The mixed
samples were labeled with lipoic acid and ATP for 3 hours, then stained as previously described and sorted
by FACS using the gate shown. Chromatograms show sequencing at residue 37 for the yeast mixtures
before and after a single round of selection. Under these conditions, -50-fold enrichment of WTLp1A is
calculated based on sequencing enrichment assay.
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Directed evolution of a picolyl azide (pAz) ligase
Rationally designed ligases have no activity on yeast cell surface
After we validated the evolution platform using a model selection for lipoic acid,
the next step was to use the platform to select for an LplA variant with improved picolyl
azide ligation activity. The general selection scheme is presented in Figure 6-6. In the
first step, the yeast are incubated with pAz and ATP allowing for enzymatic ligation of
the pAz probe to LAP2 on the cell surface. Then, in order to maximize the fluorescent
labeling signal, we perform cell-compatible copper-click with a biotin alkyne followed by
streptavidin-PE detection. The enzyme expression level is detected using anti-HA
antibody as previously described. This protocol produces an effective fluorescent readout
of the enzymatic pAz ligation activity.
LpIA "pAz"A ga2 ju N HN NN N' . HN
Agalp p 0 LAP2 A C(P2 o Delt with
+ ATP Biotin-alkyne phyc iin -(
Yeast Cell phycoerythrin (PE)
Figure 6-6. Labeling strategy for pAz selection scheme. In the enzymatic ligation step, LplA catalyzes
the ATP-dependent attachment of pAz to LAP2. In order to detect pAz ligation, a two-step protocol is used.
First, the azide is derivatized with biotin alkyne using cell-compatible copper-click. Then, the biotin is
detected using a streptavidin-phycoerythrin (PE) conjugate.
Before performing the selection, we wanted to first test pAz labeling on the yeast
cell surface using the best rationally designed ligases. This experiment would provide a
benchmark for the selection and further demonstrate the decreased activity of LplA
mutants when expressed on the cell surface. We therefore tested the pAz ligation activity
in cis using w37vLp1A and w37ALplA, the two most active pAz ligases in vitro. While pAz
labeling of the LAP2 yeast using exogenous W37 vLplA produced very high signal in just
one hour, no cis labeling was observed with either w37 vLplA or W3 7 ALp1A, even after 12
hours of probe incubation (Figure 6-7A). In fact, over 20 hours of probe incubation was
required to observe any pAz cis labeling signal using W3 7 ALplA on the yeast cell surface
(Figure 6-7B). This result was encouraging because it demonstrated that cis pAz ligation
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is achievable on the yeast cell surface, although the ligation activities of the rationally
designed ligases are simply not high enough to accumulate appreciable labeling signal
within a biologically relevant timescale.
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Figure 6-7. Testing cis pAz ligation using rationally designed ligases. (A) Yeast cells expressing eitherW3 vLplA or W37ALpIA were labeled with ATP and the indicated concentration of pAz probe for the
indicated reaction time. Detection of pAz labeling was carried out as previously described. As a control,
pAz labeling with exogenous W3 7vLpIA produces very high labeling signal, even at short incubation times.
(B) In order to observe cis pAz labeling of LAP2, very long incubation times (20 hours) were required with
W37ALplA-expressing yeast. Even at long incubation times W37vLplA-expressing yeast do not show
appreciable cis pAz labeling.
Selection for an improved pAz ligase
The next step was to create LplA enzyme libraries for the pAz-based activity
selections. Although W37vLpLA is the best pAz4 ligase in vitro, the libraries were made
using w37ALplA as a template. We chose this template because w37ALplA has been shown
to ligate the pAz probe in vitro4 and has superior expression to w37vLplA on the yeast cell
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surface (Figure 6-7B, x-axes). As previously described for the LplA-NTD libraries
(Chapter 5), error-prone PCR was used to generate libraries of LplA gene variants which
were then incorporated into the yeast display vector using gap homologous
recombination. Since it was not initially clear whether a high mutation rate would be
beneficial or detrimental to the activity of LplA, six libraries were produced with varying
mutation rates. In the interest of brevity, this thesis will only discuss the two libraries that
produced promising LplA variants. The first library, Library A, was made using a low
mutation rate, with 1-2 non-silent mutations per gene (8.0 x10 7 transformants). Library B
was made using a moderate mutation rate of 1-6 non-silent mutations per gene (2.5 x 107
transformants).
Each library was independently subjected to four rounds of selection for pAz4
ligation; yeast pools were amplified between rounds but no further library diversification
was performed. Evolutionary pressure for improved catalytic activity was introduced by
decreasing the labeling times (from 12 hours to 1 hour) and by collecting a smaller
fraction of cells in each successive round. For rounds 3 and 4, we applied additional
evolutionary pressure for improved pAz substrate recognition by reducing the
concentration of pAz probe (from 200 pM to 100 pM) (Figure 6-8).
Library A:
Round 1 Round 2 Round 3 Round 4
22
enzyme, AF488 enzymeAF488 enzyme, AF488 enzymd"AF488
Library B:
Round 1 Round 2 Round 3 Round 4
enzyme, F488 enzyme, AF488 enzyme)AF488 enzyme, F'488
Figure 6-8. Sort windows for each round of pAz selections. Selections were performed using
increasingly stringent labeling for each round: Round 1- 200 pM pAz, 12 hours; Round 2- 200 M pAz, 6
hours; Round 3- 100 piM pAz, 2.5 hours; Round 4- 100 piM pAz, 1 hour. Sort gates are indicated in red
with the raw sort percentages reported for each round. Note: recovery percentages reported in Figure 6-9
correct these raw values based on the induction percentage from each round.
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After completing the selections, we assayed the yeast from each round under
identical conditions to validate our selection strategy (Figure 6-9). While enzyme
expression levels (x-axis) remained relatively constant through the selections, we
observed a steady increase in pAz labeling intensities (y-axis), with maximal labeling
signal observed at round 4. From this FACS data, we concluded that the selection
strategy successfully enriched library members with improved pAz ligation activity.
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Figure 6-9. FACS analysis of individual sort rounds demonstrate enrichment for improved pAz
labeling activity. Re-amplified yeast pools from each round of selection on Library A were labeled under
identical conditions (100 jiM pAz, 1 hour). Selection conditions used for each round are reported above
each arrow along with percentages of cells recovered. To better illustrate the difference between the pAz
ligation activities of round 3 and round 4, these rounds were also analyzed using a 30 minute labeling
protocol (bottom panels). Library B shows similar enrichment (data not shown).
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In order to monitor the library diversity and identify trends in conserved
mutations, sequencing analysis was performed on clones isolated from each round for
each of the libraries (Table 6-1). For Library A the original library of 8.0 x 107 members
was reduced through four rounds of selection to just two consensus clones (A4.6 and
A4.7), while Library B was reduced from 2.5 x 107 members to three consensus clones
(B4.2, B4.3, and B4.8). While we will discuss the individual mutations in more detail
later in this results section, it is interesting to note that the majority of highly conserved
mutations were located either in the C-termiiial domain of LplA (after residue 256) or in
areas far from the small-molecule binding pocket. In fact, only one highly conserved
mutation, F147L, is located in a buried region of the protein and near the small molecule
binding pocket.
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A1.1 A P287T
A1.2 A L291V
A1.3 A W52R, A110T
A1.4 A D157N
A1.5 A A
A1.6 V A R
A1.7 A S R
A1.8 A T
A2.1 A E265K
A2.2 A F318L
A2.3 A L
A2.4 A S
A2.5 A T
A2.6 A T
A2.7 A T
A2.8 A R
A3.1 A G
A3.2 A G
A3.3 A L
A3.4 A R
A3.5 A L R
A3.6 A L T
A3.7 A T
A3.8 A T
A4.1 A G
A4.2 A G
A4.3 A G
A4.4 A G
A4.5 A G
A4.6 A G
A4.7 A L R
Table 6-1. Sequencing results from each round of selection. After each round, yeast samples were plated
and individual clones were randomly selected for sequencing. The LplA clone names sequenced from each
round are listed down the rows of the table and the LpIA residues that were mutated in the selected clones
are listed across the columns. Positions with highly conserved mutations are highlighted in yellow. The
W37A mutation was part of the original library design.
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Evaluation of evolved ligase mutants on yeast and mammalian cell surface
Evolved ligases are specific on the yeast cell surface
Since we had observed issues with non-specific labeling using consensus clones
from previous libraries (Chapter 6), we first wanted to test the activity and specificity of
the individual consensus clones on the yeast cell surface. The activities of the five
consensus clones were compared by performing pAz cis ligation onto the LAP2 peptide
(Figure 6-10 top row). To monitor the extent of nonspecific ligation using these mutants,
pAz cis labeling was performed on yeast cells constitutively expressing the acceptor
peptide for biotin ligase (AP), which should not be recognized by LplA (Figure 6-10,
bottom row). While most of the consensus clones were highly specific, some nonspecific
labeling of AP was observed when using B4.3.
A4.6-Aga2p A4.7-Aga2p B4.2-Aga2p B4.3-Aga2p B4.8-Aga2p
-I
LAP-Agaip
CLa
HA (AF488) HA (AF488) HA (AF488) HA (AF488) HA (AF488)
AP-Agaip
'i-, c' "" in in ' "' 7-i: Tin- .
HA (AF488) HA (AF488) HA (AF488) HA (AF488) HA (AF488)
Figure 6-10. Activity and specificity of the five consensus clones. The two consensus clones from
Library A and three consensus clones from Library B were amplified after the fourth round of selection.
FACS plots show the extent of pAz cis ligation onto LAP2 observed using each LpIA variant as a function
of its expression level (HA, x-axis) (top row). To analyze the specificity of pAz ligation, we isolated the
expression plasm ids and introduced them into yeast displaying the acceptor peptide for biotin ligase (AP),
which should not be recognized by LplA. FACS plots in the bottom row show an absence of pAz ligation
onto AP for all clones except B4.3, which shows significant labeling signal. For all samples, labeling was
performed with ATP and 100 piM pAz for 1 hour.
Evolved ligases are active on the mammalian cell surface
We next wanted to demonstrate that the activity we evolved is not context-
dependent, and that we are able to achieve high pAz labeling with the enzymes when
taken out of the context of the yeast cell surface. To that end, we developed an assay to
test pAz labeling in cis on the surface of mammalian cells. We first expressed the ligases
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as fusions to neurexin-1p (NRX). Neurexin-1p was chosen because this protein gives
good surface expression in mammalian cells and we have previously demonstrated that
WTLplA can catalyze the ligation of lipoic acid in cis when fused to this protein (Chapters
4 and 5). LAP2-CFP-TM was co-expressed and the cells were incubated with ATP and
pAz, which was followed with click chemistry using an AlexaFluor647-alkyne (Figure 6-
11, scheme). In this assay, we observed labeling of the LAP2 peptide using all of the
mutants, which demonstrates that labeling with the evolved ligases is not dependent on a
yeast-display context (Figure 7-1 1A). More importantly, this result was the first
demonstration of PRIME labeling using enzymes expressed on the cell surface.
To better assess activity trends, we quantified the extent of labeling signal and
compared it to both enzyme and substrate expression levels (Figure 6-11B). The highest
ratios were observed with A4.7 (W37A/F147L/H267R) followed by A4.6
(W37A/S1OOG) and then B4.2 (W37A/A248T) and much lower labeling to expression
ratios were obtained with the other consensus clones from Library B. While consistent
with the yeast cell surface activity trends, the cis labeling signal observed when using the
evolved ligases on the mammalian cell surface was still 3- to 8-fold lower than the
exogenous labeling signal.
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Figure 6-11. Analysis of the cis pAz ligation activity using evolved LpIA variants on mammalian cell
surface. (A) Each LpIA mutant was fused to the N-terminus of neurexin-l IP (NRX) and co-expressed with
LAP2-CFP-TM on the surface of HEK cells. Cis labeling was performed with addition of 100 pM pAz and
ATP for 1 hour. The pAz-LAP2 conjugates were detected by [3 + 2] cycloaddition with AlexaFluor647-
alkyne. LpIA-NRX expression was detected by live-cell antibody staining with anti-FLAG antibody. All
consensus mutants were tested, but representative confocal images for A 4.6Lp1A and A4 .7Lp1A are shown.
(B) Quantification of pAz cis labeling extent on the mammalian cell surface for all five LplA mutants.
Fluorescence intensities were calculated from confocal images for at least 30 individual cells.
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A4. 7RLP1A labels LAP2 fusions with signal equivalent to exogenous enzyme
We next sought to improve the cis labeling activity of the evolved ligases on the
mammalian cell surface by incorporating promising mutations from the NTD selections.
Through the LplA-NTD selections, we discovered that Thr57 of LplA is a critical
position in the enzyme and, when mutated to isoleucine (T571), improves LplA
expression, stability, and activity across a range of probes and applications (see Chapter
6). We hypothesized that this mutation might also improve the activity of the evolved
ligases. To test this, we added the T571 mutation to the most active evolved ligase,
A4.7LplA (W37A/F147L/H267R), to create A4.7RLplA (W37A/T571/F147L/H267R). When
we included this new mutant in the cis mammalian cell assay, we found the A4 .7RLplA
was more active than A4.7LplA and produced cis pAz labeling signal that was equivalent
to exogenous enzyme in all conditions tested (Fig 6-12A). To ensure that the labeling was
generalizable, we tested cis labeling of LAP2 fused to neuroligin-1 (LAP2-NLG) and
observed a similar increase in activity (Fig 6-12B). When labeling signal was quantified
and compared to both enzyme expression level and substrate expression level, A4 .7RLp1A
outperformed all of the evolved ligases in the cis ligation assay (Fig. 6-12C). With this
result, we determined that A4 .7 RLplA is the best pAz ligase for mammalian cell-surface
applications.
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A4.711A4.7RFigure 6-12. A4.7RLpIA produces cis pAz labeling signal equivalent to exogenous enzyme. (A) LpIA
was fused to the N-terminus of neurexin- I P (NRX) and co-expressed with LAP2-CFP-TM on the surface of
HEK cells. Cis labeling was performed with addition of 100 pM pAz and ATP for 1 hour. The pAz-LAP2
conjugates were detected by [3 + 2] cycloaddition with AlexaFluor647-alkyne. LplA-NRX expression was
detected by live-cell antibody stainin with anti-FLAG antibody. Images of exogenous W37ALpIA pAz
labeling and cis pAz ligation using LpIA are shown for comparison. . (B) Cis pAz labeling performed
identically to (A) while using LAP2-neuroligin-1 as the target substrate. (C) Quantification of pAz cis
labeling extent on the mammalian cell surface for all five LpIA mutants. Fluorescence intensities were
calculated from confocal images for at least 30 individual cells for each condition. The labeling signal
obtained with A4 .7RLpIA greatly exceeds any of the ligases obtained from selections.
A4.7RLplA can be used for PRIME labeling in the endoplasmic reticulum
Finally, we wanted to test the ability of the optimized pAz ligase (A4.7RLpIA) to
label proteins when expressed in the endoplasmic reticulum (ER). To increase the
intracellular probe concentration and improve labeling signal, a cell-permeable form of
the pAz probe with an acetoxymethyl protecting group was used (pAz-AM). In HEK
cells, the ligase was targeted to the ER using a KDEL-motif and co-expressed with
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LAP2-neuroligin- 1, which can be labeled by the ER enzyme as it is trafficked through the
secretory pathway. After labeling in the ER, the labeled pAz-LAP2-neuroligin was
detected by performing click at the cell surface (Figure 6-13, scheme). When using ER-
targeted A4.7RLp1A, LAP2-neuroligin-1 was highly labeled (Figure 6-13). However, when
the identical experiment was performed using A4-7LplA, similar pAz labeling signal was
observed. This result suggests that the addition of T571 may improve surface activity to a
greater extent than ER activity, which is a hypothesis that we are continuing to explore.
We also note that pAz labeling using exogenously applied enzyme is still 3- to 4-fold
higher than when using A4 .7RLp1A-ER or A4.7Lp1A-ER, indicating that enzyme activity in
the ER can still be improved further. Nevertheless, this was the first demonstration of
PRIME labeling using an ER-targeted ligase.
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Figure 6-13. LpIA has improved activity in the endoplasmic reticulum. HEK cells were co-
transfected with the indicated ligase (retained in the ER via a KDEL tag) and LAP-neuroligin-1 (NLG).
Membrane permeable pAz-AM was added to cells for 4 hours, and labeling of LAP-NLG was detected by
Click at the cell surface with AF647-alkyne. For comparison (top row), labeling of LAP-NLG was
performed with exogenous W37ALpIA. Scale bars 10 pM.
In vitro characterization of evolved pAz ligases
Evolved ligases have improved activity in vitro
Although we have demonstrated that A4.7RLp1A gives the highest pAz labeling
signal on the mammalian cell surface and in the endoplasmic reticulum, we wanted to
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more thoroughly compare the activities of all evolved ligases in vitro. We first used high-
performance liquid chromatography (HPLC) assays to monitor the extent of pAz ligation
onto LAP2 peptide in a ten minute labeling protocol with either 200 tM or 50 [tM pAz
probe using the LplA variants. Table 6-2 summarizes the results of this assay using the
five evolved ligases, A4.7RLp1A, and the best rationally designed pAz ligases: W37 v LplA
and W3 7ALplA. We also included the individual mutations of A4 .7LplA with the hope of
deconvoluting the contributions of each mutation on activity. To investigate whether
increases in enzyme activity were probe-specific, we also performed these assays using
both lipoic acid and 7-hydroxycoumarin probe (Table 6-2).
We note that the trends for in vitro pAz ligation activity follow closely with the
trends we observe on both the mammalian and yeast cell surface. All of the evolved
ligases except for B4.3 give improved labeling over W37ALp1A, the library starting-point.
However, only A4.7 and A4.7R give improved pAz in vitro labeling compared to the best
rationally designed ligase, W37vLplA. We also observed that A4.7RLplA did not show
improvement over A4. 7LplA at high pAz probe concentrations, and only minimal
improvement at the lower pAz probe concentration (Table 6-2). This result contrasts with
the mammalian cell surface data, where the addition of T57I drastically improved pAz
labeling activity. Given these results, we hypothesize that the T571 mutation may be
serving to stabilize or solubilize the enzyme when it is expressed on the cell surface,
which is neither advantageous nor deleterious when working with purified enzymes. This
conclusion is supported by the previous analysis of how T571 may contribute to improved
activity (see Chapter 5). We also found that, for pAz ligation, it seems that the effects of
F 147L and H267R in combination are largely additive (Table 6-2).
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Table 6-2. In vitro ligation activities of LpIA variants with pAz, lipoic acid, and 7-hydroxycoumarin
probes. Ligases were used at 2 pM concentration and with the indicated probe concentrations. All reaction
times were 10 minutes. Extent of probe ligation onto 150 pM LAP2 peptide was monitored by HPLC. All
measurements were performed in triplicate. Cell shading indicates relative activities, darker colors indicate
higher relative activities. Errors, +/- I s.d.
A4. 7RLPlA mutations may contribute in various ways to increased pAz ligation activity
We next sought to rationalize how the two evolved mutations (F147L and H267R)
might be contributing to overall activity improvements of the enzyme. The F147L
mutation has frequently appeared in previous LplA library selections, and always
occurred when performing selections against alkyl azide probe ligation (see Chapter 5).
We had previously hypothesized that this mutation may be involved in accommodating
the bound azide structure or otherwise contributing to catalysis in a pAz probe-specific
manner. This hypothesis is supported by the result that when F147L is introduced into
wild-type LpIA, it does not improve the kcat for lipoylation (Figure 6-14). However, two
results indicate that this hypothesis might be incorrect. First, when we docked the pAz-
AMP structure into the lipoyl-AMP binding pocket of LplA 5 the F147L mutation is not
in close proximity to the azide moiety (Figure 6-15), which places in doubt the direct
involvement of F147L in pAz4 binding or recognition. Second, in contrast to the result
obtained when F147L was added to WTLplA, we observed significantly improved
lipoylation activity when F147L was combined with the W37A mutation (Table 6-2).
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This result indicates that F147L may be a potentiating mutation that serves to improve
enzyme activity only when Trp37 is mutated. Future work exploring this issue will
involve analysis of the alkyl azide probe ligation activity of F147L mutants with and
without mutation at the Trp37 residue.
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Figure 6-14. Lipoylation kinetics when mutations of A4.7RLpIA are added individually to WTLpIA.
Ligation reactions were assembled with 400 pM lipoic acid, 400 gM LAP2 peptide, and 200 nM of the
indicated enzyme. Product amounts were quantified by HPLC. We estimate that these reaction conditions
are saturating for all three LplA substrates, such that the slopes of these lines represent Vm15., and from these
values kca, can be determined. Reactions were performed in triplicate; errors, +/- 1 s.d.
Figure 6-15. F147 is probably not directly involved in pAz binding. Docked structure of pAz-AMP in
lipoyl-AMP binding pocket of LpIA (PDB 3A7R). W37 position is shown in green stick and F147 position
is shown in red stick.
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Unlike F147L, the H267R mutation seems to generally increase enzyme activity
independent of the small molecule probe being used (Table 6-2). His267 is located at the
interface between the N- and C-terminal domains of the apo LplA structure 16 (Figure 6-
16A). As discussed in Chapter 5, LplA undergoes a global conformational change after
formation of the lipoyl-AMP and before transfer to the protein substrate' 5 (Figure 6-16B).
Upon formation of the adenylate ester, the C-terminal domain of LplA flips
approximately 180 degrees, adopting a stretched conformation and exposing the site of
protein substrate binding. We propose that the mutation of His267 to a bulky arginine
residue is helping to promote this global conformational change by pressing the C-
terminal domain away from the N-terminal domain and pre-ordering the open
conformation of the enzyme' 5 (Figure 6-16C). This hypothesis is supported by the fact
that when the H267R mutation is introduced into the wild-type LplA, we notice a 2-fold
improvement in the kca of the lipoylation reaction (Figure 6-14). We note that the other
individual mutations of A4.7RLpIA did not produce this increase in lipoylation activity
when introduced into the wild-type ligase (Figure 6-14). This suggests that the
contributions of these mutations to improved pAz ligation activity may be the result of
probe-specific effects or require the cooperation of the W37A mutation (as we suspect
with F147L). It is also possible that the rate enhancement effects are only are evident in
the context of cell surface expression and stability and are thus less apparent when
performing in vitro reactions (as we suspect with T571).
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Figure 6-16. H267R may promote conformational change upon lipoyl-AMP formation and pre-order
the activated complex. (A) Apo E. coli LpIA (PDB IX2G) (B) Lipoyl-AMP bound E. coli Lp1A (PDB
3A7R). N-terminal domain and C-terminal domain are in grey and green, respectively. LplA undergoes a
lobal conformational change upon lipoyl-AMP formation (cyan stick). In both proteins the amino acids of
4.7R LpIA are shown in spheres. All structure views created using PyMol.
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In vitro characterization of optimized pAz ligase
A4. 7RLp1A covalently ligates pAz onto LAP2 site-specifically
We further characterized the optimized pAz ligase (A4. 7RLplA) in vitro with
specificity controls. Figure 6-17A shows HPLC traces from 10 minute in vitro LAP2
labeling reactions using A4.7RLplA, d W37ALplA. This result clearly shows
that A4 .7RLplA is more active than the best rationally designed ligases under identical
labeling conditions. A control experiment where ATP is omitted demonstrates that pAz
ligation using A4.7RLplA is ATP-dependent. Finally, the identity of the pAz-LAP2
conjugate was confirmed by mass spectrometry (Figure 6-17B).
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Figure 6-17. A4.mLpIA in vitro characterization and specificity controls. (A) HPLC traces show
conversion of LAP2 peptide to picolyl azide-LAP2 conjugate by A4 .7RLpIA, W37 ALpIA and W37vLpIA. A
negative control, with ATP omitted, is shown in black. (B) Starred peak in (A) was analyzed by mass
spectrometry and confirmed to be the covalent pAz-LAP2 conjugate.
Next, the sequence specificity of A4.7RLp1A was confirmed by performing pAz
ligation on mammalian cell lysate. To demonstrate that the ligase obtained from yeast-
display selections is also sequence-specific, we performed this experiment in parallel
using A4.7LpIA. We prepared lysate from HEK cells expressing LAP fused to yellow
fluorescent protein (LAP2-YFP) and performed pAz labeling using either A4.7RLplA or
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A4 .7LpLA followed by detection using biotin-alkyne and western blot with streptavidin-
HRP (Figure 6-18). While lanes 1 and 4 demonstrate specific labeling of LAP2-YFP,
control lanes using untransfected lysate or lysate expressing a LAP2 mutant where the
target lysine is mutated to an alanine do not show labeling. This result demonstrates that
the optimized pAz ligase and the best pAz ligase obtained by yeast-display evolution
both retain the high sequence-specificity of LplA.
A4.7LpIA A4.7RLpIA
LAP-YFP + - - + - -
LAP(K-+A)-YFP - + - - + -
1 2 3 4 5 6 1 2 3 4 5 6
100 kD -
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50 kD -
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Coomassie Streptavidin-HRPdetection of biotin alkyne
Figure 6-18 A4.7RLplA and ^4'7LplA retain the high sequence specificity of the original ligase. HEK
cells expressing LAP2-YFP were lysed and labeled with either A4.7Lp1A or A4 7"LpA. Ligated pAz was
detected using biotin-alkyne followed by western blotting with streptavidin-HRP. Controls are shown using
untransfected lysate or lysate prepared from HEK cells expressing LAP2(K-*A)-YFP.
A4. 7RLplA has a faster kcat compared to rationally designed pAz ligases
We next used HPLC to measure the kinetics of pAz ligation onto LAP2. For
A4.7RLp1A we determined the kca, to be 0.30 sec~1, while for ^4.7Lp1A we calculated a kcat of
0.41 sec-' (Figure 6-19). These values can be compared to those calculated for W37 ALplA
and W37 vLplA (kca, 0.09 and 0.21 sec4 , respectively). The kca, values for pAz ligation
using the evolved and optimized ligases are -2 to 4-fold higher than for the best
rationally designed ligases. This result confirms that the evolutionary pressure we applied
during our selections was successful in enriching for ligases with improved catalytic
activities.
197
40 
k 0.999 * A4.7RLpA
e w37^LpLA, = 0.21 sec1 A4.730~R
2 
-0.993 [
vie- *W 37ALpIA
20 (
kc = 0.09 sec-'
R' = 0.990
100 200 300 400 500 600 700
Time, sec
Figure 6-19. A4.7RLplA has improved pAz ligation kinetics compared to rationally designed ligases.
Ligation reactions were assembled with 400 pM LAP2 peptide, 400 pM pAz probe, 1 mM ATP, and 200
nM of the indicated enzyme. Product amounts were quantified by HPLC. Reactions were performed in
triplicate; errors, +/- 1 s.d. Assuming reaction conditions are saturating for all LpIA substrates, the slopes of
the lines give Vmax and ke, was calculated for each enzyme.
Application to labeling protein-protein interactions
A4. 7RLP1A can be used to visualize intercellular protein-protein interactions in HEK cells
We have demonstrated in this chapter that the optimized pAz ligase produces
better pAz labeling in vitro, in the endoplasmic reticulum, and in cis on the mammalian
cell surface. We next wanted to apply A4 .7RLpIA to the labeling of inter-cellular contacts
and explore the potential for using the evolved ligase to extend ID-PRIME and allow for
the labeling of intercellular protein-protein interactions.
First, we developed a trans pAz labeling assay to test the ability of A4 .7LplA to
label intercellular contacts between HEK cells. In this assay, we transfect one pool of
HEK cells with A4 .7RLplA-neurexin-1p and a separate pool of HEK cells with LAP2-
neruoligin-1. After transfection, we lift the two populations and then mix and co-plate
them on the same coverslip. If we can successfully label inter-cellular protein-protein
contacts, when the two populations of HEK cells come into contact should result in
labeling of the LAP2-neuroligin by the A4 .7RLplA-neurexin (Figure 6-20, scheme). While
the goal is to ultimately label neurexin and neuroligin interactions at a synapse, where
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this interaction is biologically relevant, intercellular labeling in HEK cells serves as an
important proof-of-principle.
Figure 6-20 shows that we are able to label the inter-cellular contact of these two
proteins with just a 5-minute pAz labeling protocol in HEK cells. Controls where the
experiment was performed identically but using either W37ALplA or the alanine mutant of
LAP2 demonstrate the specificity of the inter-cellular labeling. Interestingly, when
performing trans pAz labeling using A4. 7RLplA, the labeling signal observed after the 5-
minute labeling protocol is brighter than that observed when using exogenously applied
enzyme.
Encouraged by this result, we next wanted to determine whether the labeling
signal we observe in the trans assay is dependent on the interaction between the neurexin
and neuroligin. To test this, we performed the trans labeling experiment using a fusion of
A4.7RLp1A to an interaction-deficient mutant of neurexin- 1s (D1 3 7ANRX) (Figure 6-20).
Although some intercellular contacts were labeled using the interaction deficient version
of neurexin, the labeling signal never exceeded 25% of what we observed in the presence
of protein-protein interaction. This control demonstrated that labeling is largely
interaction dependent. We propose that with some further optimization this method may
be applicable to the imaging of biologically relevant protein-protein interactions on the
surface of living mammalian cells or even perhaps at the neuronal synapse.
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Figure 6-20. Imaging neurexin and neuroligin interactions using trans pAz labeling. HEK cells
expressing A4.7RLplA as a fusion to neurexin-1p (NRX) were co-plated with HEK cells expressing LAP2 as
a fusion to neuroligin-1 (NLG, with a nuclear CFP co-transfection marker). When the two populations of
cells come into contact, A4 .7RLpIA can ligate pAz onto LAP2-NLG in just 5 minutes. As controls, trans
labeling fails when using LAP2(K--+A)-NLG or w37 ALpIA-NRX (second and third rows). When A4 .7RLpIA
is fused to an interaction-deficient mutant of neurexin- 1 b, trans labeling is inhibited (fourth row). Labeling
signal can be compared to that observed using exogenous W37ALplA for 5 minutes (bottom row).
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Comparison of GRASP methodology and trans pAz ligation using A4. 7RLplA
We were eager to compare our method to GRASP methodology (GFP
Reconstitution Across Synaptic Partners), another method that can image protein-protein
interactions in live cells. This method uses a split super-folder GFP (sfGFP) to image
protein-protein contacts across cells or synapses and has been demonstrated in tissue
cultur even17,18
culture and even transgenic mice . A large portion of sfGFP is fused to one interacting
partner and the remaining smaller portion of sfGFP is fused to the other interacting
partner. When expressed separately, the two proteins are non-fluorescent. Upon co-
localization of the protein interaction partners, the sfGFP is reconstituted and becomes
fluorescent after chromophore maturation.
We first tried the trans experiment using the exact GRASP constructs described in
the work of Kim and colleagues, where the larger piece of sfGFP is fused to CD4 and the
smaller piece of sfGFP is fused to neuroligin-1 18. These constructs were designed as a
pair that would report on synapse formation as determined by spatial proximity.
Unfortunately, we weren't able to observe GFP complementation in a trans assay in HEK
cells, despite observing GFP complementation when the two pieces were expressed in the
same cell (data not shown). We hypothesized that when these constructs are expressed in
neurons, scaffolding proteins and endogenous protein assemblies force the inter-cellular
interaction of CD4 and neuroligin, which in turn promotes sfGFP complementation. In
support of this hypothesis, when the sfGFP pieces were fused to neurexin- 1p and
neuroligin-1, which we have already demonstrated interact well across HEK cells, we
observed good GFP complementation in the trans assay (Figure 6-21). Moreover, when
we used an interaction-deficient form of neurexin-lp we observed a significant decrease
in number of GFP complementation events and a decrease in the GFP fluorescence
intensity at those events. These two results, taken together, suggest that the GRASP
method may be interaction-dependent in some contexts.
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Figure 6-21. Imaging of neurexin and neuroligin interactions using GRASP. HEK cells expressing
sfGFPI-10 fused to neurexin-lp (NRX, with mCherry co-transfection marker) were co-plated with HEK
cells expressing sfGFP1l fused to neuroligin-1 (NLG, with CFP co-transfection marker). Where the two
populations of cells come into contact, GFP can reconstitute between the cells (top row). When a mutant of
neurexin that is incapable of interacting with neuroligin is used (D137 ANRX), GRASP signal decreases
dramatically (bottom row).
To get a direct comparison of the GRASP method and our pAz labeling method,
the labeling signal to noise ratio was determined for each protocol (additional fields of
view for both experiments can be found in Figure 6-22). We found that the trans pAz
ligation method gives a signal to noise ratio of 26, while the GRASP method produces a
signal to noise ratio of 11. This indicates that the trans pAz labeling technique is more
sensitive, producing higher labeling signal on average. An additional advantage of our
method is that while GFP complementation is trapping, our label is not and persists after
interaction. We envision that, using our method, a protein-protein interaction could be
detected and then time-lapse imaging can be used to monitor subsequent trafficking of
the labeled interacting partner.
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Figure 6-22. Additional fields of view showing labeling of intercellular interactions between neurexin
and neuroligin. (A) Trans pAz labeling of LAP2-neuroligin using A4 .7RLplA-neurexin- I. From the same
experiment as Figure 6-20. Scale bars, 10 gM. (B) Trans GRASP labeling using GFPl l-neuroligin and
GFP1-10-neurexin-1P. From same experiment as figure 6-2 1. Scale bars, 10 pM.
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Conclusion
Using yeast-display evolution of E. coli lipoic acid ligase, we have engineered a
PRIME ligase (A4. 7RLplA) with improved picolyl azide (pAz) labeling properties. We
have demonstrated the improved pAz ligation activity of this ligase in vitro, and also
report the first demonstrations of PRIME labeling using enzyme expressed on the surface
and in the endoplasmic reticulum of living cells. While there have been other recent
examples using yeast-display to evolve improved enzyme function3, 19, to our knowledge
this is the first example of the evolution of activity for an application where there was no
observable activity using the original enzyme.
The expansion of the PRIME labeling methodologies to the endoplasmic
reticulum designates PRIME as one of the most versatile labeling methods currently
available. While other protein-based methods such as SNAP/CLIP20 and HaloTag2' are
applicable to oxidizing compartments of the cell, the large size of these tags can interfere
with target protein function. With the developments described in this chapter, the PRIME
method now uniquely combines a peptide tag, high labeling specificity, and the ability to
label target proteins in both reducing and oxidizing compartments of the cell. Moreover,
the wide variety of fluorophores and probes that can be incorporated using PRIME make
it an attractive method for a wide range of biological applications.
We have further demonstrated the application of this ligase to the labeling of
intercellular protein-protein interactions. We were able to label the interaction of
neurexin-lp and neuroligin-1 in HEK cells in just 5 minutes. This result is the first
demonstration of interaction-dependent PRIME (ID-PRIME) labeling of cell-surface
protein-protein interactions. Compared to the GRASP method for labeling synaptic
partners, our method gives better signal and produces a label that is non-trapping. We
hope to soon extend this trans pAz4 labeling method to the imaging of synaptic partners
in live neurons.
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Experimental
General yeast display methods
Growth and induction. Unless otherwise noted, cells were grown in SDCAA growth
media [2% dextrose, 0.67% yeast nitrogen base without amino acids (BD Difco), 0.5%
Casamino acids (BD Difco), 0.54% Disodium phosphate, 0.86% Monosodium
phosphate] at 30'C with shaking for 20 hours. To induce protein expression, the cultures
were diluted to a cell density of ~106 cells/ml in SGCAA media (identical to SDCAA
above but with 2% galactose as the carbon source). Induction in SGCAA was performed
at 30'C for 20 hours.
Transformation. For single clones, LAP2-YIP (see below) yeast cells were transformed
with DNA using the Frozen-EZ Yeast Transformation II kit (Zymo Research). The
transformed yeast cells were plated on selective plates (SDCAA -W, -U) and single
yeast colonies were selected for amplification. For the libraries, LAP2-YIP yeast cells
were electroporated with the error-prone PCR library (see library construction below)
using a BioRad GenePulser Xcell.
Long-term storage. For individual clones, glycerol stocks were made. Isolated colonies
were grown in 5 mL SDCAA overnight at 30'C. 812 tL of saturated overnight yeast
culture was combined with 188 tL of 80% glycerol (sterile) and placed into a 2 mL cryo-
vial, stored at -80'C. For libraries and rounds, frozen stocks were made. At least 1010
freshly grown cells from each library were inoculated into 1 L low-dextrose SDCAA [as
above but with 0.5% dextrose] and grown at 30'C for approximately 3 days. Cells were
pelleted and then resuspended in freezing solution (2% glycerol, 0.67% yeast nitrogen
base) to a final concentration of ~6 x 1010/mL. Cells were divided into 1 mL aliquots in
cryovials. The tubes were then put into a Mr. Frosty (Nalgene) and allowed to slow-
freeze overnight -80'C. The next day, cells were moved to liquid nitrogen for long-term
storage.
FACS instrumentation. All fluorescence activated cell sorting was performed on a BD
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FACSAria (BD Biosciences). For all analysis where sorting was not required, a BD
LSRII-HTS (BD Biosciences) was used. Both of these instruments are located in the
Flow Cytometry Core Facility at the Koch Institute for Integrative Cancer Research at
MIT.
Preparation of yeast cells constitutively expressing LAP2-Agalp
The LAP2-Agalp yeast integrating plasmid was cloned from the YIPlac2 1-GPD-
Avitag-Agalp plasmid, which was a gift from Irwin Chen at Harvard University. First,
two restriction sites, AfIlINhel were introduced on either side of the Avitag to create
YIPlac2ll-GPD-AflII-Avitag-NheI-Agalp. The LAP2 peptide was then introduced by
pre-annealing LAP2 primers with AflI/NheI sticky ends and ligating into AflII/NheI
digested YIPlac2 11 -GPD-AflII-Avitag-NheI-Agal p. This produced the yeast integrating
plasmid YIPlac2 11 -GPD-AflI-LAP2-NheI-Agalp.
To integrate the plasmid into the yeast genome, YIPlac2 11 -GPD-AflII-LAP2-NheI-
Agalp was linearized by digestion with BsiWI and transformed into Saccharomyces
cerevisiae strain TM134 using the transformation protocol described above and plated on
SDCAA plates lacking uracil. Colonies were picked and grown in SDCAA lacking uracil.
A yeast colony with the LAP2-Agalp construct correctly inserted and with good
expression was designated "LAP2-YIP" yeast and displays the LAP2 peptide sequence
constitutively on the cell surface as a fusion to the N-terminus of Agalp.
Lipoylation on Yeast cell-surface (Figure 6-4)
Yeast cells constitutively displaying the LAP2 peptide and inducibly displaying E
Coli LplA or W37ALplA (see General yeast methods for LplA induction details) were
pelleted and washed twice with phosphate-buffered saline (pH 7.5) with lmg/ml bovine
serum albumin (PBS-B). Cells were resuspended to a cell density of 2 x 108 cells/ml in
PBS-B with 500 tM lipoic acid, 5 mM Mg(OAc)2 and 3 mM ATP and incubated on a
rotator at 30'C for 1-3 hours. The reactions were stopped by pelleting the cells and
washing with ice-cold PBS-B containing 100 mM EDTA. Cells were washed an
additional time with ice-cold PBS-B. The ligated lipoic acid was detected using rabbit
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polyclonal anti-lipoic acid antibody (Calbiochem) and LplA surface-expression level was
detected using mouse monoclonal anti-HA antibody (Roche) in PBS-B at 1:200 dilutions
for 40 minutes at 4'C. Cells were pelleted and washed twice with ice-cold PBS-B. Then
the yeast cells were incubated with anti-rabbit R-phycoerythrin (Invitrogen) and anti-
mouse AlexaFluor-488 secondary antibodies (AF488; Invitrogen) in PBS-B at 1:100
dilutions for 40 minutes on a rotator at 40C. Cells were pelleted and washed twice with
ice-cold PBS-B then resuspended in PBS-B to a density of ~1 x 107 for FACS.
Model Selection (Figure 6-5)
LAP2-YIP yeast displaying wild-type LplA or the less-active w 37ALplA mutant
were mixed in ratios of 1:100 and 1:10 wt:W37A and labeled for 3 hours as described
above in Lipoylation on Yeast cell surface. After incubation with fluorophore-
conjugated antibodies, 107 cells from each mixture were sorted. The top 0.1% and top
1.0% of the PE/AlexaFluor488 double positive population for the 1:100 and 1:10
experiments, respectively, were collected. Collected cells were cultured until saturation in
SDCAA growth media with 50 tg/mL penicillin, 25 tg/mL kanamycin, and 50 tg/mL
streptomycin. Plasmid DNA was harvested using the Zymoprep Yeast Plasmid Miniprep
kit (Zymo Research), and the recovered LplA genes were amplified using the primers
PctAmp-F 5'-CGTTCCAGACTACGCTCTGCAG and PctAmp R 5'-
CGAGATCTGATAACAACAGTGTAG and sent for sequencing analysis. Pre-and post-
sort yeast were re-propagated and labeled again as described above and analyzed by
FACS for qualitative comparison. Quantitative analysis of enrichment from pre- to post-
sort was determined by analyzing nucleotide intensities on the sequencing chromatogram.
Creating LplA libraries A and B
The round zero (RO) LplA libraries were cloned into LAP2-YIP S. cerevisiae using
gap repair homologous recombination.
For Library A, the PCR reaction contained 2 [pM 8-oxo-2'deoxyguanosine (8-oxo-
dGTP), 2 tM 4-dihydro-8H-pyrimido-[4,5-C][1,2]oxazin-7-one (dPTP), 200 tM each
dNTP, and 0.2 [tM each of primers IF and 1R and reactions were thermocycled 10 times.
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For Library B, the PCR reaction was assembled as above but with 200 tM dNTP
analogues and was thermocycled 5 times.
For Library C, the PCR reaction was assembled as above but with 20 [tM dNTP
analogues and was thermocycled 10 times.
For Library D, the PCR reaction was assembled as above but with 20 tM dNTP
analogues and was thermocycled 20 times.
For both Library A and B, mutagenized genes were further amplified in PCR
reactions without mutagenic dNTP analogs using primers:
IF (3'- caaggtctgcaggctagtggtggaggaggctctggtggaggcggtagcggaggc-5')
1R (3' -ctacactgttgttatcagatctcgagetattacaagtcctcttcagaaataagcttttgttc-5').
The pCTCON2-Aga2p vector was prepared by digestion with NheI and BamH, and
gel-purified. The PCR-amplified inserts and digested pCTCON2 vector were mixed in
1:3 ratios and transformed together into LAP2-YIP S. cerevisiae by electroporation as
described previously 22. Homologous recombination occurred inside the yeast, giving the
desired product. Serial dilutions of transformed yeast were plated on SDCAA plates and
colonies were counted, to determine transformation efficiencies for each library. A total
of - 109 cells from the fully grown library cultures were pelleted and induced as described
above for the first round of selection.
pAz labeling and selections on yeast cell surface (Figure 6-7, 6-8, 6-9, 6-10)
Yeast cells constitutively displaying the LAP2 peptide and either the induced LplA
libraries or individual clones (see General yeast methods for LplA induction details) were
pelleted and washed twice with phosphate-buffered saline (pH 7.5) with lmg/ml bovine
serum albumin (PBS-B). Cells were resuspended to a cell density of 2 x 108 cells/ml in
PBS-B with 100-200 M picolyl azide (pAz), 5 mM Mg(OAc) 2 and 3 mM ATP and
incubated on a rotator at 30'C for 1-12 hours (see Figure 2A and Supporting Figure x for
exact library selection conditions). The reactions were stopped by pelleting the cells and
washing with ice-cold PBS-B containing 100 mM EDTA. Cells were washed twice with
ice-cold PBS to remove residual BSA, which inhibits the subsequent click reaction.
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The ligated pAz was detected by performing Cu-catalyzed click chemistry with
biotin-alkyne. The click reagents were prepared as follows: 500 [tM THPTA, 100 1 M
CuSO4, 2.5 mM sodium ascorbate were incubated at room temperature for 10 minutes
then diluted with PBS to appropriate volume for the given final concentrations. Biotin-
alkyne was then added to a final concentration of 4 tM. The labeled yeast cells were
incubated with the click reagents at room temperature on a rotator for 10 minutes, then
pelleted and washed twice with PBS-B.
The biotin was detected using phycoerythrin-conjugated streptavidin (SA-PE;
Jackson Immunoresearch) in PBS-B at 1:50 dilution. The LplA surface-expression level
was detected using mouse monoclonal anti-HA antibody (Roche) in PBS-B at 1:200
dilution. Incubation with SA-PE and anti-HA occurred simultaneously at 4'C for 40
minutes. Cells were pelleted and washed twice with ice-cold PBS-B. Then the yeast cells
were incubated with anti-mouse AlexaFluor-488 secondary antibody (AF488; Invitrogen)
in PBS-B at 1:100 dilution for 40 minutes at 4'C. Cells were pelleted and washed twice
with ice-cold PBS-B then resuspended in PBS-B to a density of -1 x 107 /mL for FACS.
For the libraries, sorted cells were cultured until saturation in SDCAA growth
media with 50 [tg/mL penicillin, 25 tg/mL kanamycin, and 50 [tg/mL streptomycin.
After the culture was saturated, -101 yeast cells were pelleted and induced in SGCAA
and prepared for the next round of selection.
Analysis of Yeast Pools from Individual selection rounds (Figure 6-9)
Yeast harvested from each round of selection were amplified and induced as
described above. All pools were then treated identically with 100 [tM pAz, 5 mM
magnesium acetate, and 3 mM ATP for 1 hour at 30'C. Rounds 3 and 4 were also labeled
under identical concentrations for only 30 minutes at 30'C to distinguish between the
activities of these rounds.
To sequence individual clones, yeast were plated on SDCAA plates, single colonies
were amplified in SDCAA media, and plasmid was isolated using the Zymoprep Yeast
Plasmid Miniprep kit (Zymo Research). To increase DNA concentration, LplA genes
were PCR-amplified from plasmid using the primers PctAmp-F and PctAmp-R
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(sequences under Model Selections) and sent for sequencing analysis.
General mammalian cell culture methods
Human embryonic kidney (HEK) cells were cultured in Minimum Essential
Medium (MEM; Cellgro) supplemented with 10% v/v fetal bovine serum (FBS; PAA
Laboratories). All cells were maintained at 37'C and under 5% CO2. For imaging, cells
were plated as a monolayer on glass cover slips. Adherence of HEK cells was promoted
by pre-coating the coverslip with 50 pg/ml fibronectin (Millipore).
Fluorescence imaging
Cells were imaged in Dulbecco's Phosphate Buffered Saline (DPBS) in confocal
mode. All images shown are using a Zeiss Axiovert 200M inverted microscope with a
40x oil-immersion objective. This instrument is equipped with a Yokogawa spinning disk
confocal head, a Quad-band notch dichroic mirror (405/488/568/647), and 405 (diode),
491 (DPSS), 561 (DPSS), and 640 (DPSS) lasers (all 50 mW). CFP (405 laser excitation,
445/50 emission), YFP and AlexaFluor-488 (491 laser excitation, 528/38 mission),
AlexaFluor-568 (561 laser excitation, 617/73 emission), AlexaFluor-647 (630/20
excitation, 680/30 emission).
Cis pAz ligation on mammalian cell surface (Figure 6-11, 6-12)
HEK cells were transfected at ~70% confluency with expression plasmids for
FLAG-W3 7 ALplA-neurexin1p (or variant) (600 ng for a 0.95 cm2 dish) and the LAP
fusion protein of interest (600 ng) using Lipofectamine 2000 (Invitrogen). Where
indicated, a nuclear co-transfection marker (H2B-YFP) was used (50-100 ng). 12-24
hours after transfection, cells were incubated with 100 jtM pAz, 5 mM Mg(OAc) 2, and 3
mM ATP in serum-free MEM for 1 hour at 370 C. The cells were then rinsed with MEM
twice and Dulbecco's Phosphate Buffered Saline (DPBS) once.
The ligated pAz was detected by performing Cu-catalyzed click chemistry with
biotin-alkyne. The click reagents were prepared as follows: 500 [tM THPTA, 100 ptM
CuSO 4 , 2.5 mM sodium ascorbate were incubated at room temperature for 10 minutes
then diluted to volume with DPBS. AlexaFluor-647-alkyne was then added to a final
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concentration of 4 M. The labeled HEK cells were incubated with the click reagents at
room temperature for 10 minutes, washed twice with 1 mg/mL BSA in DPBS (DPBS-B).
The LplA surface-expression level on the HEK cells was detected using mouse
monoclonal anti-FLAG antibody (Stratagene) in DPBS-B at 1:300 dilution with
incubation at room temperature for 10 minutes. After washing, cells were incubated with
either anti-mouse AlexaFluor-568 or anti-mouse AlexaFluor-488 secondary antibody
(Invitrogen) in DPBS-B at 1:300 dilution for 10 minutes at room temperature. Cells were
washed twice with DPBS-B and then imaged.
Quantification of cis labeling signal (Figure 6-11, 6-12)
For quantification of imaging data, cells with surface signal:background >2:1 in the
AlexaFluor647 channel were selected for analysis. The background corrected mean
intensity data for each ROI was calculated using Slidebook 5.0 software. The bar graphs
show average fluorescence intensity ratios for -25 cells for each condition (With B4.3
and B4.6 cis labeling onto LAP-NLG, we were unable to find 25 cells with
signal:background >2:1, these values reflect averages for just 8-10 cells).
ER labeling (Figure 6-13)
HEK cells were transfected at ~70% confluency with expression plasmids for
FLAG-W37ALplA-ER (or variant) (600 ng for a 0.95 cm2 dish) and LAP-neuroligin (600
ng) using Lipofectamine 2000 (Invitrogen). A nuclear co-transfection marker (H2B-YFP)
was used (50 ng). 24 hours after transfection, cells were incubated with 25 1 M pAz-AM
in serum-free MEM for 4 hours at 37'C. The media was then replaced 3 times over 30
minutes at 37'C. The cells were then rinsed with DPBS once and the ligated pAz was
detected by Cu-catalyzed click as described in Cis pAz ligation on mammalian cell
surface.
Trans pAz ligation on mammalian cell surface (Figure 6-20, 6-22)
One 0.95 cm2 dish of HEK cells was transfected with FLAG- W37ALplA-neurexinlb
(or variant). Another 0.95 cm2 dish of HEK cells was transfected with LAP-neuroligin-1
(600 ng) and a nuclear CFP co-transfection marker (H2B-CFP, 50 ng). Transfection was
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performed at -70% confluency using Lipofectamine 2000 (Invitrogen). 4 hours after
transfection cells were washed twice with MEM and then placed back in the incubator
with complete media. After 6 hours of incubation, cells from each dish were rinsed
quickly once with DPBS and then incubated in each dish with trypsin-EDTA ( for
5 minutes at 370 C. The two pools of cells were then mixed well and co-plated on fresh
cover slips coated in with 50 tg4nl fibronectin (Millipore).
After co-plating, cells were incubated an additional 12 hours and then labeled. For
labeling, cells were incubated 100 [tM pAz, 5 mM Mg(OAc) 2, and 3 mM ATP in serum-
free MEM for 5 minutes at room temperature. The cells were then rinsed with MEM
twice and Dulbecco's Phosphate Buffered Saline (DPBS) once.
Cu-catalyzed click chemistry and live-cell antibody staining were then performed
as described in Cis pAz ligation on mammalian cell surface.
Grasp comparison (Figure 6-21, 6-22)
One 0.95 cm 2 dish of HEK cells was transfected with sfGFP1-10 fused to neurexin-Ib (or
variant, 400 ng) and a whole-cell mCherry co-transfection marker (50 ng). Another 0.95
cm2 dish of HEK cells was transfected with sfGFP 11 -neuroligin- 1 (400 ng) and a nuclear
CFP co-transfection marker (H2B-CFP, 50 ng). Transfection was performed at ~70%
confluency using Lipofectamine 2000 (Invitrogen). Co-plated cultures were prepared as
described in Trans pAz ligation on mammalian cell surface. After co-plating cells
were incubated for 20 hours and then imaged.
Protein expression and purification
LplA mutants demonstrating activity on the mammalian cell surface were cloned
into bacterial expression vector (pYFJ16) and enzymes were expressed in BL21-DE3
bacteria with IPTG induction as previously described (cite).
After Ni-NTA purification, LplA enzymes were stored in a stabilizing buffer: 20
mM Tris pH 7.5, 1 mM DTT and 10% glycerol in aliquots at -80 'C.
Western blotting of mammalian cell lysate (Figure 6-18)
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HEK cells expressing LAP2-YFP or LAP2(K-+A) were lysed under hypotonic
conditions in 1 mM HEPES pH 7.5 with 5 mM MgCl 2, 1 mM phenylmethylsulphonyl
fluoride, and protease inhibitor cocktail (Calbiochem). After three cycles of freeze-thaw,
cells were mixed by vortexing for 2 min. Lysate was cleared by centrifugation and stored
in aliquots at -80 'C. To label with azide, lysates were incubated with 200 tM pAz, 3
mM ATP, 5 mM Mg(OAc) 2 and 200 nM of the indicated enzyme for 10 hours at 30 'C.
Azide derivatization was performed by adding 500 tM THPTA, 100 tM CuSO 4 ,
2.5 mM sodium ascorbate and 40 [tM biotin-alkyne and incubating for 20 minutes at
room temperature. Each reaction sample was boiled in protein loading buffer containing
2-mercaptoethanol for 10 minutes then divided in half and run on duplicate 12% SDS-
PAGE gels. One gel was subjected to Coomassic staining, the other was transferred to a
nitrocellulose membrane for western blot analysis.
The membrane was blocked with 3% BSA in TBS + 0.5% Tween-20 (TBS-T) for
1 hour at room temperature. The membrane was then incubated with streptavidin-
horseradish peroxidase conjugate (Pierce, 1:3000 dilution) in 3% BSA in TBS-T for 40
minutes at room temperature. The membrane was washed four times with TBS-T then the
blot was developed with Supersignal West Femto substrate (Pierce) and visualized on an
Alpha Innotech Chemilmager 5500 instrument.
In vitro ligation reactions (Figure 6-17, Table 6-2)
LplA mutants were purified as described above. For pAz ligation reactions:
reactions were assembled with 2 tM enzyme, 150 tM LAP2 (GFEIDKVWYDLDA), 5
mM Mg(OAc) 2, 3 mM ATP and either 200 M pAz4 or 50 tM pAz4 in DPBS + 10%
glycerol. Reactions were incubated for 10 minutes then quenched with EDTA (Cf = 150
mM) and analyzed via HPLC. For lipoic acid and coumarin ligations: reactions were
assembled with 2 tM enzyme, 150 tM LAP2, 5 mM Mg(OAc) 2, 3 mM ATP and 500
1 M probe in DPBS + 10% glycerol. Reactions were incubated for 10 minutes then
quenched with EDTA (Cf = 150 mM) and analyzed on a Varian Prostar HPLC using a
reverse-phase C18 Microsorb-MV 100 column (250 x 4.6 mm). Chromatograms were
recorded at 210 nm. For analysis of reactions using the LAP2 synthetic peptide
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(GFEIDKVWYDLDA), we used a 14-minute gradient of 25-60% acetonitrile in water
with 0.1% trifluoroacetic acid at 1 ml/minute flow rate. Percent conversions were
calculated by dividing the product peak area by the sum of (product + starting material)
peak areas.
Mass spectrometric analysis (Figure 6-17)
Starred peaks from Fig. 3A were manually collected and injected onto an Applied
Biosystems 200 QTRAP mass spectrometer. The flow rate was 10 pl/min and mass
spectra were recorded under the positive-enhanced multicharge mode.
Kinetic measurements (Figure 6-14, 6-19)
Reactions were assembled with 400 ptM pAz4, 400 ptM LAP2
(GFEIDKVWYDLDA), 1 mM ATP, 5 mM Mg(OAc)2, and 200 nM of enzyme and kept
at 30C. After 3, 5, 8, and 11 minutes, an aliquot was drawn from the reaction vial,
quenched with EDTA (Cf = 150 mM) and the product was quantified via HPLC as
described previously in the section on in vitro ligation reactions. A plot of product
concentration vs. time was made and the data was fit to a simple linear regression
wherein the slope corresponds to the initial rate of the reaction (Vo). The value of kcat
was calculated from the Michaelis-Menten equation Vmax= kcat*[Enzyme] at substrate-
saturating conditions. Measurements were performed in triplicate.
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Chapter 7. Combining yeast-display evolution and in vitro
compartmentalization for the directed evolution of LplA
The results of this chapter are unpublished. This project was performed in collaboration
with Dr. Pascaline Mary and Dr. Ilke Akartuna, members of the Weitz Lab at Harvard
University. Pascaline and Ilke fabricated all microfluidic devices and picoinjection
devices used in this project. We thank Dr. Irwin Chen (Harvard University) for providing
plasmids.
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Introduction
Yeast-display can be a powerful tool for the evolution of enzymatic activity. As
we showed in Chapter 6, just four rounds of selection on a yeast-display library produced
LplA variants with ~5-fold increase in catalytic activity over the parent enzyme and
drastically improved activity in the secretory pathway. Further demonstrating the power
of this technique, the two other examples of evolving improved catalysis using yeast
1,2display have produced variants with 2- to 150-fold increases in catalytic activity
However, the application of yeast-display to enzyme evolution does present some
significant problems. First, the method requires that the enzymatic product be linked to
the yeast cell surface. Second, the yeast-display evolution platform may produce
artificially low turnover due to the requirement for surface-tethered ligase and the steric
constraints introduced by the protein scaffolds. For example, in our case, very active
LplA variants may have their product conversion limited by steric access to LAP2
peptide instead of by intrinsic activity. Finally, while evolutionary pressure can be easily
controlled on the yeast surface, the co-display method forces both the enzyme and
peptide substrate to be expressed with very high effective molarities. This limits the
ability to both evolve for improved catalytic efficiency and select for lower peptide
substrate Km.
The necessity of linking enzymatic product to the yeast cell surface has recently
been circumvented in a collaborative effort between the Weitz lab at Harvard University
and the Klibanov lab at MIT3 . In this work, the authors used a drop-based microfluidic
device to encapsulate yeast cells that were displaying a library of HRP mutants. The
drops essentially served as reaction vessels, with each drop containing at most one yeast
cell and a fluorogenic HRP substrate. The emulsion compartmentalized the individual
yeast cells and effectively linked the diffusible HRP product (phenotype) to the active
HRP mutant expressed on the yeast cell (genotype). Although similar in vitro
compartmentalization (IVC) techniques have been performed using protein-coated
beads4 5 instead of a yeast cell, this new method presents a few significant advantages.
First, traditional methods for IVC use homogenization or "mixing" to create the oil-in-
water emulsion6' 7, which produces polydisperse droplets with non-uniform volumes. The
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authors use microfluidic devices to create monodisperse droplets with identical and
tunable volumes8 . While this is not the first example of such a device being used for
IVC 9 'l, achieving consistent volumes and thus uniform concentrations of reaction
components is critical when evolving enzyme activity. Second, the authors were able to
directly sort the fluorescent droplets within the microfluidic device, eliminating the need
to perform bulk FACS after encapsulation and reaction incubation. This shortens the
overall protocol time and eliminates potential droplet or library loss in the transfer to
FACS sorting. Third, because the emulsion droplets can be sorted directly, there is no
need to perform downstream coupling of the diffusible product to the gene, as required
by all previous bead-based methods5 . Finally, the authors had previously introduced a
method for using voltage-controlled microfluidic channels to coalesce droplets and to add
very precise volumes to existing droplets". This ability to control timing of reagent
additions to the encapsulated yeast cells is exciting and permits extremely creative and
tailored selection strategies.
We immediately saw the advantages of combining in vitro compartmentalization
and yeast-display for the evolution of LplA. We recognized that labeling LAP2 on the
yeast cell surface with LplA library members that were freely diffusible in solution would
solve the problem of artificially low turnover due to steric inaccessibility of the enzyme.
This would also eliminate any labeling artifacts due to high local concentrations of the
tethered enzyme. As outlined in Figure 7-1, we envisioned using droplets to encapsulate
individual yeast cells at which point we could cleave LplA from the yeast cell surface.
We could then rely on the droplet to restrict soluble LplA to labeling only the LAP2 on
the yeast cell it came from, thus preserving the genotype-phenotype linkage. We hoped
this evolution strategy would evade the limitations of co-display using a surface-tethered
enzyme and produce LplA variants with still greater catalytic activity.
In this chapter, we will describe the development and optimization of a directed
evolution technique that combines yeast-display and in vitro compartmentalization for the
evolution of multiple-turnover ligases. We perform initial model selections and then
apply the method to evolve ligases with improved lipoylation activity over wild-type
LplA. Although these initial experiments demonstrate the power of the method in
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evolving ligases with improved activity, there are technical hurdles that will need to be
addressed before this platform can be used to select based on unnatural probe ligation.
Results
Combined yeast-display and IVC selection scheme
We began a collaboration with the Weitz lab to perform the microfluidic
encapsulation of yeast cells. The general scheme for the evolution platform is depicted in
Figure 7-1. We first altered the traditional co-display of LplA and LAP2 by incorporating
a tobacco etch virus (TEV) protease cleavage site between the LplA and the HA tag
(Figure 7-1A). This configuration ensures that the expression level of the enzyme can still
be monitored after cleavage by antibody staining for the HA tag, which remains on the
cell surface after enzyme cleavage. We then use a microfluidic drop-making device to co-
flow the yeast cells and a solution of TEV protease (Figure 7-1B). The aqueous phase is
then flowed into fluorocarbon oil with a biologically inert surfactant that creates the
individual droplets. The cells are introduced at a concentration such that each 6 pL
droplet contains at most 1 yeast cell. The droplets are then collected into a delay line and
the TEV protease cleaves the enzyme from the surface of the yeast (Figure 7-1 C).
After performing the TEV cleavage inside the droplet, we then need to introduce
the labeling reagents into each droplet so the cleaved LplA can label LAP2 on the yeast
cell surface. The Weitz lab has developed a voltage-controlled channel which can
precisely inject a small volume of aqueous solution into individual droplets" (Figure 7-
1D). We propose using this "picoinjection" device to deliver labeling reagents to each
droplet. The droplets can then be incubated for any desired length of time, as droplets
made using microfluidic devices are stable up to two days 3 ' (Figure 7-1E). The droplets
encapsulating very active ligases will also contain highly labeled yeast. Finally, we can
break the emulsions, collect the yeast cells, detect the extent of labeling, and sort via
FACS (Figure 7-iF).
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Figure 7-1. Selection scheme for combined yeast-display and IVC selections (A) Yeast cells are
prepared as previously, the enzyme has an HA tag and a myc tag. A TEV cleavage site was introduced
between the LpIA and the Aga2p protein. The HA tag persists after LpIA cleavage; the myc tag does not.
(B) Yeast and TEV protease are co-flowed into an oil stream. The resulting droplets are 6 pL (23 microns).
The yeast are at a concentration such that at there will be at most 1 yeast cell per droplet. (C) After
forming, the droplets are incubated at room temperature for 40 minutes so the LplA can be cleaved from
the yeast cell surface. (D) Pre-formed droplets containing cleaved LplA are flowed through a picoinjection
device. A voltage-controlled channel (electrode in black) allows for the picoinjection of 0.6 pL (1:10 drop
volume). Each drop receives a precise and consistent amount of labeling reagent. (E) Drops are incubated
for any length of time to allow labeling to occur (F) After labeling, emulsions can be destroyed, yeast
recovered, labeling detected, and FACS sorting performed. Figure modified from Agresti, et. al.3
WLPlA can be fully cleaved from the yeast cell surface and lipoylates LAP2 at low
concentrations
This is a very complicated experiment compared to the traditional tethered-
enzyme yeast display. Therefore, before embarking on model selections, we wanted to
ensure we could meet three essential criteria. First, we wanted to demonstrate that we
observe labeled yeast when LplA is provided at concentration ranges achievable within
the droplet. Second, we need to show that we can achieve complete cleavage of LplA
from the yeast cell surface using TEV protease and on a reasonable timescale. Finally, we
wanted to demonstrate that the combination of yeast-display and in vitro
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compartmentalization actually produces improved labeling signal over the traditional
tethered yeast-display method. These three achievements would demonstrate this method
is promising enough to continue on to model selections.
To meet the first criterion, we determined the range of concentrations that we
could practically produce inside each droplet. There are approximately 104 enzyme
molecules displayed per yeast cell'. If each 6 pL droplet contains a single yeast cell with
70-100% of the enzyme cleaved and in solution, then enzyme concentrations will range
from 25-40 nM. We performed lipoylation of LAP2 yeast using WTLplA at high
concentrations and at concentrations within that range and detected lipoylation using
antibody staining. Figure 7-2 shows ID FACS lipoylation histograms of those labeling
experiments. When a high concentration of WTLplA is used, the yeast cells are highly
labeled even at the shortest labeling time tested (20 min). However when WTLplA is
provided at low concentrations, LAP2 lipoylation level is very low. It requires very long
labeling times (20 hours) to start seeing a significant population of labeled yeast using
just 25 nM of enzyme. However, as previously mentioned, the drops are extremely stable
and long probe incubation times are feasible.
2 uM LpIA 500 nM LpIA 25 nM LpIA
20 hour j
Lipoylation Lipoylation Lipoylation
4 hour
Lipoylation Lipoylation Lipoylation
20 min
Lipoylation Lipoylation Lipoylation
Figure 7-2. Analysis of lipoylation activity using low concentrations of WTLpIA Yeast expressing LAP2
were labeled with lipoic acid and ATP using the indicated WTLpIA concentration for the indicated amount
of time. Lipoylation was detected by antibody staining and cells were analyzed by FACS.
The next goal was to demonstrate that efficient and high-yielding TEV cleavage
can be achieved within the droplets. We first expressed and purified the S219V mutant of
TEV protease, which has been shown to have superior cleavage properties over the wild-
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12type protease . We applied the purified protease to the surface of yeast cells expressing
WTLplA with the TEV protease site added to the linker. In this assay, the extent of
WTLplA cleavage can be monitored by loss of myc signal. Unfortunately, we observed
very little cleavage using a standard TBS-B buffer (Figure 7-3A). This is probably not
surprising given the report that TEV protease activity is improved in reducing buffers,
and 1 mM DTT is recommended 3 . However, since Agalp and Aga2p are connected to
each other via disulfides", we worried that DTT might be too reducing and disrupt the
disulfides, causing loss of the whole Aga2p scaffolding fusion. If that is the case, then
incubation with TBS-B containing 1 mM DTT will show loss of myc signal in the
absence of TEV protease, indicating that the entire Aga2p-HA-TEV-LplA-myc fusion is
being removed from the cell surface. In practice, that is exactly what we observe when
using DTT (Figure 7-3B). We therefore investigated whether a milder reducing buffer
system might provide an environment that is reducing enough for high TEV protease
activity but not so reducing as to disrupt the Agalp-Aga2p disulfide. After considerable
optimization, we determined that a mixture of 3 mM reduced glutathione and 0.3 mM
oxidized glutathione (GSH/GSSG) produced minimal disulfide cleavage in the absence of
TEV protease. When this buffer system was used with TEV protease, we noticed a huge
increase in TEV cleavage activity, with over 90% of the LplA cleaved from the yeast cell
surface after just 40 minutes of incubation with the protease (Figure 7-3 C).
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Figure 7-3. TEV cleavage in optimized buffer is complete within 40 minutes (A) Yeast expressing
WTLpIA with a linker containing a TEV protease site are incubated with and without TEV in TBS-B. (B)
The experiment is performed as in (A) but with 1 mM DTT. Under these conditions, a significant portion of
the WTLpIA is cleaved in the absence of protease, corresponding to DTT-mediated cleavage of the disulfide
between Agalp and Aga2p. (C) When a buffer system of reduced and oxidized glutathione is used, TEV
cleavage activity improves and there is no disruption of the Agalp/Aga2p disulfide.
Finally, we wanted to determine whether the IVC combined with enzyme
cleavage actually produced noticeable changes in yeast cell-surface labeling signal when
using WTLplA. To assay for this, we performed labeling using the scheme outlined in
Figure 7-1 using lipoic acid. This experiment used TEV protease cleavage of the enzyme
along with in vitro compartmentalization in droplets (+TEV, +IVC) (Figure 7-4D). We
compared the lipoylation signal observed under these conditions with the lipoylation
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A
B
C
signal observed using traditional tethered-enzyme yeast display (-TEV, no IVC) (Figure -
7A). As controls, when we perform either IVC or TEV cleavage alone we do not observe
an increase in LAP2 lipoylation (B and C). We concluded from these results that
eliminating steric restrictions for LAP2 labeling by WTLplA led to better enzyme turnover
and improved the lipoylation signal when compared to the tethered-enzyme system.
TEV
s LpIA
+NH3
Agai AP
LplA
A -TEV, no IVC
0
0
anti-HA/AF488
C -TEV, +IVC
0a
Aj 2
anti-HA/AF488
B+TEV, no IVC
anti-HA/AF488
D +TEV, +IVC
anti-HA/AF488
Figure 7-4. Demonstration of consistent picoin ction and improved labeling using combined yeast-
display and IVC. (A) Yeast cells co-expressing LplA ligase and the LAP2 are lipoylated using cis
labeling. (B) and (C) are controls where the yeast cells are treated with either IVC or with TEV, but not
both. (D) Yeast cells co-expressing the WTLpIA ligase and the LAP2 are lipoylated using in vitro
compartmentalization and incubation with TEV protease. (D) is the only condition that gives high signal in
this I hour labeling protocol. This indicates that IVC combined with yeast-display may be more sensitive
than traditional tethered yeast-display.
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Yeast-display and IVC combined selection gives enrichment equivalent to cis selections
The next step was to perform a model selection to demonstrate that the new
evolution platform can distinguish between active and inactive, or less active, ligases. To
do this, we prepared a mixture of 1:1, 1:10, or 1:100 ratios of WTLplA:w 37vLplA yeast.
We then performed one round of selection (see Experimental) for lipoylation activity
using IVC and TEV cleavage. After just one round of selection we observed -50-fold
enrichment of WTLplA over W37vLpIA (Figure 7-5). This enrichment factor matches the
enrichment we observed in model selections using tethered enzymes. We had hoped that
the new method would improve our ability to discriminate between active and less active
ligases. However, this does not appear to be the case based on the enrichment in the
model selection, at least for lipoylation.
1:1 &4A
wTLpIA W37vLPIA G T T (W37V)
yeast yeast G T (W37) T G G
+T G G (WT)
1:10
wr~IA w7%IA G TT (W37V)wTLplA warvLplAyeast* yeast GTTGT (W3) T G G
+T GG (WT) +G T T
1:100 A A4 4
w'LpIA w3 vLpIA
yeast yeast G T T T G G
+G T T
Figure 7-5. Sequencing results of model selection using yeast-display and in vitro
compartmentalization. Model selections were performed as described in experimental, when using 1:1
and 1:10 ratios of WTLpIA to W37vLpIA enrichment was complete. With 1:100 ratios, enrichment of WTLpIA
was only half complete. Therefore, enrichment using this assay is calculated at -50-fold.
Library generation and selections for increased lipoylation
We next created a series of error-prone PCR libraries based on w37ALplA. These
libraries had mutation rates that ranged from an average of just one amino acid per gene
to up to 12 amino acid mutations per gene. Unlike with the tethered yeast-display
selections, for these selections we pooled the yeast libraries, giving a final library
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diversity of 3.0 x10 8 library members. We performed four rounds of selection for lipoic
acid. We initially tried several unnatural probes such as alkyl azide and bromo-
undecanoic acid. However, we found that picoinjection using these more hydrophobic
probes presented a significant problem with drop stability. The drop coalescence and
inconsistent injection volumes that we observed were both the result of the highly
concentrated dyes disrupting the oil-water interface; only lipoic acid was capable of being
picoinjected reproducibly (data not shown). We therefore proceeded with selections
based on lipoylation activity. We performed four rounds of selection on the pooled
library. Evolutionary pressure for improved catalytic activity was introduced by
decreasing the labeling times (from 1.5 hours to 20 minutes) and by collecting a smaller
fraction of cells in each successive round (Figure 7-6). We performed sequencing of
randomly selected clones at each round. By round 4, the original library of ~10 8 mutants
had been reduced to just two consensus clones. One of the consensus clones had just one
mutation (F281 S) in addition to W37A, but the other was highly mutated with 14 amino
acid mutations in addition to W37A.
Round 1: Round 2: Round 3: Round 4:
[yeast] s2 cells er dro let [yeast] :1 cell per droplet [yeast] 51 cell per droplet [yeast] 51 cell per droplet
P4 =1.0% P4 =0.8% P4 =0.9% P4 = 0.4%
C ~0.
.22
anti-HA/AF488 anti-HA/AF488 anti-HA/AF488 anti-HA/AF488
Figure 7-6. Sort windows for each round of lipoylation selection using yeast display and IVC.
Selections were performed using increasingly stringent labeling for each round, all rounds used 500 sM
lipoic acid: Round 1- 1.5 hour incubation; Round 2- 1 hour incubation; Round 3-40 minute incubation;
Round 4- 20 minute incubation. Sort gates are indicated in red with the raw sort percentages reported for
each round. Note: for Round 1 a higher concentration of yeast cells was used to reduce the amount of time
spent performing picoinjection and sorting.
Characterization of consensus clones
We next wanted to characterize the lipoylation activity of these clones both on the
mammalian cell surface and in vitro. We first tested W37A+F28 SLplA and 5"mu'LplA in a cis
lipoylation assay. The enzymes were co-expressed as fusions to neurexin-lb along with
LAP2-CFP-TM on the HEK cell surface. The cells were incubated with lipoic acid and
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ATP for 1 hour and then cis lipoylation of LAP2 was detected by live-cell antibody
staining (Figure 7-7). We observed that neither consensus clone performed as well as
WTLplA and, more importantly, neither performed as well as W37 ALplA, the original
ligase. This was disconcerting, particularly when we also observed no increase in cis
lipoylation on the yeast cell surface using these clones (data not shown). We developed
two hypotheses for the lack of improved cis lipoylation activity. The first hypothesis was
that perhaps selection where enzyme is freely diffusing inside the droplet is biasing
against enzymes that are active as fusions. This would be unfortunate, but the enzymes
developed using this strategy might still be applicable to intracellular or in vitro protein
labeling. The second hypothesis was that the selections did not actually produce enzymes
with increased activity and the apparent increase in labeling signal is due to probe or
antibody sticking. To get more information, we decided to test the LpIA variants in a
trans lipoylation assay.
20..
LAP-CFP-TM anti-LA/AF488 DIC L IA-NRX
WTLpIA-NRX
wALpIA-NRX
W
3
7A+F
2
81 sLpiA-
16
"Lp A-
NRX
Figure 7-7. Testing cis lipoylation activity of consensus clones on the mammalian cell surface. Each
Lp1A mutant was fused to the N-terminus of neurexin-1P (NRX) and co-expressed with LAP2-CFP-TM on
the surface of HEK cells. Cis labeling was performed with addition of 500 pM lipoic acid and ATP for 20
minutes. After labeling the lipoyl-LAP2 conjugates were detected by live-cell antibody staining, which was
also performed with anti-FLAG antibody.
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In a trans ligation assay, we transfect one pool of HEK cells with LplA-neurexin-
1p and a separate pool of HEK cells with LAP2-neruoligin- 1. After transfection, we lift
the two populations and then mix and co-plate them on the same coverslip. If the
consensus clones have lipoylation activity when fused to a protein, then a contact point
between the two populations of HEK should result in labeling of the LAP2-neuroligin
(Figure 7-8, scheme). We performed the trans assay with WTLp1A and with the two
consensus clones (Figure 7-8). While 15MutLplA was inactive in this assay, the
w37A+F2 8SsLplA variant gave better trans lipoylation activity than WTLp1A. This
demonstrates that, at least for some applications, the mutants evolved using yeast-display
combined with IVC exhibit higher lipoylation activity than even the wild-type ligase.
More importantly, this result demonstrates that a ligase that was selected for activity
when freely diffusing can be expressed as a fusion and retain high lipoylation activity.
Inside cell
LpIA-NRX
LpIA-NRX + LAP-NLG/nCFP
e LAP-NLG/nCFP + DIC
wTLpIA-NRX
W37A+F281SLpIA-
NRX
15MutLpIA-
NRX
Figure 7-8 Imaging neurexin and neuroligin contacts using lipoylation. HEK cells expressing
W3 A+F281LpIA as a fusion to neurexin-1p (NRX) were co-plated with HEK cells expressing LAP2 as a
fusion to neuroligin-1 (NLG, with a nuclear CFP co-transfection marker). When the two populations of
cells come into contact, W3 7A+F281SLpIA can ligate lipoic acid onto LAP2-NLG in just 20 minutes. As
controls, trans lipoylation is very low when using WTLpIA-NRX and fails with 15MULpA-NRX.
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Finally, we sought to compare the in vitro lipoylation activity of the
W37A+F28 SLplA consensus clone. We performed a 5-minute lipoylation reaction using
purified enzyme and monitored conversion of LAP2 to lipoyl-LAP2 using HPLC (Figure
7-9). In a 5-minute lipoylation reaction, W37A+F28ISLplA produced twice as much product
than WTLplA. This was a significant result because we had not previously obtained,
through rational design or enzyme evolution, an LplA mutant that has better lipoylation
activity than WTLplA in vitro. We determined that the lipoylation kca, for the selected
mutant W37A+F 28 SLplA is 0.83 sec-1, which is almost three times higher than the
lipoylation kca for WTLp1A (0.28 sec'1). Because of the extremely poor activity we
observed with 15M"'LplA on the mammalian cell surface, we did not characterize this
variant in vitro.
modified
LAP Lipoyl-LAP
- + % product
TLpA _ 47%
Abs2 10
W37A/F281SLpIA 100%
I I I I I I
8 9 10 11 1213
retention time, min
Figure 7-9. In vitro lipoylation of LAP2 using wTLpIA and W3 7 A+F 2 81SLpIA. Reactions were assembled
with 2 [M enzyme, 150 RM LAP2 (GFEIDKVWYDLDA), 5 mM Mg(OAc) 2, 3 mM ATP and 500 [M
lipoic acid. Reactions were incubated for 5 minutes then quenched with EDTA (Cf = 150 mM) and
analyzed via HPLC.
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Conclusion
In this chapter we present initial progress towards the evolution of multiple-
turnover ligases using a technique that combines yeast display evolution and in vitro
compartmentalization. We demonstrate that this powerful method can be applied to select
for an LplA variant with improved lipoylation kinetics over even wild-type enzyme. This
evolution method allows large libraries to be processed in a short time (2,000 droplets per
second) 3 and eliminates the need for surface-linked product.
However, there are some significant challenges to this method. First,
picoinjecting hydrophobic substrates can be difficult due to miscibility issues with
the already-formed yeast droplets. Moreover, the requirement for high
concentrations of stock labeling solutions means that target probes must be able to
be synthesized in very high yields and soluble in aqueous buffer at high
concentrations. Finally, the real power of this technique is the ability to directly sort
droplets via FACS. As described herein, this method requires a purification step to
isolate the yeast, label with antibodies, and then sort by FACS. Future applications of
this method by our lab should focus on using fluorescent (or fluorogenic) substrates
so that FACS sorting can be performed on droplets within the device, which
simplifies the technology a good deal.
Experimental
General Yeast methods
Growth and induction
Unless otherwise noted, cells were grown in SDCAA growth media [2% dextrose,
0.67% yeast nitrogen base without amino acids (BD Difco), 0.5% Casamino acids (BD
Difco), 0.54% Disodium phosphate, 0.86% Monosodium phosphate] at 30'C with
shaking for 20 hours. To induce protein expression, the cultures were diluted to a cell
density of ~106 cells/ml in SGCAA media (identical to SDCAA above but with 2%
galactose as the carbon source). Induction in SGCAA was performed at 30'C for 20
hours.
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Transformation
For single clones, L2-YIP yeast cells were transformed with DNA using the
Frozen-EZ Yeast Transformation II kit (Zymo Research). The transformed yeast cells
were plated on selective plates (SDCAA -W, -U) and single yeast colonies were selected
for amplification.
For the libraries, L2-YIP yeast cells were electroporated with the error-prone PCR
library (see library construction below) using a BioRad GenePulser Xcell.
Long-term storage
For individual clones, glycerol stocks were made. Isolated colonies were grown in 5
mL SDCAA overnight at 30'C. 812 [L of saturated overnight yeast culture was
combined with 188 tL of 80% glycerol (sterile) and placed into a 2 mL cryo-vial, stored
at -800 C.
For libraries and rounds, frozen stocks were made. At least 1010 freshly grown cells
from each library were inoculated into 1 L low-dextrose SDCAA [as above but with
0.5% dextrose] and grown at 30'C for approximately 3 days. Cells were pelleted and then
resuspended in freezing solution (2% glycerol, 0.67% yeast nitrogen base) to a final
concentration of ~6 x 1010/mL. Cells were divided into 1 mL aliquots in cryovials. The
tubes were then put into a Mr. Frosty (Nalgene) and allowed to slow-freeze overnight -
80'C. The next day, cells were moved to liquid nitrogen for long-term storage.
Sorting and Scanning Instrumentation
All fluorescence activated cell sorting was performed on a BD FACSAria (BD
Biosciences). For all analysis where sorting was not required, a BD LSRII-HTS (BD
Biosciences) was used. Both of these instruments are located in the Flow Cytometry Core
Facility at the Koch Institute for Integrative Cancer Research at MIT.
Preparation of Yeast cells constitutively expressing LAP2-Agalp
The E2p and LAP2-Agalp yeast integrating plasmid was cloned from the
YIPlac2ll-GPD-Avitag-Agalp plasmid which was a gift from Irwin Chen at Harvard
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University. First, two restriction sites, AfihIlNheI were introduced on either side of the
Avitag to create YIPlac2 1-GPD-AfII-Avitag-NheI-Agalp. The E2p tag was introduced
by amplifying with primers containing AfilI/NheI sticky ends and ligating into AfihIlNheI
digested YIPlac2l1-GPD-AflII-Avitag-Nhel-Agalp. The LAP2 tag was introduced by
pre-annealing LAP2 primers with AflIINheI sticky ends and ligating into AflII/Nhel
digested YIPlac2 11 -GPD-AflII-Avitag-NheI-Agal p. This produced the yeast integrating
plasmids YIPlac2 11 -GPD-AflII-E2p-NheI-Agalp and YIPlac2 11 -GPD-AflII-LAP2-NheI-
Agalp.
To integrate the plasmid into the yeast genome, the yeast-integrating plasmids were
linearized by digestion with BsiWI and transformed into Saccharomyces cerevisiae strain
BJ5465 using the protocol described above and plated on SDCAA plates lacking uracil.
Colonies were picked and grown in SDCAA lacking uracil. A yeast colony with the
LAP2-Agalp construct correctly inserted and with good expression was designated "E2p-
YIP" yeast and displays E2p constitutively on the cell surface as a fusion to the N-
terminus of Agalp. A yeast colony with the LAP2-Agalp construct correctly inserted and
with good expression was designated "LAP2-YIP" yeast and displays the LAP2 peptide
sequence constitutively on the cell surface as a fusion to the N-terminus of Agalp.
IVC optimizations of labeling and TEV cleavage (Figure 7-2, 7-3)
Testing lipoylation sensitivity
LAP2-YIP yeast cells were incubated with 500 gM lipoic acid, 3 mM ATP, 5 mM
Mg(OAc) and the indicated concentration of WTLplA at room temperature for the
indicated reaction times. Lipoylation was detected on the yeast cell surface by 1:200
dilution of anti-lipoic acid (rabbit) and incubating with yeast cells for 1 hour at 4 C. After
2 washes with PBSB, the yeast cells were incubated with 1:100 dilution of anti-Rabbit-
phycoerythrin for 1 hour at 4C. After 2 washes with PBSB, cells were analyzed via
FACS.
Optimization of TEV cleavage buffer
Yeast cells expressing BirA-TEV (Gift of Irwin Chen, Harvard University) were
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incubated with 8 [tM TEV for 30 minutes at room temperature in either standard buffer
(TBSB) or two more reducing buffers: TBSB + 1 mM DTT and TBSB + 3 mM GSH/0.3
mM GSSG. Controls with no TEV added are included. The TBSB myc signal is set to
100% and all other conditions normalized to that value.
IVC method testing
LAP2-YIP yeast displaying WTLplA-TEV was prepared as previously described.
The yeast were pelleted and washed twice with TBS-B + 3 mM GSH/0.3 mM GSSG and
resuspended to a final concentration of 2.5 x 108 cells/mL. Yeast were prepared with 30%
OPTIPREP (vendor) and 0.00 1% Pluronic F 147. Yeast and 20 pM TEV (Cf droplet = 10
[M) were co-flowed into the dropmaking device at 50 tL/hour (for -TEV case, buffer
was used in place of TEV solution). Droplets were formed within 0.1 sec of aqueous
phase mixing by using a 75 tL/hour flow of HFE7500 + 1.8% RAS surfactant (Weitz
lab, proprietary). The droplets were collected in a 40 minute incubation line for TEV
cleavage and then flowed into the picoinjection device. lOx labeling solution was
prepared: 5 mM lipoic acid, 30 mM ATP, 50 mM Mg(OAc) 2. Droplets were collected in
6 fractions on ice for 1 hour. Then fractions were incubated at RT for 1 hour for labeling
to occur. After 1 hour labeling, 200 [tL of 20% perfluorooctanol in HFE 3500 was added
to each fraction and vortexed. Samples were spun down and the lower oil layer was
removed. Samples were washed again with 200 pL of 20% perfluorooctanol in HFE3500,
vortexed, spun, and oil removed. A final wash/vortex/spin step was performed with 200
pL of FL-40. Yeast cells were then pooled and washed 1x with PBS-B containing 100
mM EDTA followed by 2x washes with PBS-B, removing any supernatant remaining oil.
Labeling for FACS involved adding 1:200 dilutions of anti-lipoic acid (rabbit) and anti-
HA (mouse) and incubating with yeast cells for 1 hour at 4 C. After 2 washes with PBSB,
the yeast cells were incubated with 1:100 dilutions of anti-Rabbit-phycoerythrin and anti-
mouse AF488 for 1 hour at 4C. After 2 washes with PBSB, cells were analyzed via
FACS.
IVC model selections (Figure 7-5)
E2p-YIP yeast displaying wild-type LplA-TEV or the less-active W37vLpA-TEV
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mutant were mixed in ratios of 1:1, 1:10, and 1:100 wt:W37V. These samples were
subjected to in vitro compartmentalization in microfluidic devices and picoinjected with
the 1 Ox lipoylation solution described above (Cf 500 M lipoic acid, 3 mM ATP, 5 mM
Mg(OAc) 2). The emulsion was broken and yeast cells were isolated for antibody staining
for lipoylation and enzyme expression as described in IVC method testing. Cells were
sorted and the top 9.0%, 0.89%, and 0.1% of the PE/AlexaFluor488 double positive
population for the 1:1, 1:10, and 1:100 experiments, respectively, were collected.
Collected cells were cultured until saturation in SDCAA growth media with 50 tg/mL
penicillin, 25 tg/mL kanamycin, and 50 tg/mL streptomycin. Plasmid DNA was
harvested using the Zymoprep Yeast Plasmid Miniprep kit (Zymo Research), and the
recovered LplA genes were amplified using the primers PctAmp-F 5'-
CGTTCCAGACTACGCTCTGCAG and PctAmp R 5'-
CGAGATCTGATAACAACAGTGTAG and sent for sequencing analysis. Quantitative
analysis of enrichment from pre- to post-sort was determined by analyzing nucleotide
intensities on the sequencing chromatogram. Note: for the model selection, the enzymes
used have E. Coli optimized codons. It wasn't until the library design that humanized
codon versions of the LplA-TEV constructs were made.
Creating LplA libraries
The round zero (RO) LplA library was made of a mixture of libraries created with
varying mutation rates. These libraries were made by error-prone PCR and cloned into
LAP2-YIP S. cerevisiae using gap repair homologous recombination.
For all libraries, a W37ALplA was used as the template for the error-prone PCR.
For Library A, the PCR reaction contained 2 1 M 8-oxo-2'deoxyguanosine (8-oxo-
dGTP), 2 M 4-dihydro-8H-pyrimido-[4,5-C][1,2]oxazin-7-one (dPTP), 200 M each
dNTP, and 0.2 tM each of primers IF and 1R and reactions were thermocycled 10 times.
For Library B, the PCR reaction was assembled as above but with 200 [M dNTP
analogues and was thermocycled 5 times.
For Library C, the PCR reaction was assembled as above but with 20 tM dNTP
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analogues and was thermocycled 10 times.
For Library D, the PCR reaction was assembled as above but with 20 tM dNTP
analogues and was thermocycled 20 times.
For all libraries, mutagenized genes were further amplified in PCR reactions
without mutagenic dNTP analogs using primers IF and IR. The pCTCON2-Aga2p vector
was prepared by digestion with NheJ and BamH, and gel-purified. The PCR-amplified
inserts and digested pCTCON2 vector were mixed in 1:3 ratios and transformed together
into LAP2-YIP S. cerevisiae by electroporation as described previously(Chapter 5 and 6).
Homologous recombination occurred inside the yeast, giving the desired product. Serial
dilutions of transformed yeast were plated on SDCAA plates and colonies were counted,
to determine transformation efficiencies for each library. A total of ~10 8 cells from each
fully grown individual library culture were mixed together and then the pooled library
was pelleted and induced for labeling and sorting as described above.
IVC Library selections (Figure 7-7)
The pooled library described above was induced for 20 hours in SGCAA and
washed twice with TBSB + 3 mM GSH/ 0.3 mM GSSG. Cells were resuspended to 5 x
108 for the first round of selection and to 2.5 x 108 for all other rounds. Cells were
prepared for IVC as described above. For all selection rounds, the cells were picoinjected
with the lOx lipoylation solution described above (Cf droplets = 500 [M lipoic acid, 3
mM ATP, 5 mM Mg(OAc) 2). Droplets were collected on ice for 15 hours in 10 minute
fractions. For the first round, labeling was performed at RT for 90 minutes. For the
second round, labeling was performed for 1 hour, then 40 minutes and 20 minutes for
rounds 3 and 4, respectively.
Emulsions were broken and yeast cells were labeled as described previously. The
cells were sorted cultured until saturation in SDCAA growth media with 50 [g/mL
penicillin, 25 tg/mL kanamycin, and 50 [tg/mL streptomycin. After the culture was
saturated, ~109 yeast cells were pelleted and induced in SGCAA and prepared for the
next round of selection.
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Cis lipoylation on mammalian cell surface (Figure 7-8)
HEK cells were transfected with 600 ng of LAP2-CFP-TM and 600 ng of either
WT LplA-NRX, or indicated consensus mutants using Lipofectamine 2000 (Invitrogen) per
manufacturer's protocol. 12 hours post-transfection cells were labeled. For labeling with
lipoic acid: cells were incubated with 500 xM lipoic acid, 5 mM Mg(OAc) 2, and 1 mM
ATP for 20 minutes at 30C. For all samples, cells were washed 2 x 5 minutes with MEM
and then lipoylation was detected via live-cell antibody staining.
Live-cell immunofluorescence staining was performed with 4 ptg/ml anti-lipoic
acid antibody (CalBiochem) and 4 tg/ml anti-FLAG antibody (Stratagene) in 1% BSA in
DPBS for 15 minutes. After three quick washes, cells were incubated with 4 pg/ml goat
anti-rabbit antibody conjugated to AlexaFluor 488 and 4 [tg/ml goat anti-mouse
AlexaFluor 568 (both Invitrogen) in 1% BSA in DPBS for 15 minutes, then washed and
imaged.
Trans lipoylation on the mammalian cell surface (Figure 7-9)
2One 0.95 cm2 dish of HEK cells was transfected with FLAG- wLPANX (or
variant). Another 0.95 cm2 dish of HEK cells was transfected with LAP-neuroligin-1
(600 ng) and a nuclear CFP co-transfection marker (H2B-CFP, 50 ng). Transfection was
performed at ~70% confluency using Lipofectamine 2000 (Invitrogen). 4 hours after
transfection cells were washed twice with MEM and then placed back in the incubator
with complete media. After 6 hours of incubation, cells from each dish were rinsed
quickly once with DPBS and then incubated with trypsin-EDTA for 5 minutes at 370 C.
The two pools of cells were then mixed well and co-plated on fresh cover slips coated in
with 50 tg/ml fibronectin (Millipore).
After co-plating, cells were incubated an additional 12 hours and then labeled with
lipoic acid as described above in cis lipoylation on the mammalian cell surface.
Protein expression and purification
LplA mutants demonstrating activity on the mammalian cell surface were cloned
into bacterial expression vector (pYFJ16) and enzymes were expressed in BL21-DE3
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bacteria with IPTG induction as previously described.
After Ni-NTA purification, LplA enzymes were stored in a stabilizing buffer: 20
mM Tris pH 7.5, 1 mM DTT and 10% glycerol in aliquots at -80 'C.
In vitro ligation reactions (Figure 7-10)
LplA mutants were purified as described above. For lipoylation reactions:
reactions were assembled with 2 tM enzyme, 150 [tM LAP2 (GFEIDKVWYDLDA), 5
mM Mg(OAc) 2, 3 mM ATP and 500 VM lipoic acid. Reactions were incubated for 5
minutes then quenched with EDTA (Cf = 150 mM) and analyzed via HPLC. We used a
14-minute gradient of 25-60% acetonitrile in water with 0.1% trifluoroacetic acid at 1
ml/minute flow rate. Percent conversions were calculated by dividing the product peak
area by the sum of (product + starting material) peak areas.
Kinetic measurements
Reactions were assembled with 500 xM lipoic acid, 400 [tM LAP2
(GFEIDKVWYDLDA), 1 mM ATP, 5 mM Mg(OAc)2, and 100 nM of enzyme and kept
at 30 C. After 3, 5, 7, 9, and 11 minutes, an aliquot was drawn from the reaction vial,
quenched with EDTA (Cf = 150 mM) and the product was quantified via HPLC as
described previously in the section on in vitro ligation reactions. A plot of product
concentration vs. time was made and the data was fit to a simple linear regression
wherein the slope corresponds to the initial rate of the reaction (Vo). The value of kcat
was calculated from the Michaelis-Menten equation Vmax= kcat*[Enzyme] at substrate-
saturating conditions. Measurements were performed in triplicate.
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